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Venous thromboembolism (VTE), encompassing both deep vein thrombosis and pulmonary 
embolism, is a major public health concern due to substantial morbidity and mortality. Around 
50% of all VTE cases are hospital-related, and hospital-acquired VTE is considered a leading 
cause of VTE-related deaths. Importantly, VTE also has life-long implications, as a large 
proportion of VTE-patients suffer either a recurrent event or VTE-related chronic 
complications. The first aim of the thesis was to investigate hospitalization as a trigger factor 
for incident VTE. Secondly, we aimed to provide new insights to the epidemiology of 
recurrence, and to facilitate better recurrence prediction through identification of novel risk 
factors for recurrent VTE.  
 The study population was derived from one or more of the six surveys (Tromsø 1-6) of 
the Tromsø Study, with nearly 40.000 participants who were followed from 1994 through 
2012. All potential cases of first lifetime and recurrent VTE events during this time-period were 
recorded. The target population for papers I and II were participants recruited from Tromsø 4 
who had suffered a first lifetime VTE in the course of follow-up, whereas the target population 
for papers III and IV comprised of subjects participating in either of the first six surveys 
(Tromsø 1-6) who suffered an incident VTE in the period 1994-2012.  
 We found that hospitalization was a major trigger factor for incident VTE, and that the 
VTE risk was mainly influenced by the length of hospital stay rather than the frequency of 
hospital admissions in the 90-days prior to VTE. Furthermore, hospitalization was a high-risk 
situation also in the absence of immobilization, although immobilization contributed 
substantially to the VTE risk among hospitalized patients.   
 Secondly, we discovered that the rates of recurrence and mortality after a first VTE 
remain high, particularly in the following year after a VTE, despite recent advances in the 
diagnostics and treatment of VTE patients. In paper III, we found that the risk of recurrence 
among patients with a hospital-related first VTE appeared to be dependent on the reason for 
hospitalization, although not when the competing risk of death was accounted for. In the final 
model, patients with a VTE related to hospitalization for medical illness had a high risk of 
recurrence, similar to that of patients with a non-hospital-related VTE, which may imply a 
favorable risk-benefit-profile for prolonged treatment. Finally, we identified that d-dimer, 
measured at first VTE diagnosis, could be a potential biomarker to identify patients at low risk 





Venøs tromboembolisme (VTE) omfavner både dyp venetrombose og lungeemboli. VTE er et 
stort problem for samfunnshelsen på grunn av omfattende sykelighet og dødelighet. Omkring 
halvparten av alle VTE hendelser er sykehusrelatert, og sykehuservervet VTE regnes som en 
betydelig årsak til VTE-relaterte dødsfall. VTE innebærer også livslange følger, ettersom en 
stor andel av VTE-pasientene opplever residiv eller VTE-relaterte kroniske komplikasjoner. Det 
første formålet med denne avhandlingen var å undersøke sykehusinnleggelse som 
triggerfaktor for førstegangs VTE. Videre ønsket vi å bringe ny innsikt i epidemiologien av 
residiverende VTE, og fasilitere bedre prediksjon av tilbakefall gjennom identifikasjon av nye 
risikofaktorer for residiverende VTE.  
 Studiedeltakerne ble rekruttert fra en eller flere av de seks første 
Tromsøundersøkelsene (Tromsø 1-7), med nesten 40.000 deltakere som ble fulgt fra 1994 til 
utgangen av 2012. Alle potensielle tilfeller av førstegangs og tilbakevennende VTE i denne 
tidsperioden ble registrert. Målpopulasjonen til artikkel I og II var studiedeltakere fra Tromsø 
4 som utviklet en førstegangs VTE i oppfølgingsperioden, mens målpopulasjonen til artikkel III 
og IV besto av studiedeltakere fra én eller flere av de første seks Tromsøundersøkelsene 
(Tromsø 1-6), som gjennomgikk en første VTE i perioden mellom 1994 og 2012.  
 Sykehusinnleggelse viste seg å være en sterk triggerfaktor for førstegangs VTE, og 
risikoen ble i hovedsak forsterket av lengden på sykehusinnleggelsen heller enn hyppigheten 
på innleggelser i 90-dagers perioden før VTE-hendelsen. Sykehusinnleggelse viste seg å være 
en høyrisikosituasjon også blant pasienter som ikke var immobiliserte, selv om immobilisering 
bidro betydelig til økt VTE-risiko hos sykehusinnlagte pasienter.  
 På tross av fremskritt i diagnostikk og behandling av VTE, forblir residiv- og dødsratene 
etter en første VTE vedvarende høye, spesielt i det første året etter en VTE. I artikkel III, så vi 
at residivrisikoen blant de med en sykehusrelatert første VTE tilsynelatende var avhengig av 
årsaken til sykehusinnleggelsen. Dette endret seg i modellen som tok høyde for forskjeller i 
risiko for død i de ulike undergruppene. I den endelige modellen hadde pasienter med en 
sykehusrelatert VTE i tilknytning til indremedisinske tilstander en høy residivrisiko, på lik linje 
med pasienter som ikke hadde en sykehusrelatert VTE. I artikkel IV, fant vi at bruk av d-dimer, 
målt på diagnosetidspunktet for første VTE, kan være en potensiell biomarkør for 
identifikasjon av pasienter med lav residivrisiko, hvor korttids behandling med 
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Deep vein thrombosis (DVT) and pulmonary embolism (PE) were originally viewed as separate 
diseases (1, 2), but subsequent to the seminal works of Rokitansky and Virchow in the 19th 
century (3), emerging studies revealed considerable overlap in epidemiology, etiology and 
treatment, and they were regarded as a single disease entity termed venous 
thromboembolism (VTE) (4). A DVT is a blood clot arising in the deep veins of the body, and 
the first compatible description of the phenomenon dates back to the middle ages, affecting 
Raul, a young cobbler suffering from pain and swelling in the right leg (5). A DVT usually arise 
in relation to the valvular sinuses in the deep veins of the body, most often in the large veins 
of the legs, but can also occur in the upper extremities, cerebral or abdominal veins (6). 
Common signs and symptoms of DVT includes pain, swelling and erythema in the affected 
limb (7). PE was until recently merely regarded as a complication of DVT by means of 
embolization of the original thrombus to the pulmonary circulation. However, emerging 
studies have revealed that concurrent DVT is present in less than half of all patients with PE 
(8), indicating that some cases of PE attend other etiologies. Several theories on other origins 
of PE have been postulated, including de novo thrombus formation in the pulmonary arteries 
(8, 9), or embolization from a right atrial thrombus in patients with atrial fibrillation (10). This 
notion is further substantiated by evidence indicating a higher risk of PE among patients with 
atrial fibrillation, coronary artery disease and Chronic Obstructive Pulmonary Disease (COPD) 
(10-12). PEs are usually recognized by dyspnea, chest pain, cough, tachypnea, tachycardia, 
syncope and hemoptysis (7, 13), but may also present as sudden deaths, resulting from 
ventilation-perfusion defects and right ventricular failure, leading to severe hypoxia, chock 
and cardiac arrest (13-15). 
 The young cobbler Raul’s condition worsened progressively, despite many unspecified 
treatment attempts, and he was finally advised to visit the tomb of King Saint Lewis. After 
several days of praying to the tomb of King Saint Louis, Raul healed miraculously after applying 
dust from the tomb stone onto his leg ulcers (5). Since Raul’s prayers back in 1271, the 
treatment of VTE has evolved, and the emergence of anticoagulants in the late 1930s has 
revolutionized the treatment of VTE. Anticoagulants, which targets various proteases 
(coagulation factors) in the coagulation cascade, or increase the activity of regulatory proteins, 




vitamin K antagonists (VKA e.g. Warfarin), 
heparins and direct oral anticoagulants 
(DOACs) (16). Treatment of VTE consists of 
two phases, active treatment and secondary 
prevention (Figure 1) (17). In the acute 
phase of VTE, anticoagulants prevent further 
growth of the thrombus and embolization 
(active treatment). Any treatment beyond 
the acute phase is aimed at preventing 
recurrent episodes (secondary prevention). Anticoagulants are extremely effective in 
preventing recurrent thrombosis (18), although at the cost of increased risk of bleeding (18, 
19). Balancing the harms and benefits of secondary prevention is therefore the key in the 
management of VTE patients, but still remains a major challenge. 
1.1. Epidemiology of venous thromboembolism 
VTE occurs in 1-2 per 1000 persons per year in a 
general population (20-23), affecting all age 
groups, ethnicities and both genders (21, 24). 
However, VTE is mainly a disease of the elderly, 
reflected by incidence rates ranging from 10- to 
100-times greater among those >80 years of age, 
compared to middle aged- and young adults (Figure 
2) (21, 25, 26). Notably, the disease burden of VTE 
is projected to more than double from 2006 to 
2050 in the U.S. (27). The majority (two-thirds) of 
VTE cases manifest as DVT (25), although the rates 
of DVT and PE are comparable in studies including 
cases with autopsy proven diagnoses (25). The estimated number of symptomatic VTE events 
(incident and recurrent) in the European Union exceeds 1.1 million cases annually (28), and 
despite advancements in diagnostics, treatment and prophylaxis, the incidence of VTE is stable 
or slightly increasing (21, 23, 26, 29, 30), mainly owing to an increase in pulmonary embolism 
(26, 30). Moreover, increased awareness alongside better and more easily accessible 
Figure 1 The two phases of anticoagulant treatment; (i) 
active treatment for 3 months with rapid decrease in 
recurrence risk, and (ii) secondary prevention with 
individualized duration to reduce the risk of recurrent 
disease. Adapted from Kearon et al (17). 
Figure 2 Age- and sex specific incidence rates 




diagnostic procedures may have contributed to an improved detection-rate of PE. 
Additionally, increasing prevalence of VTE-related risk factors such as obesity, cancer and 
surgery may have contributed to the persistent incidence of VTE (23).  
 VTE is accompanied by substantial morbidity and mortality, and is recognized as the 
third leading fatal cardiovascular disease, after myocardial infarction (MI) and ischemic stroke 
(16, 31). The estimated annual number of VTE-related deaths in the EU amount to more than 
540.000, of which almost 60% follows undiagnosed PE (28). The acute nature of VTE is 
demonstrated by data suggesting that a quarter of PEs present as sudden death (32). The case-
fatality rates after incident VTE cases ranges from 6% to 14% (20, 22, 33) at 1 month, with a 
two-fold higher mortality rate after PE than DVT (5-10% for DVT vs 10-20% for PE) (20, 22). At 
1-year, the case-fatality rate approximately doubles (21-26% for DVT and 23-32% for PE) (22, 
33). Interestingly, the case-fatality rates following incident PE and DVT converge at 1-year (22), 
indicating a substantial but elusive mortality risk related to DVT.  
Besides the immediate short-term consequences, VTE-related chronic complications 
such as the post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary 
hypertension (CTEPH) are major concerns in the aftermath of a VTE. PTS is a debilitating 
condition resulting from valvular destruction, venous hypertension and abnormal 
microcirculation (34), presenting in one third to half of all DVT patients within 10-years 
following diagnosis (35-37), affecting nearly 400.000 patients in the EU annually (28). CTEPH 
arises from incomplete thromboembolic resolution following PE, resulting in increased 
resistance in the pulmonary circulation, which may ultimately lead to right ventricular failure 
(38). CTEPH is a rare complication, presenting in 0.5-5% of patients following an incident 
episode of PE (39-43), however, cumulative incidence rates approaching 10% have been 
reported (43). CTEPH is a severe condition with poor survival if left untreated (38). Patients 
presenting with CTEPH typically complain of exertional dyspnea and, as the disease progresses 
additional symptoms may arise such as exertion-related presyncope, frank syncope, and 
exertional chest pain (38). In advanced stages, signs and symptoms of right ventricular failure 
may also be present (43). Importantly, nearly half of all PE patients report functional 
limitations and/or decreased quality of life up to many years following the acute PE (44). 
Hence, the term post-PE syndrome, analogous to the PTS, has been suggested to grasp the 
entire burden of the disease (44). CTEPH may be regarded at the ultimate manifestation of 




1.2. Mechanistic views on venous thromboembolism  
Central to our understanding of the development of a VTE, is Virchow’s triad of 
pathophysiological alterations which includes changes in 
the composition of the blood (hypercoagulability), 
changes in blood flow (stasis) and changes to the vessel 
wall (endothelial dysfunction) (Figure 3) (16, 45). These 
alterations may overwhelm the local anticoagulant 
properties of the vessel wall and trigger the coagulation 
cascade, a sequential process of serine protease 
activation, culminating in the formation of fibrin, the 
central stabilizing component of a blood clot (46). The 
coagulation system is essential for understanding the underlying mechanisms of venous 
thrombosis. The coagulation cascade can be subdivided into three main pathways, the 
extrinsic-, intrinsic- and common pathway (Figure 4) (45). Tissue Factor (TF) is the main 
activator of coagulation through the extrinsic pathway, and is probably essential for life, 
because of its key role in 
hemostasis (46). TF is 
found in higher density in 
the brain, lung, placenta, 
heart and uterus, to 
provide additional 
hemostatic protection to 
these vital organs (46). 
Contact activation by FXII 
and FXI provides an 
alternate route of clotting 
initiation through 
activation of FIX in the 
intrinsic pathway (45, 47). 
Under pathological conditions, the extrinsic pathway can be activated by intravascular 
sources, such as circulating monocytes, microparticles, or activated endothelium expressing 
TF (45). Likewise, the intrinsic pathway can be activated by extracellular RNA and 
Figure 4 The extrinsic, intrinsic and common pathways of coagulation 
culminating in the formation of fibrin, the main stabilizing component of a 
blood clot.  




polyphosphates shed from activated platelets or bacteria, resulting in the formation of a 
venous blood clot (45).   
Historically, platelets have been regarded as key players in arterial thrombosis, 
whereas their role in VTE is assumed to be negligible. However, recent studies suggest that 
platelets may have a more important role in the pathogenesis of VTE than previously 
anticipated (48). Under normal conditions, platelets play a vital role in primary hemostasis 
through adhesion, activation and amplification, and aggregation (49, 50), which leads to the 
formation of a platelet-plug at the site of vessel injury. Additionally, platelets are highly 
important in the coagulation system through three main functions (46, 51), i.e. (1) provide a 
thrombogenic surface for assembly of the central components of coagulation, (2) by 
accelerating the coagulation cascade through binding of FXI via the GPIb-IX-V-receptor, and 
(3) by serving as an extra source for key coagulation factors, mainly 
factor V (FV). Recent studies highlight the role of platelets in the 
pathogenesis of VTE by means of genetic and acquired platelet-
associated risk factors (48). However, the most important evidence is 
provided by randomized controlled trials (RCTs), presenting risk 
reductions of 25-40% for recurrent VTE among patients with an 
unprovoked VTE who received low-dose aspirin after anticoagulation 
compared with placebo (52-54).  
Another key feature to the pathophysiology of venous 
thrombosis is that the initiation of the thrombus often occurs in 
relation to the pocket sinus of the venous valves, where the 
environment becomes hypoxic due to a vortical blood flow (Figure 5) 
(55). Hypoxia induces endothelial activation with ensuing adherence 
of circulating cells and molecules that can trigger coagulation. This 
creates a thrombogenic surface for thrombus generation, and may 
explain VTEs conceived in situations with reduced blood flow, such as 
immobility or long-haul travel.  
 A general overview of the pathophysiology of VTE is presented 
in figure 6. Several prothrombotic alterations, such as reduced blood flow and local hypoxia, 
may lead to (i) endothelial activation, with consecutive expression of the surface adhesion 
receptors P- and E-selectin, and von Willebrand Factor (vWF). (ii) Successive binding of 
Figure 5 Venous valves 
with vortical blood flow in 
valve sinuses. Adapted 




circulating leukocytes, platelets and Tissue Factor positive microvesicles (TF+ MVs) to the 
activated endothelium through the PSGL-1 ligand, induces (iii) expression of TF on leukocytes 
with subsequent  initiation of the clotting cascade and (iv) formation of a blood clot (45).  
 





1.2.1. Classification of VTE 
VTEs are generally classified as either provoked or unprovoked. If a known trigger for VTE can 
be identified preceding the VTE, the event is typically classified as provoked, whereas VTEs 
that occur in the absence of known predisposing factors are classified as unprovoked (56). Risk 
factors for VTE are further classified as major or minor, transient or persistent. A risk factor is 
considered to be transient if the effect of the risk factor is resolved following a VTE event (e.g. 
surgery or pregnancy), whereas a risk factor that continues to exert its effect after the event, 
is considered to be persistent (e.g. uncured cancer with ongoing treatment) (56). This 
classification has important prognostic implications, as it is strongly related to the risk of 
recurrence, and consequently the management of VTE patients in terms of secondary 
prevention. However, the classification of VTE events can often be challenging, particularly in 
situations where considerable uncertainty exist with regards to the association between a 
certain risk factor and VTE. For instance, some risk factors, such as inflammatory bowel 
disease with intermittent periods of 
remission and flare-ups, may have a 
fluctuating effect on VTE risk. The 
classification of VTE therefore places 
alongside a continuum from VTEs 
provoked by major transient risk factors 
associated with a low recurrence risk, through unprovoked events with intermediate 
recurrence risk, to cases provoked by persistent risk factors associated with the highest 
recurrence risks (Figure 7) (56).  
1.2.2. Triggers, risk factors and predictors 
An important distinction needs to be made between risk factors and triggers. Risk factors are 
typically identified from comparison of the probability of developing a disease between 
exposed and non-exposed individuals, and may therefore answer the question «why did I 
develop this disease?». Trigger factors on the other hand, are typically transient exposures 
with immediate and short-term effects on the risk of acute VTE, which allows us to answer the 
question «why did this disease occur right now?». This distinction has important implications, 
because the presence of a trigger factor describes a high-risk situation that warrants particular 
awareness and more aggressive prophylactic strategies. For instance, although obesity is 
Figure 7 Continuum of VTE classification. Adapted from 




considered a risk factor for VTE, obesity per se does not warrant extensive VTE prophylaxis. 
Conversely, surgery is a major VTE trigger that merit extraordinary awareness and aggressive 
prophylactic regimens.  
Another important distinction is between causes, risk factors and predictors. 
Pragmatically, a cause may be defined as something that alters the disease frequency, health 
status, or associated factors in a population (57), and risk factors are conditions associated 
with an increased risk which relation is considered to be causal (58). A predictor on the other 
hand is not necessarily a cause of disease, but rather a marker of an underlying process 
associated with an increased risk (59). The basis for this vital distinction, is that true causes for 
VTE (e.g. age or thrombophilia) are rather poor predictors of recurrence (59). Thus, 
identification of predictors of VTE are important for two main reasons; first, to help identify 
patients at high or low risk to guide decisions on treatment duration and secondary 
prophylaxis, and second, to understand the underlying mechanisms of venous thrombosis and 
identify true causes of VTE.  
1.3. Venous thromboembolism – A multi-causal disease  
The thrombosis potential model  (Figure 8), proposed by professor Frits Rosendaal in the late 
1990s, illustrates the key 
concepts in the pathogenesis 
of VTE (60). This model 
emphasizes the interaction 
between genetic and acquired 
risk factors, and that 
thrombosis develops once a 
set of sufficient causes have 
accumulated in a patient, so that the thrombosis threshold is exceeded. Another favorable 
feature of the thrombosis potential model is that it is dynamic, i.e. it allows for various forms 
of interaction between risk factors, such as additive or synergistic effects. One of the main 
reasons for this necessity is the strong age-dependency of VTE, as more risk factors needs to 
accumulate for thrombosis to develop in children than in adults and elderly (60). In figure 8, 
the green line represents the effect of a genetic risk factor (e.g. factor V Leiden (FVL)), and the 
red line represents the effect of age. The blue line represents the effect of FVL and age, 




together with provoking factors (e.g. surgery or immobilization) early and late in life, with the 
latter producing sufficient pathophysiological changes to exceed the thrombosis threshold.  
1.3.1. Risk factors for VTE 
A common classification of risk factors for VTE, categorizes risk factors as genetic or acquired. 
Several acquired risk factors for VTE have been identified. As previously described, advancing 
age amplifies the VTE risk exponentially (20, 22, 26, 58, 61). Cancer is another major risk factor 
for VTE, generally associated with a 4- to 7-fold increased risk of VTE, and is estimated to 
attribute to 20-30% of the total VTE burden (62-65). The notion of medical illnesses as risk 
factors for VTE, was established already in 1810 by Ferrier, who noted that VTE occurred 
during debilitating infectious diseases such as typhus (3). Since then, several medical and 
autoimmune diseases, including congestive heart failure (66-69), myocardial infarction (12, 
68, 69), acute infections (67-70), ischemic stroke (66-69), inflammatory bowel disease  (69, 
71-74), chronic kidney disease (75-77) and systemic lupus erythematosus (71, 72) have been 
recognized as risk factors for VTE. The historic view of VTE as a complication of surgery is 
embedded in vast amounts of evidence presenting risk estimates ranging from 6- to 22-fold 
for various types of surgery (63, 69, 78, 79), although the multi-causal nature of VTE has now 
been illuminated. Even though the underlying etiological factors of VTE were not fully 
understood, awareness of mobility in the prevention of thrombophlebitis was early 
recognized (80). Immobility has subsequently been comprehensively documented as an 
important risk factor for VTE, acting in a dose-response related matter depending on the 
length and type of immobility, spanning from use of plaster casts and long-haul travel to 
complete neurologic paralysis and prolonged bed-confinement (58, 66, 78, 81, 82). Other 
important risk factors for VTE include trauma (63, 79), use of central venous catheters (62, 
79, 83, 84), blood transfusions (85), pregnancy and the puerperium (86, 87), oral 
contraceptives (69, 79, 88) and hormone replacement therapy (69, 89, 90). Recently, growing 
evidence supporting a link between anthropometric measures, such as obesity and body 
height, and VTE has been established. Obesity is acknowledged as a growing global epidemic 
and a major public health concern, also with regards to VTE risk, as observational studies 
indicate a 2- to 3-fold increased risk for VTE in obese compared to normal-weight individuals 




estimates ranging from 2- to 4-fold among tall individuals, depending on the reference 
category and stratification levels of height (94, 95).  
VTE is a highly hereditary condition, and evidence from family-based studies indicate 
that 50-60% of the susceptibility to thrombosis can be attributed to genetic risk factors (i.e. 
thrombophilia) (96, 97). Currently known genetic risk factors for VTE promote thrombus 
formation through two main mechanisms (98), loss-of-function of anticoagulant proteins and 
gain-of-function of procoagulant proteins, the latter mainly resulting from impaired 
downregulation or increased synthesis. Loss-of-function mutations in genes encoding for 
anticoagulant proteins result in deficiency of either of the natural anticoagulants 
antithrombin, protein C and protein S. Loss-of-function mutations are generally less prevalent 
than gain-of-function mutations (99), but associated with an 8 to 10-fold increased thrombosis 
risks (98, 100). Gain-of-function mutations in procoagulants are relatively common, and 
generally associated with a 1.3 to 3-fold increased risk of VTE (101). These include mutations 
in genes encoding for factor V (FVL or APC-resistance), prothrombin (rs20210A), non-O blood 
type, fibrinogen and FXI. The emergence and rapid improvement of genome wide association 
studies during the recent decades, has enabled identification of several novel single 
nucleotide polymorphisms (SNPs) associated with VTE. Individually, most of the newly 
discovered VTE-related SNPs are associated with modest or weak risk estimates for VTE (102). 
Consequently, emerging studies have attempted to create genetic risk scores (GRS) based on 
several VTE-associated SNPs to improve the prediction of VTE. Results from a large case-
control study (102), showed that a GRS based on the 5 SNPs most strongly associated with VTE 
performed similarly as a GRS based on 31 VTE-associated SNPs, with predictive accuracy (AUC) 
of 0.69 and 0.70 for a first VTE, respectively. Combining either of the GRS’ with a nongenetic 
risk score significantly improved the predictive accuracy of the model to 0.82. 
Importantly, as demonstrated by the thrombosis potential model, VTE is a multicausal 
disease that involve combinations of acquired and genetic risk factors, which is often set off 
by a trigger factor. Thus, the individual thrombosis risk may vary greatly according to the 
presence of concurrent risk- and trigger factors, the individual thrombosis-inducing properties 
of the risk factors, as well as the interaction between them. However, a fundamental challenge 
in the management of VTE patients and prevention of the disease, is that no obvious preceding 
cause or risk factor can be identified in approximately 30-50% of the cases (i.e. unprovoked 




are necessary to unravel the causes of VTE and to identify novel risk factors and predictors to 
facilitate improved strategies for prevention of thrombogenesis.  
 
1.4. Hospitalization and venous thromboembolism 
Hospitalization is a major concern with respect to VTE risk, associated with 40-60% of all VTE 
cases (20, 28, 62, 104), affecting surgical and medical patients equally (62). Furthermore, more 
than 70% of all VTE-related deaths are estimated to result from hospital-acquired VTE (28). 
PE has been shown to account for 5-10% of all in-hospital deaths (105, 106), making it a 
prominent cause of preventable deaths in hospitalized patients. Importantly, three-quarters 
of these deaths occur in medical patients (107), even though VTE has traditionally been 
considered as a complication of surgery. Moreover, hospital-associated VTE is shown to be 
the leading cause of disability-adjusted life-years lost in low- and middle-income countries, 
and the second leading in high-income countries, responsible for more disability-adjusted life-
years lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse 
drug events (108).  
The annual incidence of in-hospital VTE is reported to be 960 per 10.000 person-years, 
exceeding 100-times that of community residents (109). Previous case-control studies have 
reported a 7 to 21-fold increased risk of VTE following recent hospitalization (58, 63, 78), and 
results from a recent cohort reported that the risk of experiencing a first or recurrent VTE was 
35-fold increased during the 92-days following hospitalization (104). Notably, VTEs occur more 
frequently after than during hospitalization (104, 110), and within a relatively short time-
frame from hospital discharge (104, 110, 111), indicating that thrombosis might have been 
initiated already during hospitalization, although clinically silent upon hospital discharge. 
Furthermore, the hospital-related VTE risk may be influenced by both the length of hospital 
stay and the frequency of hospital admissions (111-113), as well as the reason for 
hospitalization (70, 107, 114-116) and patient-related risk factors, such as age (70, 114-116), 
obesity (116-118) and genetic abnormalities (107, 119). Importantly, the risk of VTE in 
hospitalized patients increases dramatically as the number of concurrent risk factors 
accumulates (68, 70, 107, 120).  
Despite that hospitalization is widely acknowledged as a high-risk situation, there is still an 




cross-sectional study, showed that only 60% of surgical patients and 40% of medical patients 
considered to be at risk of VTE received thromboprophylaxis according to the ACCP guidelines 
(121). Similar or worse results have been presented in previous studies among hospitalized 
medical patients (122-125). Given that hospital-acquired VTE is a largely preventable 
condition, risk assessment upon hospital admission to aid decisions on use of 
thromboprophylaxis should be mandatory. Furthermore, since both disease entity and 
severity, degree of mobility, in-hospital procedures, and length of hospital stay influences the 
VTE risk, the patient needs to be reassessed periodically with regards to VTE risk throughout 
the hospital stay, and upon hospital-discharge. In 2010, The National Venous 
Thromboembolism Prevention Program was launched in England. This program warrants a 
mandatory VTE risk assessment for all adult patients on admission to an acute NHS hospital 
(126). In the first 9 months following implementation, documented VTE risk assessment 
improved from below 40% to over 90%, resulting in a 12% reduction in the relative risk of 
hospital-associated thrombosis (HAT), corresponding to a 15% reduction in HAT attributable 
to inadequate thromboprophylaxis (127). Furthermore, following implementation, there was 
a 15% reduction in the mortality rates with VTE as the primary cause of death in hospitals 
achieving >90% risk assessment (128). However, no effect was found on non-fatal VTE 
readmissions up to 90 days after discharge. Likewise, in a study from the United States (104), 
hospital-related VTE attack rates (incident or recurrent VTE in-hospital or within 92-days post 
discharge) remained essentially unchanged after implementation of a near universal VTE 
prophylaxis regimen. Considering that the prevalence of hospitalization and hospital-related 
risk factors (e.g. active cancer, surgery and leg paresis) are increasing (23, 129), that the 
population attributable risks for VTEs related to hospitalization, surgery or active cancer 
remain high (23), and that near universal strategies for thromboprophylaxis have produced 
modest risk reductions (104, 127), current attempts to prevent hospital-related VTEs have 
likely been inadequate. There has been numerous attempts to create risk assessment models 
(RAMs) to enable better risk stratification among hospitalized patients to aid decisions on 
thromboprophylaxis (107, 130-137). However, current RAMs lack generalizability and 
adequate validation (138), some are highly complex and inconvenient to use, and most lack 
integrated bleeding risk assessment. Furthermore, the decision to prescribe 
thromboprophylaxis in medically ill hospitalized patients is complicated by a high frequency 




risk, which may partly explain the low adherence to practice guidelines described above. Given 
the large potential to reduce morbidity and mortality from VTE, the Steering Committee of 
the International Society on Thrombosis and Haemostasis called out for routine VTE-risk 
assessment in all patients admitted to hospital in 2016 (139). However, the need for better 
and more accurate tools to enable accurate risk stratification to ensure the safety of 
prophylactic therapy is urgent.  
Although hospitalization is acknowledged as a major risk factor for VTE, few studies have 
addressed hospitalization as a trigger factor for VTE. Consequently, we do not know whether 
hospitalization acts a proxy for the underlying VTE risk already accumulated upon hospital 
admission, or whether it reflects exposure to additional hospital-related risk factors. Studies 
on hospitalization as a trigger for VTE are therefore necessary to answer the question «why 
did this VTE event occur right now?». Moreover, hospitalization is often accompanied by 
immobilization, which is associated with a 1.5- to 2.5-fold increased VTE risk in hospitalized 
patients (81), and up to a quarter of medical patients with hospital-acquired VTE have been 
shown to be immobilized preceding the event (130, 140). Previous studies have not been able 
to elucidate the role of immobility in the hospitalized setting due to lack of data on immobility 
and varying definitions, as well as differences in prophylaxis policies. In a previous case-
crossover study, any non-surgical hospitalization or nursing home facility stay was found to be 
a significant trigger associated with a 4.2-fold higher risk of VTE (141). Interestingly, 
adjustment for other hospital-related factors like major surgery, infection, blood transfusion, 
use of central venous catheters, injuries and medication, did not markedly influence the risk 
estimates, although many of these factors most likely are in the causal pathway. Recent results 
from the ARIC study (142), confirmed that hospitalization with infection was a trigger of VTE, 
and results from two recent case-crossover studies derived from the Tromsø study, showed 
that immobilization had a synergistic effect when combined with hospitalization for infection 
and stroke (143, 144). 
 
1.5. Recurrent venous thromboembolism  
VTE is a chronic condition that recurs in 30-40% of VTE patients within 10-years (36, 145-148). 
The recurrence risk is highest in the initial 6 to 12 month period following the incident event 




149-151), and from 7% to 14% at 1-year (35, 145, 147, 150-152). Moreover, the absence of a 
plateau in the cumulative recurrence curve reinforces the notion that VTE is a chronic disease 
with a persistent recurrence risk, even a decade after the index event (36). The reported 
recurrence rates vary widely. Current estimates rely partly upon data from previous decades, 
often restricted to a particular clinical setting (e.g. hospital or community) (35, 153, 154), and 
with differences with regard to start of follow-up (e.g. time of diagnosis or following 
completion of 3-12 months of anticoagulation) (35, 154, 155). Subsequently, there have been 
advancements in the treatment and prevention of VTE. The introduction of low molecular 
weight heparins (LMWH) in the early 1990s improved the efficacy of antithrombotic therapy 
(primarily by ease of use) (4), and has contributed to reducing the duration of hospital stays 
following VTE, with ambulatory treatment now becoming the main strategy for many VTE 
patients (30, 151). Later on, the emergence of direct oral anticoagulants (DOACs) around 2010 
has improved the safety of anticoagulant therapy, and they now serve as first-line treatment 
for VTE (156, 157). Additionally, progress in the prevention of VTE, such as increased 
awareness and improved prophylactic strategies (e.g. risk assessment, use of medical or 
mechanical prophylaxis and early and frequent mobilization), have contributed to reduce the 
incidence of first and recurrent VTEs, despite an increase in the prevalence of risk factors (126, 
127, 129, 158). Consequently, as previous reports on the rates of recurrence might portray an 
inaccurate outline of the current situation, updated estimates from more recent studies are 
needed.  
1.5.1. Case-fatality and long-term complications following recurrent VTE  
The case-fatality rates following recurrent VTE are substantial. In a large review of 13 
prospective cohorts and 56 randomized controlled trials (159), the reported rate of fatal 
recurrent VTE during the initial 3 months of anticoagulation was 0.4%, with a case-fatality rate 
of 11.3%. After the initial phase of anticoagulation however, the rate of fatal recurrent VTE 
rapidly declines, with a reported rate of 0.3 per 100 patient-years (159, 160), corresponding 
to a case-fatality rate of 3.6-5.1% (159, 160). The case-fatality rates following recurrent VTE 
are particularly high among elderly patients, with reported rates of 20.5%, with even higher 
rates among those with unprovoked VTE (23%) and cancer-related VTE (29%) (161).  
In addition to the risk of immediate mortality, recurrent VTEs are associated with 




have reported a 6-fold higher risk of developing PTS following recurrent DVT (35), whereas 
previous PE has been associated with a 19-fold higher odds of CTEPH after acute PE (40). These 
findings have important implications, as PTS and CTEPH is associated with considerable 
morbidity and mortality, and further emphasizes the need for improved preventive measures 
to reduce the risk of recurrent VTE.  
1.5.2. Clinical risk factors for recurrence  
Currently, patient characteristics (e.g. age, sex) and clinical features related to the index event 
(e.g. PE vs. DVT, provoked vs. unprovoked) are most reliable for recurrence prediction, 
whereas laboratory markers (i.e. genetic risk factors and biomarkers) are less useful for 
assessing recurrence risk. Most studies report that the clinical manifestation of VTE as either 
proximal DVT or PE does not influence the probability of recurrence (145, 148, 153, 163-165), 
although, some studies report higher recurrence rates in patients with DVT (147, 166). Some 
of these differences could potentially be attributed to differences with regard to 
inclusion/exclusion of patients with isolated distal DVT and those with concomitant DVT and 
PE, as distal DVT is generally associated with a lower recurrence risk than proximal DVT and 
PE (148, 153, 163-165). Importantly, the initial presentation of VTE as PE or DVT is strongly 
predictive of the clinical manifestation of the recurrent event, as studies indicate a 3- to 5-fold 
higher probability of recurrence manifested as PE rather than DVT in patients with initial PE, 
and vice versa for patients with a first DVT (11, 36, 148, 163, 167). These findings have vital 
implications, as patients with incident PE are more likely to suffer a recurrent PE, meaning that 
they are also at higher risk of succumbing a fatal recurrence than patients with DVT. Moreover, 
although patients with a first proximal DVT are more likely to suffer a recurrent VTE than 
patients with a first distal DVT, up to one-third of patients with an unprovoked distal DVT 
experience a recurrence within 20-years (148), with a similar risk of suffering a recurrent PE 
as patients with proximal DVT (165).   
Male sex is a strong indicator of recurrence risk, generally associated with a 2-fold 
increased risk of recurrent VTE (36, 145, 148, 168-171). Obesity has been proposed as a causal 
risk factor for VTE by means of three main mechanisms; (1) increased intraabdominal pressure 
predisposing to stasis in the lower extremities, (2) coagulation and fibrinolytic abnormalities 
producing a hypercoagulable state, and (3) low-grade inflammation which can promote 




substantiated by evidence from Mendelian randomization studies (174-176). However, the 
recurrence risk related to obesity is conflicting, as some studies report no association (145, 
177-179), while other studies indicate a moderate to high recurrence risk in obese individuals 
(172, 180, 181). Residual vein thrombosis (RVT) refers to the persistence of thrombotic 
material inside a vein following treatment of a DVT, which may form a substrate for 
thrombosis formation. RVT is a clinically reliable predictor which is associated with an 
approximately doubled risk of recurrent VTE (182-185). However, the risk estimates differ 
according to detection criteria and measurement timing, and in various subgroups of VTE 
patients (184). Sex-specific risk factors such as pregnancy (145, 186, 187) oral contraceptives 
(145, 168, 187-189) and hormone replacement therapy (168, 187-189) are associated with a 
30-60% lower recurrence risk. However, resumption of hormone replacement therapy in 
women with a previously verified VTE has been shown to increase the recurrence risk 
dramatically (190), and women who suffer a VTE are therefore strongly discouraged to resume 
hormonal treatment. Accordingly, hormone related risk factors (including pregnancy and the 
puerperium) may explain some of the observed sex differences in recurrence risk but not in 
risk of incident VTE, indicating a higher intrinsic VTE risk among men (191). Interestingly, 
although age is considered a major risk factor for incident VTE, conflicting evidence exist with 
regards to the association between age and recurrence risk, as some studies report positive 
associations (36, 145, 165, 169), while others do not (148, 153, 154, 192).  
As previously described, the classification of VTE as provoked or unprovoked is strongly 
related to recurrence risk, and therefore has important prognostic implications. The 
recurrence risk among patients with an unprovoked first VTE is generally 2- to 3-times greater 
than that of patients who suffer a first VTE provoked by a transient risk factor (164, 165, 182, 
193, 194). The recurrence risk for transient risk factors are generally low, as long as the risk 
factor is removed and the effect reversible (145, 153, 193-195). On the other hand, patients 
with VTE provoked by persistent or irreversible risk factors are generally at high risk of 
recurrence (59, 145, 196). However, previous studies vary widely with respect to the 
classification of VTE events as provoked or unprovoked, and whether risk factors are 
considered to be transient or persistent. Consequently, the Scientific and Standardization 
Committee of the International Society of Thrombosis and Haemostasis recently published 
universal guidelines for the classification of VTE as unprovoked or provoked by major or minor 




these categories, as this would benefit clinical practice and research. However, this 
classification may not be clinically useful as there exist considerable diversity in recurrence 
risk within each subgroup (151, 178, 197-199). Thus, continued efforts are needed to provide 
more refined risk estimation within subgroups of provoked and unprovoked VTE, to tailor 
prophylactic regiments at an individual level.  
1.5.3. Genetic risk factors and recurrence 
Given the high heritability of VTE, the role of genetic risk factors in predicting recurrent disease 
has received vast attention. During the 1990s, thrombophilia screening became popular under 
the rationale that identification of underlying genetic predisposition to thrombosis, would 
identify patients at high risk of recurrence who would benefit from extended anticoagulation 
(200). However, emerging evidence revealed that most genetic risk factors for VTE seemingly 
have a weak impact on recurrence risk (171, 194, 200-207), a phenomenon known as «the 
thrombophilia paradox» (59). Consequently, the concept of thrombophilia screening was 
abandoned (200). Recently, this concept has again been materialized accompanying the 
derivation of genetic risk scores (GRS) combining multiple VTE-associated SNPs to improve 
recurrence prediction (204, 206, 208). Nevertheless, the prevalence of multiple concurrent 
prothrombotic genetic abnormalities is low (204, 206), and the benefit of such a model is 
therefore limited to a small subgroup of VTE patients, indicating that universal screening for 
thrombophilia is still not warranted. Notably, a more simplified approach using family history 
of VTE (FHVTE) as a proxy for the genetic burden of VTE, may be clinically valuable for 
recurrence prediction, as FHVTE is reported to be associated with a near two-fold increased 
recurrence risk (183, 203). However, advances in genetic research recent decades may help 
unravel the genetic basis of recurrent VTE (209), as demonstrated in a recent genome wide 
association study, which identified a novel genetic marker of VTE located on chromosome 18, 
associated with a 1.7-fold increased recurrence risk (210).  
1.5.4. Hospital-related VTE and risk of recurrence  
As previously described in this thesis, the role of hospitalization in VTE is extensive. Recent 
data suggest that more than half of all VTE cases are hospital-related (28, 104), and hospital-
acquired VTE is a paramount cause of mortality, accounting for more than two-thirds of VTE-
related deaths (28). The transient nature of hospitalization could imply a low recurrence risk, 




recurrence risk (HR: 0.98, 95% CI: 0.70-1.37) in a previous cohort from Olmsted County, USA. 
(145). In fact, patients who acquired a first VTE during hospitalization had an almost 50% (HR: 
1.46, 95% CI: 1.08-1.98) increased recurrence risk as compared to patients with community 
acquired VTE. Similar results were found in the Worchester VTE study (178), in which 
hospitalization due to non-surgical illness before the index event was associated with a 30% 
(HR: 1.30, 95% CI: 1.03-1.63) increased recurrence risk.  
Hospitalized patients compose a heterogeneous population, and the recurrence risk 
among hospitalized individuals may therefore relate to the circumstances of the event 
including the reason for hospital admission, hospital- and patient-related risk factors. 
Hospitalization for surgery is one of the strongest risk factors for a first VTE, and VTE occurs 
in approximately 0.5-2% of patients post-operatively (114). However, surgery is generally 
associated with a low recurrence risk (145, 153, 193-195), although somewhat diverging 
depending on the type of surgery (195). Consequently, patients with a first VTE after 
hospitalization for surgery do not have a high recurrence risk because the thrombotic state 
post-operatively is transient and reversible. Conversely, cancer, another major risk factor for 
first VTE, involves a persistent or progressively elevated recurrence risk in the range between 
2- to 7-fold compared to cancer-free VTE patients (145, 153, 178, 211, 212). The recurrence 
risk among patients with active cancer can be further stratified on whether treatment requires 
chemotherapy (145), and according to the type of cancer, tumor site, stage and stage 
progression (145, 211, 213). Moreover, survival is significantly worse for cancer patients who 
suffer a recurrent VTE, particularly among patients with recurrent PE (213). Interestingly, a 
number of studies present similar recurrence rates following VTE provoked by non-surgical 
risk factors as those following unprovoked VTE (178, 193, 197, 214), indicating that certain 
non-surgical risk factors (e.g. acute medical illness) considered to be transient, may instead 
have a persistent nature. For instance, results from a multicenter trial comparing secondary 
prophylaxis with VKA for 6 weeks or 6 months (36), showed similar recurrence rates among 
patients with VTE related to infection or immobilization as among those with unprovoked VTE. 
Several other medical conditions have been associated with increased recurrence risk 
including chronic lung-, heart- and renal disease, inflammatory bowel disease and neurologic 
disease (145, 212, 215). These are chronic conditions shown to be associated with coagulation 
and fibrinolytic abnormalities (71, 73, 216-218), endothelial dysfunction (71, 73, 216-218), 




elicit a persistently elevated thrombosis potential. Moreover, hospitalized patients often 
present with comorbidities, which may interact and amplify recurrence risk in these patients. 
However, in a previous study (219), patients with any, a single or two or more comorbidities 
did not have a significantly increased recurrence-risk compared to patients without any known 
comorbidities (219).  
Importantly, the survival after a hospital-related VTE may also vary according to the 
same factors influencing the recurrence risk, meaning that the reported recurrence rates 
might be overestimated due to differential losses to follow-up caused by the competing risk 
of death (220, 221). Currently, few studies have addressed the role of the competing risk of 
death when estimating the recurrence risk among patients with hospital-related VTE. Ay and 
colleagues demonstrated that the 1–KM method slightly overestimated the 1- and 2-year 
cumulative incidence of VTE among cancer-patients compared to models accounting for the 
competing risk of death, and that the magnitude of bias was a direct function of the competing 
mortality (221). Furthermore, in a recent study, the reported 5-year cumulative recurrence 
rates dropped from 43.4% to 33.8% in patients with incident cancer-associated VTE, whereas 
the rates remained essentially unchanged among those with incident idiopathic (27.3% to 
26.2%) and secondary non-cancer associated VTE (18.1% to 16.8%), when the competing risk 
of death was taken into account (149). Accordingly, competing risk models appear to be 
beneficial to produce accurate and unbiased risk estimates in subgroups of VTE-patients with 
a high risk of a competing event (e.g. death). As decisions on treatment duration are based on 
the balance between risk of recurrence and risk of bleeding, precise recurrence estimates are 
crucial to identify the optimal equipoise of anticoagulation. Therefore, future studies that 
incorporate competing risk models, especially in high-risk situations for both VTE and death, 
as imposed by hospitalization or hospital-related risk factors such as cancer or medical illness, 
are needed.  
1.5.5. D-dimer and risk of recurrent VTE  
The distinction between risk factors and predictors is particularly evident in the case of 
biomarkers, as biomarkers are rarely causal factors in the pathogenesis of a disease, but 
rather a reflection of an ongoing disease process. In recent years, vast resources have been 
dedicated towards identification of novel biomarkers to enable prediction of VTE recurrence. 




fibrinolysis, and is a highly sensitive biomarker of VTE. D-dimer is vital in the diagnostic work-
up of patients with suspected VTE, with a negative predictive value of nearly a 100% (222). 
Furthermore, d-dimer is the most established biomarker of recurrent VTE, and studies have 
shown that elevated d-dimer after discontinuation of anticoagulation is associated with a 2- 
to 4-fold increased recurrence risk (223-227). However, d-dimer is positively correlated with 
several clinical characteristics and medical conditions, including age, sex, cancer, heart 
disease, infection and inflammatory diseases (228-233), and therefore has a low specificity for 
VTE. For a biomarker to be clinically useful for prediction purposes, high specificity is a key to 
avoid the possibility that a negative results is impeded by other conditions. However, results 
from a prospective interventional study (234), showed that patients with elevated post-
anticoagulation d-dimer randomly assigned to resume anticoagulation had a significantly 
lower recurrence risk than those who did not resume anticoagulation, demonstrating that d-
dimer could potentially be used to guide decisions on the duration of anticoagulant treatment, 
despite lack of specificity. Nevertheless, because d-dimer is a non-specific biomarker, the 
clinical utility to identify patients at high risk of recurrence is limited as d-dimer may be 
elevated due to other conditions. However, whether d-dimer may be used to identify patients 
at low risk of recurrence in whom anticoagulant therapy may be safely discontinued is 
debated. Furthermore, as d-dimer is widely available already at the time of incident VTE 
diagnosis, it would be reasonable to explore whether these d-dimer measurements could be 
used for prediction purposes, as it would reduce the need for additional out-patient clinic visits 
and save time and resources for the health care system.  
  
1.6. Mortality after incident venous thromboembolism  
Besides the high risk of recurrence and chronic complications (i.e. PTS and CTEPH) in 
the aftermath of a VTE event, VTE is accompanied by substantial mortality and reduced short- 
and long-term survival. Extrapolated data from 6 EU countries indicate that there are more 
than 540.000 VTE-related deaths in the EU per annum (28), making VTE responsible for more 
than 1 out of 10 deaths each year, putting further emphasis on VTE as a tremendous burden 
on public health. Previous data on survival after VTE are scattered, ranging from 72% to 94% 
at 30 days (22, 32, 33, 152), from 63.6% to 99.1% at 1-year (22, 32, 33, 35, 152, 235) and from 




clinical presentation of VTE as either PE or DVT, especially in the short-term, with reported 
case-fatality rates around two-fold higher at 1-month in patients with PE compared to patients 
with DVT (20, 22). Similar as the risk of recurrence, survival after VTE is dependent on the 
circumstances surrounding the incident VTE event, as well as patient-related risk factors. 
Survival is particularly poor in VTE-patients with concomitant cancer, medical illness or 
neurological disease (20, 22, 32, 35, 236, 237), and patient-related risk factors associated with 
reduced survival after VTE includes advancing age, male sex, and low BMI (32).  
Current reports on the rates of both recurrence and mortality after incident VTE are 
widespread. The diverging results may partly be explained by differences with regard to the 
time-period in which the studies were conducted, dissimilarities in study design, study 
population, inclusion and exclusion criteria, start and length of follow-up (i.e. before or after 
termination of anticoagulant therapy), and outcome ascertainment. However, it is not well 
known whether recent advances in diagnosis, treatment, prophylaxis and management of VTE 
patients have influenced the rates of adverse events after a first VTE. Updated reports on 
recent trends in recurrence and mortality after VTE are therefore crucial to determine 




2. Aims of the thesis  
The specific aims of the thesis were:  
 
A. To investigate the impact of hospitalization as a trigger of VTE, and to explore the influence 
of immobility on this relationship in a population-based case-crossover study of VTE 
patients. We also investigated the influence of hospital-related factors, such as length of 
hospital stay and frequency of hospital admissions, on the risk of VTE.  
 
B. To estimate the cumulative incidence of recurrence and mortality after a first VTE by using 
cases derived from a general population cohort including both the hospital and outpatient 
setting, during the period 1994-2012.  
 
C. To investigate the risk of recurrence and mortality among patients with a first hospital-
related VTE, and to compare the impact of transient and persistent hospital-related risk 
factors such as surgery, cancer or other medical conditions on the risk of recurrence in 
models with and without death as a competing event.  
 
D. To investigate the association between d-dimer, measured at the time of first VTE 






3.1. Study population – The Tromsø study 
The Tromsø study is a single center prospective population-based study with repeated health 
surveys of the inhabitants of Tromsø, in the North of Norway (238). Overall, seven surveys 
(Tromsø 1-7) have been conducted, starting with Tromsø 1 in 1974, followed by the second 
(1979-80), third (1986-87), fourth (1994-95), fifth (2000-01), sixth (2007-08) and seventh 
survey completed in 2015-16. The study originated in an attempt to combat the high mortality 
of cardiovascular diseases in the northern part of Norway, and was therefore initially termed 
the Tromsø Heart study. However, the study has evolved over four decades and now includes 
a wide range of diseases (238). The study offers several favorable features, including a 
longitudinal design, long-term follow-up, repeated measurements, high attendance rates and 
single center follow-up.  
 The study population for papers I and II of this thesis was recruited from the fourth 
survey of the Tromsø study, while the source population for papers III and IV comprised of 
subjects participating in either of the first six (Tromsø 1-6) surveys of the Tromsø study. 
Overall, 39,825 unique individuals participated in at least one of the surveys, of which 27,158 
subjects were recruited to Tromsø 4. The average participation rate was 78.5% across the six 
surveys, and 77% of the eligible population participated in Tromsø 4. VTE registration started 
on January 1, 1994 and ended on December 31, 2012. All potential cases of first lifetime and 
recurrent VTE events during this time-period were recorded.  
3.2. Outcome ascertainment – Venous Thromboembolism 
All possible VTE events in the study-period (January 1, 1994 through December 31, 2012) were 
identified and validated by trained personnel using the hospital discharge diagnosis registry, 
the radiology procedure registry and the autopsy registry at the University Hospital of North 
of Norway (UNN). UNN is the sole provider of all VTE-related health care and diagnostic 
radiology procedures for VTE in the area. The discharge diagnosis codes of interest were the 
International Classification of Diseases (ICD)-codes 325, 415.1, 451, 452, 453, 671.3, 671.4 and 
671.9 for the period 1994-98, and the ICD-10 codes I26, I80, I81, I82, I67.6, O22.3, O22.5, 
O87.1 and O87.3 for the period 1999-2012. A diagnosis of VTE was verified and recorded when 
the presence of clinical signs and symptoms was combined with objective confirmation tests 




ventilation scan, pulmonary angiography, or autopsy), and resulted in a VTE diagnosis that 
required treatment. For cases derived from the autopsy registry, a VTE-event was only 
recorded when the autopsy-record indicated PE as the sole cause of death or as a significant 
contributing cause of death. Patients with concurrent DVT and PE were registered as having 
PE. Recurrent episodes of VTE were identified and validated using the same criteria as 
described above for first lifetime VTE events. For papers II, III and IV, information on mortality 
was derived from the Norwegian Population Registry by use of the unique national person 
identification number.  
3.3. Baseline measurements and design 
The baseline data for each participant of the Tromsø study was obtained by physical 
examination, blood samples and self-administered questionnaires upon study inclusion in the 
Tromsø study. Body height and weight were measured in participants wearing light clothing 
and no shoes, and was used to estimate the body mass index (BMI, kg/m2) as the body weight 
(kg) divided by height squared (m2).  
Study I followed the design of a case-crossover study (Figure 9). Information regarding 
all VTE cases enrolled in study I were acquired by review of medical records. Trained personnel 
systematically collected 
information on potential 
trigger factors in the 90-
days immediately 
preceding the VTE event 
(defined as the risk 
period), as well as four 
consecutive 90-day periods (i.e. control periods) prior to the risk period, except from a 90-day 
wash-out period in-between the risk- and control periods. Additional information regarding 
diagnostic procedures, surgical and medical treatment, laboratory tests and diagnosis during 
hospital admissions, day-case and outpatient clinic visits in any of the control or risk periods 
were recorded. Exposures that extended over several days, were registered and considered 
to have occurred if any of the days of exposure fell within the specified 90-day period.  




For studies II, III and IV, the medical records for each potential VTE case derived from 
the hospital discharge registry, the autopsy registry and the radiology procedure registry at 
UNN were reviewed by 
trained personnel. The 
participants were followed 
from the date of their first 
VTE until the first occurring 
event of either recurrent VTE, 
death, migration or end of 
study (Figure 10). Information 
on clinical risk factors, comorbidities, provoking factors and laboratory markers at the time of 
and eight weeks preceding the VTE event was extracted from the medical records using 
standardized forms. Clinical risk factors included obesity (BMI>30 kg/m2 according to the WHO 
definition (239)), previous VTE, use of estrogen, family history of VTE, varicose veins, as well 
as pregnancy and the puerperium. Comorbid conditions encompassed myocardial infarction 
or a stroke within the last 12 months preceding the VTE, chronic obstructive pulmonary 
disease, myeloproliferative disorders, systemic lupus erythematosus and chronic infections. A 
VTE was considered provoked if preceded by (i) surgery, trauma or acute medical illness within 
the 8 weeks preceding the event, (ii) marked immobilization such as bedrest >3 days, 
confinement to wheelchair or long distance travel exceeding 4 hours within the last 14 days 
prior to the VTE, (iii) active cancer at the time of VTE, or (iv) any other factor specifically 
described in the medical records, such as other immobilization (e.g. plaster cast), or other 
provoking factors (e.g. central venous catheters). D-dimer was assessed as part of the 
diagnostic work-up of patients with suspected VTE. All blood samples were analyzed at the 
Department of Clinical Chemistry at the UNN. Two different assays were used in the study 
period; The NycoCard D-dimer (Nycomed Pharma, Oslo, Norway) in the period 1994-98 and 
the STA®Liatest® D-Di FM from Stago (Diagnostica Stago, Asnières, France) in the remaining 
period from 1998-2012.  
 




4. Main results 
4.1. Paper I – Hospitalization as a trigger of venous thromboembolism – Results 
from a population-based case-crossover study 
Previous studies have reported that around 50% of patients with venous thromboembolism 
(VTE) has undergone recent hospitalization. However, studies on the impact of hospitalization 
as a trigger factor for VTE, and the influence of immobility on this relationship are limited. The 
aim of this study was to investigate the impact of hospitalization with and without concurrent 
immobilization as a trigger factor for VTE using a case-crossover study of 530 cancer-free VTE 
patients. Hospitalizations were registered during the 90-day period preceding the VTE 
diagnosis (hazard period), and in four preceding 90-day control periods. A 90-day washout 
period between the control- and hazard periods was implemented to avoid potential carry-
over effects. Overall, 159 (30%) of the VTE-patients had been hospitalized in the hazard 
period, corresponding to an odds ratio (OR) of 9.4 (95% confidence interval (CI): 6.8–12.8) for 
hospitalization. The risk increased slightly with the total number of days spent in hospital (OR 
per day: 1.11, 95% CI: 1.04–1.18), and with the number of hospitalizations (OR 8.9, 95% CI: 
6.4–12.4 for 1 hospitalization and OR 12.3, 95% CI 6.4–23.6 for ≥2 hospitalizations). After 
adjusting the number of hospitalizations for the total number of days spent in hospital, there 
was no significant difference in the VTE risk between those with one compared to patients 
with two or more hospitalizations (OR: 1.8, 95% CI: 0.6-5.2). Hospitalization without 
immobilization was 6-times (OR: 6.3, 95% CI: 4.4–9.2) more common, whereas hospitalization 
with immobilization was near 20-times (OR: 19.8, 95% CI: 11.5–34.0) more common in the 90-
days prior to a VTE compared to the control periods. These findings imply that hospitalization 
is a major trigger factor for VTE also in the absence of immobilization. However, 
immobilization contributes substantially to the risk of VTE among hospitalized patients. 
Furthermore, the hospital-associated VTE-risk is mainly dependent on the length of hospital 




4.2. Paper II – Recurrence and mortality after first venous thromboembolism in a 
large population-based cohort 
The rates of recurrence and mortality after a first episode of VTE vary considerably in previous 
reports. Advances in the management and treatment of VTE during the last 15 years may have 
influenced the rates of clinical outcomes. The purpose of this study was to estimate the rates 
of recurrence and mortality after a first VTE in a large cohort of 710 VTE patients recruited 
from a general population. Patients with a first, symptomatic, objectively confirmed VTE were 
included and followed in the period 1994–2012. Recurrent episodes of VTE were identified 
from multiple sources and carefully validated by review of medical records. During a median 
follow-up of 7.7 years (range 0.04-18.8 years), 114 patients experienced a recurrent VTE, and 
333 patients died. The overall recurrence rate was highest during the first year following 
incident VTE diagnosis, corresponding to an annual rate of 7.8% (95% CI: 5.8-10.6), whereas 
VTE recurred at an annual rate of 3% (95% CI: 2.4-3.8) in the remaining 17 years of follow-up. 
The overall 1-year all-cause mortality rate (MR) was 29.9 (95% CI: 25.7-34.8) per 100 person-
years, and was particularly high among patients with cancer-related VTE (MR: 114.4 per 100 
person-years, 95% CI: 94.0-139.3). Consequently, the cumulative incidence rates of recurrence 
dropped from 26.4% to 11.4% in competing risk of death analysis. Our results highlight, that 
despite recent advances in the management of VTE patients, the rates of adverse events 
remain high, particularly in the following year after a VTE, and the trend persists for at least a 




4.3. Paper III – Hospital-related first venous thromboembolism and risk of 
recurrence  
Hospitalization is a well-established risk factor for incident VTE. However, the recurrence risk, 
particularly in patients hospitalized for conditions other than cancer or surgery, is uncertain. 
Furthermore, the cumulative incidence of recurrence in hospital-related VTE may be 
influenced by the competing risk of death. We aimed to elucidate the risk of recurrence and 
mortality among patients with a first hospital-related VTE with and without death as a 
competing event. We collected information on hospital-related risk factors in 822 patients 
with a first-lifetime VTE derived from the Tromsø study. Recurrent VTEs and deaths during 
follow-up (1994-2012) were recorded. During a median follow-up of 2.8-years, VTE recurred 
in 132 patients and 442 patients died. A hospital-related VTE per se was not associated with 
increased risk of recurrent thrombosis (HR: 0.99, 95% CI: 0.69-1.41). However, stratification 
on hospital-related factors revealed considerable differences in recurrence risk. The 5-year 
cumulative incidence of recurrence was 27.4%, 11.0% and 20.2% in patients with incident VTEs 
related to cancer, surgery or other medical illness, and 18.4% in patients with a non-hospital 
related first VTE. The corresponding relative risk estimates showed a 73% (HR: 1.73, 95% CI: 
1.06-2.81) higher risk, and a 47% (HR: 0.53, 95% CI: 0.28-0.99) lower risk among patients with 
a first VTE related to hospitalization for cancer or surgery, whereas patients with a VTE related 
to other medical illness had a similar risk (HR: 1.02, 95% CI: 0.61-1.72) as patients with a first 
VTE that was not hospital-related. All subgroups displayed an increased mortality risk, except 
for those with a surgery-related first VTE. Consequently, the cumulative recurrence rates 
dropped in analyses accounting for the competing risk of death, showing a 5-year cumulative 
recurrence rate of 14.4%, 11.7% and 9.7% in patients with a first VTE related to hospitalization 
for other medical illness, cancer or surgery, respectively, whereas the 5-year cumulative 
recurrence rate remained high (16.4%) among patients with a first VTE that was non-hospital-
related. Our findings suggest that patients with a first VTE related to hospitalization for other 
medical illness have a high recurrence risk, even in the presence of competing risk of death, 
indicating that prolonged anticoagulation similar to that recommended for unprovoked VTE 




4.4. Paper IV – D-dimer at venous thrombosis diagnosis is associated with risk of 
recurrence 
D-dimer is essential in the diagnostic work-up of patients with suspected VTE, and 
measurements of d-dimer after discontinuation of anticoagulant therapy is used to aid 
decisions on treatment prolongation. However, whether d-dimer measured at first VTE 
diagnosis can be used to assess recurrence-risk is unknown. We set out to explore the 
association between d-dimer, measured at first VTE diagnosis and risk of recurrent VTE. We 
collected information on clinical risk factors and laboratory markers in 454 cancer-free 
patients with a first VTE enrolled in the Tromsø study, and recorded all recurrent VTEs and 
deaths during follow-up (1994-2012). During a median 3.9 years of follow-up, 84 patients 
experienced a recurrent VTE. The absolute recurrence risk was 1.7 (95% CI: 1.0-2.9) per 100 
person-years in the lower quartile of d-dimer, and 4.9 (95% CI: 3.9-6.1) per 100 person-years 
in the upper three quartiles combined, yielding an absolute risk difference of 3.2 per 100 
person-years. Accordingly, patients with a low d-dimer (≤1500 ng/mL) presented with a 54% 
(HR: 0.46, 95% CI: 0.25-0.82) lower recurrence risk compared to patients with a high d-dimer 
(>1500 ng/mL). Stratification according to the manifestation (DVT or PE) and classification 
(unprovoked vs. provoked) of the index event, revealed that the association was particularly 
pronounced among patients with a low d-dimer and a first DVT and among those with an 
unprovoked VTE. Patients with a first DVT and a d-dimer ≤1500 ng/mL displayed a 68% (HR: 
0.32, 95% CI: 0.14-0.71) lower risk of recurrence, whereas patients with a first unprovoked 
VTE had a 66% (HR: 0.34, 95% CI: 0.15-0.74) lower recurrence-risk, compared to corresponding 
patients with a high d-dimer. These findings advocate that a clinical decision to avoid 
prolonged anticoagulant treatment could potentially be considered based on low D-dimer at 




5. General discussion 
In most epidemiological studies, observations are made on a study sample, and based on 
these observations, inference is drawn onto the population from which the study sample 
comes from. Since we only observe a small part of the target population, we cannot be sure 
that these observations applies to the entire population, and consequently there will always 
be some degree of uncertainty. The research methodology is the key in reducing this 
uncertainty so that inference drawn from a study can be as valid and precise as possible.  
5.1. Methodological considerations 
5.1.1. Study design 
Study I in the present thesis followed the design of a case-crossover study. The case-crossover 
design is a type of self-controlled case series method where cases are selected based on the 
outcome of interest, and each case serves as his or her own control (240). A hazard period is 
then defined based on assumptions of the target person-times at risk from previous studies 
and presumed biological mechanisms. Control periods are designated for comparison, and a 
wash-out period is fitted between the hazard and control periods to avoid potential carry-over 
effects. The exposures of interest are recorded in the risk period and in each of the comparison 
periods to compare frequency of exposures in the risk period compared to control periods. 
The results are expressed in terms of odds ratios (OR), and interpreted as the «odds of being 
exposed to X in the risk period, compared to the control period(s)». This allows for answering 
two important questions: (I) «was the event triggered by something unusual that happened 
just before the event?» and, (II) «how unusual was this?» (240). Case-crossover studies are 
therefore especially suited to study triggers of disease, and allows us to separate acute effects 
from more chronic effects of a given exposure. The key driver of statistical power in case-
crossover studies are the number of discordant pairs, i.e. the number of periods discordant 
with respect to the presence or absence of the exposure. The key strengths of the case-
crossover design is the so called self-matching, in which is each case serves as their own 
control, thereby implicitly controlling for confounding by factors that are fixed within, but 
vary between individuals. The main limitation of case-crossover studies is confounding by 
factors that change over time. Other limitations include that potential trigger factors needs to 
be well defined in order to avoid misclassification and recall bias, challenges in determining 




avoid risk of confounding by factors that vary over time within individuals, comparison 
periods should be fitted as close to the risk period as possible. Furthermore, an inherent 
weakness of this design is the risk of survival bias, as only cases who survive a disease to 
receive a diagnosis may contribute to the results, meaning that those who die before receiving 
the correct diagnosis and in whom autopsy is not performed, are left out. The case-crossover 
design mostly resembles a case-control study, in which cases and controls are compared with 
respect to a given exposure. The main drawback of a case-control study is that information on 
potential exposures are retrieved after the outcome and this information may therefore be 
influenced by the outcome by means of reverse causation or recall bias. Case-crossover 
studies may also be susceptible to recall bias, especially when the information is gathered by 
means of self-administered questionnaires or interviews. However, in paper I, information on 
potential trigger factors were derived from medical records, and recall bias was therefore not 
an issue.  
Papers II-IV in the present study follows the design of a cohort study. In a cohort study, 
information on exposure and various predefined characteristics are collected for each 
participant at the time of enrollment, with subsequent follow-up and outcome registration or 
censoring (e.g. death, migration, or end of the study). Upon study completion, comparisons 
are made between exposed and non-exposed individuals with respect to the outcome. The 
prospective design allows for estimating incidence rates (IR) as a measure of the absolute risk, 
which can be used to derive relative risk estimates, usually expressed in terms of relative risks 
(RR) or hazard ratios (HR), as measures of the strength of association between a given 
exposure and the outcome. The cohort design offers a major advantage in that the exposure 
information is obtained prior to the outcome, thereby satisfying the only absolute criterium 
among Hills criteria for causality, namely the temporal sequence between exposure and 
outcome (i.e. temporality). Satisfying the criterium of temporality also rules out reverse 
causation, a special type of temporal bias, in which the outcome influences exposure status 
(241). Furthermore, most cohort studies offer an adequate sample size, which (given a 
representative sample) improves the internal validity, and permits generalization of the 
results onto the source population or even on to other similar populations (i.e. external 
validity). There are several disadvantages of a cohort study. Most important, a cohort study 
is not sufficient to establish causality, because it does not provide the necessary experimental 




controlled trial (RCT). RCT studies are recognized as the gold standard for making causal 
inference in epidemiology, as the process of randomization makes the comparison groups 
similar in all other aspects apart from the exposure/intervention, thereby drastically reducing 
confounding and bias. However, RCTs are expensive and time-consuming, and may have 
limited generalizability in situations where strict inclusion- and exclusion criteria are applied. 
Furthermore, RCTs may be not be feasible due to ethical concerns. Among other drawbacks 
of the cohort design is that it requires a high number of participants and long-term follow-up 
for an appropriate amount of outcomes to accumulate to yield adequate statistical power to 
detect small differences between comparison groups. This also makes it both time-consuming 
and costly, and it also makes cohort studies poorly suited to study rare diseases with a low 
incidence rate.  
5.1.2. Validity and generalizability  
Validity may refer to screening tests, as the tests ability to distinguish between subjects with 
and without disease, which again is reflected by the sensitivity and specificity of a test (242). 
Alternatively, validity may also refer to the degree to which the results from a study may be 
generalized beyond the study population. In this sense, validity is usually separated into two 
components, internal and external validity (243). Internal validity concerns whether or not an 
observed association is true for the population studied, whereas external validity, often 
referred to as generalizability, concerns whether or not an observed association can be 
transferred to other populations outside the study population as well (243). Most violations 
of internal validity can be classified into three general categories, i.e. confounding, selection 
bias and information bias (243). The Tromsø study is derived from a general population and 
the participation rates were high. Notably, the participation rates among young males <40 
years and among elderly >80 years were low (238), which may reduce the validity of our results 
for these age groups. However, in all studies included in the present thesis, patients were 
selected based on the occurrence of a first-lifetime VTE. The age distribution of the source 
population is therefore less important because the results are not inferred onto the source 
population, but rather patients who suffer a first VTE. 
5.1.3. Confounding and interaction 
In epidemiology, confounding refers to a situation where a non-causal association between a 




confounder (241). A confounder is defined according to three main criteria (244, 245), (i) it 
has to be associated with both exposure and the outcome, (ii) it has to be unevenly distributed 
between the groups of interest and, (iii) 
it cannot be an intermediate step in the 
causal pathway from the exposure to 
the outcome. Confounding can 
influence the risk estimates so that the 
«true» effect is either over- or 
underestimated, or it can even reverse 
the apparent direction of effect (243). 
Use of directed acyclic graphs (DAGs) may help visualize the concept of confounding (Figure 
11). The black arrow between exposure and outcome represents a causal pathway. The 
confounder is associated with both the exposure and the outcome, illustrated by the dashed 
lines, but importantly, not an intermediate step in the causal pathway between exposure and 
the outcome.  
There are three main strategies for dealing with confounding, i.e. randomization, 
stratification/restriction, and statistical adjustments/regression techniques (57). In RCTs, the 
risk of confounding is reduced through the process of randomization, which makes the groups 
equal on all other characteristics than the intervention. Since cohort studies are by nature 
non-randomized with respect to allocation of exposure classification, stratification/ restriction 
or regression techniques are the predominant methods for dealing with confounding. 
Regression techniques is the most frequently used method to reduce confounding in cohort 
studies (246). This entails statistically «conditioning» or «adjusting» on the confounder which 
removes the association (i.e. closes the path in the DAG) between the confounder and the 
exposure or outcome and reduces bias. When using regression to adjust for a confounder, you 
get an estimate of the association between the independent and dependent variables that is 
conditioned for the effect of all the other variables you include in your model. The main 
advantage of using regression to adjust for a confounder is that it takes data from all subjects 
into account (246). Stratification is a second method for approaching confounding in cohort 
studies. Stratification entails dividing your data into subgroups on the variable you believe to 
be confounding the association of interest. In studies on VTE, stratifications on sex and 
whether the event was classified as provoked or unprovoked are common. The main 




advantage of stratification is that you create subgroups that are more similar with regards to 
baseline characteristics than the population as a whole (246). Matching may be viewed as a 
special type of stratification. Potential confounders in papers II, III and IV in the current thesis, 
are age and sex. These were therefore included as covariates in the statistical models, thereby 
conditioning for the effect of age and sex on the examined associations. Alternative ways of 
dealing with age as a confounder would be by using age as a time scale or by 
stratification/restriction. When using age as a time scale comparisons are made between 
individuals who contribute with the same age interval, rather than the same study interval, 
which is generally shown to yield less bias than using time-on study as the time scale (247). 
However, when the baseline hazard is an exponential function of age, the two approaches 
yield identical estimates (247). For the three papers on recurrence (Paper II-IV) in the thesis, 
time to event was used as time scale rather than age, as time to event is more important for 
recurrence, since the recurrence risk is strongly related to the time after a first VTE. In paper 
II, we conducted subgroup analysis stratified on patient sex to account for any possible 
confounding or interaction, as men are generally considered to be at higher risk of recurrence 
than women.  
In studies II, III, and IV, comparison of the baseline characteristics and distribution of 
risk factors indicated that there were only small differences between the comparison groups 
and therefore a low potential for confounding. Nevertheless, there were some dissimilarities 
that needs to be addressed. In paper III, 6% of those with non-hospital-related VTE reported 
to have a positive family history of VTE, as oppose to 1% of those with a hospital-related VTE, 
indicating potential differences in genetic susceptibility for VTE. However, the low prevalence 
of a positive FHVTE in both groups advocates that extensive confounding due to such 
differences is unlikely. In paper IV, patients with a d-dimer value in the lowest quartile tended 
to be treated with anticoagulants for a shorter duration of time compared to those with a d-
dimer in the upper three quartiles. This could potentially be explained by a higher prevalence 
of women with estrogen-related first VTEs and patients with distal DVT among those with a 
low d-dimer, as these patients have previously been shown to have a low recurrence risk (146, 
163, 168, 189, 248). However, subgroup analysis excluding women with estrogen-related VTE, 
and analysis restricted to patients with proximal DVT, produced essentially similar results. 
Furthermore, including the length of anticoagulant therapy in a multivariate model had 




Residual confounding refers to a situation where the effect of a confounder is not fully 
resolved due to incomplete adjustments (241). Residual confounding can occur in cohort 
studies when there are unknown, unmeasured or misclassified confounders, or when the 
stratification categories are broad. Despite rigorous efforts to minimize confounding, residual 
confounding will always remain a challenge in observational studies. 
The term interaction may refer to either (i) statistical interaction or, (ii) biological 
interaction, which are profoundly different. Statistical interaction, also known as effect 
modification, is used to describe a situation in which two or more independent variables are 
correlated, such that the effect of the exposure variable on the outcome differs across the 
level of another covariate, i.e. an effect modifier (241). Statistical interaction is dependent on 
the statistical model relative to the nature of the interaction (i.e. additive, multiplicative, 
synergistic, antagonistic, etc.) (57). Statistical interaction needs to be distinguished from the 
phenomenon of confounding, as it rarely influences the «true» association, but rather 
produces risk variation across levels of the effect modifier. Biological interaction however, 
refers to a situation in which two or more causes of disease together exert their effect on 
disease risk (249), which results in departure from additivity of disease risk (249, 250). 
Biological interaction can be approached in several ways, e.g. by assessing the synergy index, 
or by calculating the relative excess risk due to interaction or the proportion attributable to 
interaction.  
5.1.4. Bias and misclassification 
Bias may be defined as «any systematic error in the design, analysis or conduct of the study 
that results in the mistaken estimate of an exposures effect on the risk of a disease» (242). 
Most biases in epidemiology occur under the caption selection- or information bias.  
 Selection bias refers to any systematic error in the enrolment or retention of study 
participants, which influences the association between exposure and outcome (241). 
Selection bias occurs when the study-subjects are not representative of the target population 
about which conclusions are to be drawn (251). Selection bias can be particularly severe in 
RCTs because of high non-participation, strict inclusion or exclusion criteria, and because the 
intervention may only be appropriate for a part of the target population (57). Cohort studies 
are also vulnerable to selection bias due to self-selection, in which the subjects who volunteer 




minimized due to the high participation rates, with an average of 78.5% across Tromsø 1-6. 
However, selection bias caused by non-responders will always be an issue. As previously 
mentioned, many of the non-attendees in the Tromsø study were young single males. 
Additionally, the participation rates among patients >80 years were low (238). As participation 
required physical presence at the study site, elderly people with poor health could have had 
trouble to attend. High rates of non-responders in these groups may reduce the 
generalizability of our results onto these age groups. In the studies included in the thesis 
however, the participants were selected based on the occurrence of a first VTE event. Since 
all incident and recurrent VTE events were identified from a single hospital, which is the 
exclusive provider of all VTE-related health care and diagnostic radiology procedures within a 
250-km radius, complete identification of all outcomes is conceivable, and the chance of 
selection bias is likely minimized. Nonetheless, missed outcomes due to patients treated and 
diagnosed elsewhere, or that patients with classical signs and symptoms were diagnosed and 
treated in primary care, could be a potential source of bias. However, any bias due to the latter 
is highly unlikely, as the diagnosis and treatment of VTE relies on strict criteria and requires 
diagnostic procedures only available at hospitals.  
The best way to reduce selection bias in cohort studies is by careful selection of 
comparison groups. The goal is to find a comparison group that is as similar as possible to the 
exposure group on all other variables, except from the exposure (252). In choosing 
comparison groups, restriction is a powerful way of reducing selection bias, in which the 
groups you are to compare are selected based on a set of predefined characteristics. By 
restricting, you will reduce differences related to these characteristics and have more similar 
comparison groups.  
Differential losses to follow-up is another form of selection bias, which occurs in 
epidemiological studies when the participants lost to follow-up differ from the subjects 
remaining under observation (241). This problem is particularly evident in the case of cancer 
and VTE, where the competing risk of death has been shown to produce an overestimation 
of the associated risk (221). In conventional survival analysis, death is usually handled as a 
censoring event, meaning that those who die do not contribute with more person-time 
beyond that point. Importantly, a requisite of survival analysis is the assumption of random 
censoring (also called non-informative censoring), meaning that all study subjects should have 




differ with regards to mortality risk, they also differ with regard to the probability of being 
censored by death. Consequently, the person-times at risk among patients with cancer-
related VTE is reduced due to non-random censoring by death, producing an overestimation 
of the recurrence risk. One way of handling the competing risk of death is the statistical 
method proposed by Fine and Grey by use of sub-distribution hazard, which treats death as a 
competing event rather than a censoring event (253). This method was used in papers II-IV in 
the thesis, and produced weaker risk estimates compared to regular Cox proportional hazard 
methods, indicating that overestimation due to differential loss to follow-up had occurred.  
 Index event bias, also known as collider stratification bias, is a type of selection bias 
that is common in studies on disease recurrence, as subjects are selected based on the 
occurrence of an index event (254). This selection induces dependence between risk factors 
and influences the distribution of risk factors among the enrolled participants, which may 
affect the association between the independent exposure variables and the outcome. Index 
event bias will often bias studies toward the null, causing the contribution of the risk factors 
to be substantially underestimated or even reversed (254). Index event bias may help clarify 
why true causes of VTE, such as age and thrombophilia, are rather poor predictors of 
recurrence, a phenomenon known as «the Paradoxes of Recurrence» (59). Index event bias is 
of particular concern in paper III of the thesis when comparing the recurrence risk among 
patients with hospital- and non-hospital related VTE. As previously described, hospitalized 
patients are often exposed to multiple concurrent risk factors, whereas those with non-
hospital related VTE compose largely of patients with unprovoked VTE. This selection 
particularly influences the distribution of risk factors among the enrolled participants. 
Moreover, as almost half of all VTE cases have an unknown etiology, there could be residual 
confounding due to unknown risk factors operating to cause the disease (254).  
Information bias refers to an error in the methods used for gathering information 
about the study participants that results in inaccurate or erroneous information regarding 
exposures or outcome (242). Information bias may lead to misclassification, which refers to 
the incorrect allocation of study participants according to exposure or disease status. 
Misclassification predominantly occurs when the means of gathering information on the study 
participants are inadequate so that the information on exposure/outcome is incorrect (242). 
Misclassification can be random/non-differential or non-random/differential. Non-




of the outcome, and results in equal amount of participants being misclassified in each 
direction. Differential misclassification on the other hand, occurs when the misclassification 
of exposure or the outcome is dependent of the other, resulting in either an apparent 
association or an apparent lack of association that is untrue (57, 242). In the Tromsø study, 
self-administered questionnaires were used to obtain information on a broad spectrum of 
variables and characteristics of the participants. A particular problem with this way of 
gathering information is that it may introduce misclassification, as some questions may be 
open for interpretation, they may be misunderstood or skipped entirely. Furthermore, the 
potential for recall bias in questionnaires is considerable if the participant has an inaccurate 
recollection of exposure information, or the exposure information may be influenced by the 
outcome. The latter is a particular problem of case-control studies, in which exposure 
information is collected after the outcome, as this could give rise to differential 
misclassification. In cohort studies however, information bias will normally be non-differential 
because of the temporal sequence between registration of exposure and outcome, meaning 
that any observed association will tend to be diluted. The vulnerability for information bias in 
self-administered questionnaires can be reduced by using validated questionnaires.  
In all four studies of the thesis, information on the most important exposure variables 
and clinical risk factors was derived from retrospective review of medical records. The 
information therefore relied on thorough reporting from the doctors, nurses and other health 
care professionals. Any information not reported in the medical records could not be taken 
into account, and could potentially have led to exposure misclassification because the 
exposure variable or risk factor was considered absent. However, most of the main exposure 
variables in each paper were hospital-related risk factors, such as cancer, surgery and other 
medical illness. These are major clinical events, and it is unlikely that these were 
underreported and thereby a source of misclassification. Immobilization on the other hand, 
might be more vulnerable to misclassification. Immobilization was of particular interest for 
paper I in the thesis. For this paper, information on immobility was mainly extracted from the 
nurse’s report in the patient’s medical records. The nurse’s report is a thorough day-to-day 
record, encompassing daily functioning, activity level, mobility and ambulation, nutrition, 
sleep, fluid balance and bowel function, among other things. These records are standardized 
and reported by each nurse during a work-shift. Consequently, there is a high probability that 




particularly among those who were severely immobilized. However, in patients with moderate 
restrictions of mobility, there might have occurred some underreporting. In this context, any 
misclassification due to missed information on immobilization would lead to an 
underestimation of the observed association between hospitalization, immobility and VTE.  
Information gathered on laboratory markers may be another potential source of 
exposure misclassification, as the blood sample extraction and laboratory analysis may be 
prone to technical errors. In paper IV, the laboratory marker d-dimer was the main exposure 
variable and was investigated as a predictor of recurrence. Information on d-dimer was 
extracted from medical records, and represents blood samples taken and analyzed at first VTE 
diagnosis. These tests were also subject to measurement errors. However, these are most 
likely random errors and would therefore serve as a source of non-differential 
misclassification. Furthermore, we had a large cohort of 454 VTE cases and d-dimer was 
modeled in relatively broad categories by dividing the study population into quartiles, which 
would serve to reduce the effect of any such measurement errors.  
In all the studies of the present thesis, misclassification of VTE cases as false-positives 
were largely avoided by using strict criteria for case validation, combining signs and symptoms 
with objective confirmation tests with a subsequent diagnosis that required treatment. 
Identical criteria were used for identification and validation of incident and recurrent VTE 
events. In the case of recurrences, all patients presenting with new or reoccurring signs and 
symptoms of DVT or PE, whether or not this event was clinically and phenotypically similar as 
the index event, and whether it affected the same vein or not, were regarded as a recurrent 
event. Accordingly, we could not completely differentiate between a recurrence and a relapse, 
which could give rise to some outcome misclassification. Moreover, the hospital registries 
used for case validation were retrospectively reviewed, meaning that any information not 
reported in the medical records was lost, which could potentially lead to misclassification.  
5.1.5. Missing data 
Missing data is a concept all studies have to deal with, and the prime concern is whether the 
missing observations bias the available data (255). There are three main approaches for 
handling missing data: (i) omitting variables with many missing observations, (ii) omitting 
individuals with incomplete data, and (iii) estimating what the missing values were (i.e. 




missing data on d-dimer. This could potentially introduce bias. However, comparison of the 
patient characteristics and the incidence rates of recurrence among those with and without 
missing values, showed that the groups were essentially similar in most respects, indicating 
that the missing value was presumably at random, and any misclassification that might have 
occurred due to missing d-dimer values is likely non-differential.  
 As information on the most important exposure variables in the papers of the present 
thesis relied on comprehensive and exact documentation from health care professionals in 
medical records, some independent variables may also be prone to missing data. For instance, 
in VTE cases that occurred in the presence of an obvious provoking factor (e.g. surgery or 
trauma), the treating physician might not have considered to ask the patient about family 
history of VTE, hormone replacement therapy or other minor risk factors considered to be 
insignificant at that time-point. Again, as the main exposure variables were major clinical 
events (e.g. hospitalization, cancer, surgery, other medical illness), they were less likely to be 
missed by the treating physicians, and the probability of differential misclassification on 




5.2. Discussion of main results 
5.2.1. Hospitalization as a trigger of venous thromboembolism 
In paper I, we reported that hospitalization was a major trigger factor for VTE, associated with 
a 9-fold higher risk of VTE. Importantly, hospitalization was a trigger factor also in the absence 
of immobilization, emphasizing that hospitalization is a high-risk situation even in patients 
who are hospitalized without restricted mobility. Although the role of hospitalization as a risk 
factor for VTE has been extensively studied, the role of hospitalization as a trigger factor for 
VTE is not well documented. Most previous studies on hospitalization and risk of VTE are case-
control or cohort studies that are designed to answer the question «why me?». However, it is 
equally important to answer the question «why did this disease occur right now?», for which 
case-crossover studies are especially suitable. Results from a nested case-control study of 624 
patients with a first VTE and 635 patients without VTE, reported that institutionalization 
(hospital- or nursing home confinement) was independently associated with an 8-fold 
increased risk of VTE (63). In the AT-AGE study, a case control study of elderly individuals, 
hospitalization was associated with a 15-fold higher risk of VTE within the first 2 weeks 
following hospital-discharge (78), and in a recent cohort study, the risk of VTE was 35-fold 
higher in the 92 days following hospitalization (104). Few studies have addressed the role of 
hospitalization as a trigger of VTE. In a previous case-crossover study, immobility defined as 
any non-surgical hospitalization or skilled nursing home facility stay, was found to be a 
significant trigger associated with a 4.2-fold higher VTE risk (141). Interestingly, this 
association was not markedly influenced by adjustments for other hospital-related factors, 
such as major surgery, infection, blood transfusion, use of central venous catheter, injuries 
and medication. Compared to our results, these risk estimates were considerably lower, 
however, the studies differ profoundly with regards to patient selection and exposure 
definition, which could potentially explain some of the observed differences.  
 Although hospitalization was a major trigger for VTE in the absence of immobility, the 
VTE risk was augmented in patients who were concurrently immobilized, as the OR for 
hospitalization with immobilization was essentially 3-times higher than the OR of 
hospitalization without immobilization. Even though immobility often concur with 
hospitalization, the role of immobility in the hospitalized setting has previously not been well 




on immobilization and VTE-risk among hospitalized inpatients (81), immobilization was 
associated with a relative risk of 1.5 across 7 cohort studies and a 2.5-fold higher odds of VTE 
across 3 case-control studies. Results from two previous case-control studies on elderly 
patients (66, 78), reported that immobility mediated the risk of VTE in a dose-response related 
manner, depending on both the type and duration of immobility, with the highest risk 
estimates among patients who were bedridden in hospital. Furthermore, three recent case-
crossover studies derived from the Tromsø study, emphasized the mediating effect of 
immobility alongside hospitalization with infection, stroke or myocardial infarction (143, 144, 
256). Notably, patients who are immobilized in-hospital more often receive 
thromboprophylaxis than those who are not (257), which could lead to an underestimation of 
the observed risk.  
 Hospitalization per se is not likely a causal factor for VTE, but certainly a strong 
predictor and may therefore act as a proxy for other causal hospital-related risk factors. 
However, both hospitalized medical- and surgical patients, constitute a heterogeneous 
population ranging from those receiving weeks of ICU care to those briefly admitted to general 
wards for elective diagnostic procedures. Consequently, the individual VTE risk associated 
with hospitalization depends upon patient-related risk factors (i.e. age, sex, obesity, 
comorbidities, thrombophilia), as well as the reason for hospital-admission (i.e. acute medical 
or surgical illness, infection, cancer, trauma), in-hospital medical or surgical procedures and 
degree of mobility. Furthermore, the risk can be directly related to the number of present risk 
factors (68, 70, 79, 107). However, the separate as well as the mutual interaction between 
genetic and acquired risk factors is complex (258, 259), as many risk factors act synergistically 
amplifying the risk multiplicatively rather than the additively (258, 259). This highlights the 
multi-causality of VTE and that interaction between risk factors is especially relevant in the 
hospitalized setting, as multiple concurrent risk factors (e.g. surgical- or medical illness and 
immobility) are particularly common among hospitalized individuals. Appropriate risk 
stratification among hospitalized patients is extremely challenging, and identification of risk 
factors, or in particular, combination of risk factors which have a high thrombotic potential in 
hospitalized individuals is crucial for disease prevention. This concept and the multi-causal 
nature of hospital-acquired VTE may be illustrated in a thrombosis potential model (Figure 
12). In this example, a hospital-admission early in life produced a transient increase in the 




together with a hospital-
admission accompanied by 
immobilization, produced a 
synergistic amplification in the 
thrombosis potential, and the 
employment of a central venous 
catheter during hospitalization 
triggered an overshooting of the 
thrombosis threshold.   
Importantly, we found that the triggering effect of hospitalization was associated with 
the length of hospital stay, but not with the frequency of hospital admissions in the 90-days 
prior to VTE diagnosis, highlighting hospitalization as a high risk situation that is mainly 
dependent on duration rather than the frequency of exposure. Few observational studies have 
explored the role of duration and frequency of hospital stay with respect to VTE risk. In a 
previous case-control study of older adults (112), hospitalization for 4 to 6 days and for more 
than 7 days was associated with a 2.4- and 3.4-fold increased risk of VTE, compared to patients 
who were hospitalized for 0-3 days. Furthermore, results from a matched case-control study 
(111), showed that each additional hospital admission in the 90 days preceding VTE diagnosis 
approximately doubled the risk of VTE, and the risk increased with 17% for each additional 
day spent in hospital. In comparison, we found that the VTE risk increased with 11% per one 
day increase in total days spent in hospital during the 90-days prior to VTE diagnosis, and the 
risk was 5-fold in those with hospital admissions for≥5 days compared to those with shorter 
hospital stays (i.e. 1–4 days). However, there were no substantial differences in VTE-risk in 
those with a single hospitalization (OR: 8.9) compared to those with ≥2 hospitalizations (OR: 
12.3) prior to their VTE. Furthermore, after conditioning on the length of hospital stay there 
was no differences in the risk of VTE in those with one compared to ≥2 hospitalizations. In a 
recent study (260), Amin et al found that length of hospital stay was associated with VTE both 
during hospital stay, as well as within the 6 months beyond hospital-discharge in patients 
hospitalized for acute medical illness. Importantly, the study showed that a higher proportion 
of patients with longer duration of hospital stay received thromboprophylaxis, which could 
indicate that the true association between length of hospital stay and risk of VTE might be 
underestimated. Furthermore, the study showed that increased length of hospital stay was 
Figure 12 The thrombosis potential model in a hospitalized 




associated with older age and greater comorbidity, and presumptively, length of stay likely 
correlates with disease severity and immobility, which may be assumed to mediate the VTE-
risk among these patients.  
In summary, our findings highlight that hospitalization is a major trigger of VTE also in 
the absence of immobilization. However, the VTE risk among hospitalized patients is strongly 
augmented by concurrent immobilization. Furthermore, the hospital-related VTE risk is mainly 
dependent on the length of hospital stay rather than the frequency of admissions.  
 
5.2.2. Recurrence and mortality after incident venous thromboembolism  
In paper II, we presented results on recurrence and mortality rates among patients who had 
experienced a first lifetime VTE recruited from a large cohort derived from the general 
population. The crude recurrence rate was 3.9 per 100 patients-years, but was 4-fold higher 
in the initial 6 months after a first VTE compared to the period 5-10 years after VTE (IR: 9.2 vs 
2.3 per 100 person-years, respectively). The cumulative recurrence rates were 4.3% at 6 
months, 7.2% at 1-year, 18.8% at 5-years and 28.3% at 10-years, respectively, but varied 
according to patient sex (35.4% in men vs. 22.0% in women at 10-years) and classification of 
the initial VTE event as unprovoked, provoked or cancer-related (17.9% vs. 16.7% vs. 26.4% at 
5-years, respectively). In a previous cohort of patients with a first VTE in the period 1960-1999 
from Olmsted County (145), the reported cumulative recurrence rates were 30.4% at 10-years. 
The corresponding cumulative recurrence rates were 12.9% at 1-year, and results from the 
more recent (1999-2003) Worchester study (155), showed that the cumulative incidence of 
recurrence was 10.9% at 1-year. In comparison, the 1-year probability of recurrence was 7.2% 
in our study, which is almost half of that reported in the former cohort from Olmsted County. 
We found that >60% of the VTE patients were treated with anticoagulants for 3 months or 
more, and almost 30% were treated more than 6 months after the incident VTE. Moreover, 
the majority of patients with isolated calf DVT in our study received anticoagulant treatment. 
Accordingly, the improved short-term recurrence rates may to some extent be attributable to 
improved treatment strategies recent years. Conversely, our results on long-term recurrence 
rates are largely similar to those of previous studies, which provides further evidence for a 
«catch-up» effect or «rebound phenomenon», in which recurrences appear to aggregate 




certain whether this reflects a return to the previous prothrombotic state (i.e. catch-up), or a 
transient overshooting with subsequent normalization of coagulation (i.e. rebound) (264). 
Consequently, recent advances in treatment and diagnosis of VTE have not improved the rates 
of long-term recurrences following a VTE, which persists even a decade after a VTE.   
The mortality rates were high, especially among cancer patients, who presented 
cumulative all-cause mortality rates of 19.4% and 62.0% at 30-days and 1-year, respectively. 
The corresponding rates were 9.0% at 30-days and 16.6% at 1-year among cancer-free 
patients. Accordingly, when the competing risk of death was taken into account, the 
cumulative recurrence rates dropped substantially among cancer patients, from 26.4% at 5-
years in conventional 1-KM analysis to 11.4% in the competing risk analysis.   
In accordance with previous studies (147, 163, 265), the clinical manifestation of the 
primary VTE as DVT or PE predicted the phenotype of the recurrent event, with a 2.4-fold 
higher risk of recurrent PE than DVT among patients with index PE. Likewise, patients with a 
first unprovoked VTE were more likely to have a second unprovoked VTE, however, VTE 
recurred at similar rates as provoked and unprovoked in patients with a first VTE that was 
provoked. This observation could potentially be explained by provoking factors or 
comorbidities which could invoke a persistently elevated thrombosis potential, or by other 
factors which increases the baseline thrombosis potential, such as residual vein thrombosis or 
local damage at the initial thrombus site which may lead to impaired endothelial function with 
subsequent loss of anticoagulant properties in the vessel wall. The thrombosis potential model 
may be used to demonstrate this concept. After a first episode of VTE, three things can happen 
to the thrombosis potential: it can either increase, stay the same or decrease (59). This 
concept relates to the nature and influence of different risk factors on the course of the 
disease. In the case of transient risk factors (e.g. surgery or pregnancy) (Figure 13, panel A), 
the thrombotic potential is lowered immediately once the risk factor is removed, given that 
the effect of the risk factor is reversible. However, when a VTE event is unprovoked or 
provoked by a persistent or irreversible risk factor, the thrombotic potential may either stay 
the same or even increase. In patients with unprovoked VTE (Figure 13, panel C), the causes 
of the index event persist, and the thrombosis potential stays the same. In the presence of a 
persistent risk factor such as cancer (Figure 13, panel B), the post-VTE thrombotic potential 
may stay the same, or even increase due to metastasis, disease progression or disease-related 





dysfunction, may influence the 
recurrence risk as a result of an 
elevated baseline thrombosis 
potential as illustrated in panel B 
and C. This notion may be 
supported by findings from a 
recent study, showing a similar 
recurrence risk among patients 
with VTE provoked by minor 
persistent or transient risk factors 
as in those with a unprovoked VTE 
(266), but could also suggest a 
higher intrinsic baseline thrombus 
potential among these patients. 
Likewise, in a retrospective study of 
cancer-free VTE patients (197), the 
risk of recurrence following travel-
related VTE, normally classified as a 
minor transient risk factor, was 
found to be comparable to that of 
unprovoked VTE, thus 
substantiating the claim of a high 
baseline thrombosis potential in 
patients with VTE provoked by 
minor risk factors, which could be further elevated by disease-related factors induced by the 
first VTE event. Furthermore, even in patients with VTE provoked by surgery, a major transient 
risk factor, the recurrence rates exceeds the rates of incident VTE in a general population, 
indicating that the risk does not fully return to baseline after a first VTE (198), which could 





Figure 13 The thrombosis potential model demonstrating the 
influence of a transient (A) and persistent (B) provoking factor, 
alongside unprovoked VTE (C) on the risk of recurrence. Adapted 




5.2.3. Hospital-related venous thromboembolism and risk of recurrence   
In paper III, we found that the risk of recurrence among patients with a hospital-related first 
VTE was similar to those with a non-hospital-related VTE (including unprovoked VTEs), but 
varied considerably according to the reason for hospitalization in conventional Kaplan-Meier 
analyses. The recurrence risk was similar in patients with a VTE related to hospitalization for 
medical illness and in those with non-hospital-related VTE, and in accordance with previous 
studies (145, 153, 193, 194, 196, 211), patients with a cancer-related VTE had a high 
recurrence risk, whereas those with a surgery-related index event had a low recurrence risk.   
 The mortality rates following a hospital-related VTE were 3-times higher than among 
patients with VTE not related to hospitalization, and they were elevated in all subgroups of 
hospital-related VTE, except in patients with VTE related to surgery. Our findings of a 6- and 
2-fold higher mortality risk among patients with cancer and acute medical conditions are 
consistent with previous studies (20, 32, 35, 236, 267, 268). Accordingly, the cumulative 
incidence of recurrence were lower in competing risk of death analysis, particularly among 
those with cancer-related VTE. In this analysis, patients with cancer-related VTE presented 
with lower cumulative recurrence rates than those with VTE related to hospitalization for 
other medical illness, as well as in patients with VTE not related to hospitalization. In the 
presence of competing risk of death, the cumulative recurrence rate is dependent on both the 
hazard of recurrence and the hazard of dying. Consequently, differential losses to follow-up 
due to dissimilarities in mortality risk between the groups compared might bias the risk 
estimates towards an overestimation of the recurrence risk (220, 221, 269). Our results 
confirmed this observation, however, the degree of the competing risk of death varied 
between subgroups, and as expected, the largest change in risk estimates was observed in 
patients with cancer, where the cumulative recurrence rate dropped from 27.4% at 5-years in 
conventional analysis to 11.7% in analysis accounting for the competing risk of death. These 
results emphasize the importance of competing risk regression to produce accurate risk 
estimates in situations where the comparison groups differ with regards to a competing event.  
 In paper I, we showed that hospitalization was a major trigger factor for VTE associated 
with a 9-fold higher risk. The low recurrence risk among patients with VTEs provoked by 
transient reversible risk factors is widely acknowledged. Accordingly, the transient nature of 
hospitalization could imply a low recurrence risk. However, in paper III, a recent (within 8 




which is also in line with the results from a previous cohort study (145). However, there 
appeared to be considerable heterogeneity depending on the reason for hospitalization. 
Patients with a VTE related to hospitalization for medical illness other than cancer or surgery, 
had a high recurrence risk in both conventional and competing risk analysis, which could imply 
a persistently elevated thrombosis risk following the first VTE. Two previous observational 
studies have indicated a higher recurrence risk among patients with VTE related to 
hospitalization for medical illness (147, 149). Furthermore, in a recent study using data from 
2 RCTs comparing Rivaroxaban with Aspirin for extended VTE treatment (266), the recurrence 
rates did not significantly differ between patients with incident VTE provoked by a minor 
persistent- or a minor transient risk factor and in those with unprovoked VTE (HR: 0.82 and 
HR: 0.68, respectively). In this study, inflammatory bowel disease, lower extremity paralysis 
or paresis and congestive heart failure, (among others) were classified as minor persistent risk 
factors, whereas immobilization, travel >8 hours and lower limb trauma with transient 
impaired mobility (among others) were classified as minor transient risk factors. The diversity 
in recurrence risk within each subgroup of provoked and unprovoked is further emphasized 
by recent findings from the MEGA-study (199), which found that men with a VTE provoked by 
other factors than surgery and a high d-dimer level had a high absolute recurrence risk of 6.8% 
per year, which was essentially similar to that among men with an unprovoked VTE and a high 
d-dimer level. Conversely, women with a first unprovoked VTE and a low d-dimer had an 
absolute recurrence risk of 2.3% per year, which was virtually similar as that of patients who 
had a first provoked event.  
There are several identified pathophysiological mechanisms supporting the notion of 
a prothrombotic state related to medical illness, as chronic heart- and lung disease, as well as 
autoimmune and inflammatory conditions, have been shown to influence the balance 
between coagulation and fibrinolysis (71, 73, 216-218), as well as endothelial- and platelet 
function (71, 73, 216-218). Additionally, these are chronic conditions which cause a persistent 
or intermittent inflammatory state (71, 73, 216, 217), which may add to the elevated 
thrombosis potential. Furthermore, disease specific mechanisms, such as hypoxia in COPD 
patients (216) and right ventricular failure with subsequent venous stasis in patients with 
congestive heart failure (217, 218), may add to the VTE risk, and flare-up periods (73, 74, 215) 
or exacerbations (270, 271) that lead to re-hospitalization may in itself cause a transiently 




previous case-cohort study (149), interim rehospitalization for medical illness after a first VTE 
was reported to be associated a 6-fold increased risk of VTE recurrence, and the risk remained 
increased for at least 92-days following discharge. In our study, 31.1% and 21.6% of the 
hospital-related VTEs were related to surgery and acute medical conditions, respectively. In 
comparison, among patients with a hospital-related first VTE who suffered a recurrence, 
13.7% of the recurrences were related to surgery and 17.6% were related to acute medical 
illness. Consequently, it is likely that re-exposure to potential triggers occur more frequently 
among medical- than surgical patients, which could further explain the high recurrence rates 
observed among medically ill patients.  
Current guidelines recommend short-term (3 months) over indefinite anticoagulant 
treatment in patients with a VTE provoked by a non-surgical transient risk factor (157). 
Considering that VTEs related to hospitalization for medical illness might invoke a more 
persistent underlying VTE risk, prolonged treatment similar to those recommended for 
unprovoked VTE might be justified. 
 
5.2.4. D-dimer and risk of recurrence  
In paper IV, we found that patients with a low d-dimer level (≤1500 ng/mL) at first VTE 
diagnosis had a markedly lower recurrence risk compared to patients with a high d-dimer 
(>1500 ng/mL), with an absolute risk difference of 3.2 (IR: 1.7 vs. 4.9) per 100 person-years for 
a d-dimer above and below 1500 ng/mL, respectively. The association was particularly 
pronounced among patients with a low d-dimer and a first DVT and among those with an 
unprovoked event, displaying a 68% and 66% lower recurrence risk compared to 
corresponding patients with a high d-dimer, respectively. Although the predictive value of d-
dimer measured after withdrawal of anticoagulant treatment is extensively documented (224, 
227, 234, 272), to our knowledge, no previous study has addressed the predictive ability of d-
dimer, measured at index VTE diagnosis, on the risk of recurrence. The absolute recurrence 
rates in the lowest d-dimer category in the present study concur with other studies on the 
recurrence rates among patients with a normal d-dimer (i.e. <500 ng/mL) assessed after 
withdrawal of anticoagulant therapy (224, 234, 272). However, whether d-dimer levels 
measured after anticoagulation can be used to select patients at low risk of recurrence who 




recurrence rates in patients with a low d-dimer was 1.7% at 1-year and 8.5% at 5-years. The 
corresponding rates among patients with a first unprovoked VTE and a low d-dimer was 1.4% 
and 10.5% at 1- and 5-years, respectively. Importantly, these rates are below the rates 
considered acceptable to justify stopping anticoagulation (5% at 1-year and 15% at 5-years) 
according to the recommendation from the Subcommittee on Control of Anticoagulation of 
the International Society of Thrombosis and Haemostasis (273). However, because of limited 
statistical power in subgroups, some of the confidence intervals exceeded the upper limit of 
the recommended rates, meaning that these findings should be interpreted with some 
caution. Furthermore, we do not know whether the patients with a low pre-treatment d-dimer 
are the same patients as those with negative d-dimer after discontinued anticoagulation, 
especially in view of studies indicating a transient period of rebound hypercoagulability 
following withdrawal of anticoagulation (264, 274, 275), with a successive increase in d-dimer 
formation accompanied by thrombin generation.  
Our findings could have important implications. First, as d-dimer is widely available for 
most patients at the time of VTE diagnosis, the potential use of d-dimer to identify patients at 
low recurrence risk may have great clinical utility for the initial decision on treatment duration 
and further follow-up of the patients. Current risk prediction models, such as the Vienna 
prediction model (146), the DASH prediction rule (276), and the Men continue and HER DOO2 
rule (277), all make use of d-dimer tests during or after anticoagulation, together with clinical 
predictors, to discriminate between patients at high and low risk of recurrence among those 
with a first unprovoked VTE. The clinical components in these prediction models can usually 
be assessed at the initial patient examination. Thus, if pre-treatment d-dimer assessment can 
replace current use of post-anticoagulation d-dimer in future prediction models to detect 
patients at low risk of recurrence, it may prove valuable for the patients, as well as for the 
clinician and the health care system. For the patients, information on the disease prognosis 
may provide appreciated reassurance and, as the need for additional blood sampling is 
reduced, they will avoid additional discomfort, as well as additional sick leave to attend follow-
up outpatient visits. For the clinicians, it may provide the opportunity to make decisions on 
treatment duration upon hospital discharge, and reduce the need for additional outpatient 
care after discontinued treatment, saving both time and resources for the health care system.  
Current treatment guidelines recommend an initial 3 months of therapy, followed by 




VTE (157). To aid this decision, the guidelines suggest stopping anticoagulation and repeating 
d-dimer measurements after 1 month. Importantly, withholding anticoagulation for 1 month 
in patients with a high recurrence risk before repeating d-dimer measurements, implies a 
transient elevation of recurrence risk during this period without anticoagulant protection. 
Thus, if d-dimer levels at incident VTE diagnosis could be used to detect high risk patients as 
well, the transient increase in recurrence risk accompanied by withheld anticoagulation could 
be avoided. In the present study, we found a high recurrence risk among patients with a high 
d-dimer, which was similar across the upper 3 quartiles, with a 10-year cumulative incidence 
approaching 35%, compared to 14.4% in quartile 1. The corresponding estimates at 1- and 5-
years were 6-9% and 23-24% in the upper quartiles, compared to 1.7% and 8.5% in quartile 1. 
The results were similar or even more pronounced among those with a first DVT or 
unprovoked VTE, although not as consistent in subjects with provoked VTE and PE. 
Accordingly, the majority of recurrences occur beyond the initial year after a VTE, indicating 
that VTE prevention strategies needs to be tailored for the long-term. Our findings and those 
of others (223, 224, 227, 234, 272), show that d-dimer can be useful to distinguish patients at 
high and low risk of recurrence, and could therefore also potentially be used to aid decisions 
on prolonged treatment. Ideally, given the high rates of recurrence in the long-term, all 
patients with a high d-dimer would be offered indefinite antithrombotic therapy. However, 
the decision to sustain treatment is complicated by the increased risk of bleeding 
accompanied by anticoagulation. In a recent study, elevated d-dimer >8.3 g/mL (upper 20th 
percentile) was associated with a 2.6-fold increased risk of major bleeding in the initial 3 
months of anticoagulation after VTE (278). This implies that particular attention and careful 
consideration of the risk-to-benefit ratio are warranted among those with the highest d-dimer. 
The latest guidelines are the first to implement DOACs as the primary choice of 
anticoagulation for most patients. The introduction of DOACs has improved the safety of 
anticoagulant therapy considerably, with a substantial decrease in the risk of bleeding (156). 
Consequently, the improved safety of DOACs could have implications for the decision on 
treatment duration and secondary prophylaxis, as more patients could be treated indefinitely 
with an acceptable risk of bleeding.  
In the present study, patients with a low d-dimer (≤1500 ng/mL) appeared to be 
treated for a shorter duration of time with anticoagulants compared to those with a high d-




with estrogen-related first VTEs and patients with distal DVT among those with a low d-dimer, 
as these patients have previously been shown to have a low recurrence risk (146, 163, 168, 
189, 248). Our results could therefore have been driven by such low-risk subgroups. To test 
this hypothesis, we conducted sensitivity analyses excluding patients with estrogen-related 
VTE and analysis restricted to those with proximal DVT. The results showed no substantial 
differences compared to the results of the overall analysis and analysis of all DVT patients, 
indicating that no bias had occurred on account of these subgroups. Additionally, adjusting for 
length of anticoagulation and accounting for the competing risk of death produced essentially 
similar results.  
Another issue of concern in this study, was that two different d-dimer assays were used 
in the study period, i.e. the NycoCard D-dimer (Nycomed Pharma, Oslo, Norway) and the 
STA®Liatest® D-Di FM from Stago (Diagnostica Stago, Asniereès, France). The two tests are 
principally different as the NycoCard assay is based on the immunometric flow-through 
principle, whereas the Sta-Liatest is based on the immunoturbidimetric method. The Sta-
Liatest has consistently been reported to produce excellent analytical properties (279-281), 
whereas conflicting results exist regarding the NycoCard d-dimer assay (282-284). Analytical 
differences between these tests could potentially have biased our results. However, the 
NycoCard d-dimer assay was used in the period 1994-1998, and the Sta-Liatest was used in 
the remaining period from 1998-2012. Over 90% of the VTE events occurred in the time-period 
in which the Sta-Liatest was used, and the majority of d-dimer measurements were therefore 
assessed using the Sta-Liatest. Furthermore, we performed sensitivity analysis restricted to 
include only measurements using the validated Sta-Liatest, which revealed no significant 
differences in our results, meaning that comprehensive misclassification due to poor analytical 
properties of the NycoCard assay is unlikely.  
In summary, a low d-dimer measured at incident VTE diagnosis identified a quarter of 
the patients as having a low recurrence risk. Stratified analysis revealed that the association 
was particularly pronounced among those with a first DVT or an unprovoked index event. 
These findings suggest that d-dimer, measured at first VTE diagnosis could potentially be used 
to guide decisions on duration of antithrombotic therapy. However, this study has novel and 





 We found that hospitalization was a major trigger factor for VTE, and that the risk mainly 
depended on the length of hospital stay rather than the exposure frequency (i.e. the 
number hospitalizations). Furthermore, hospitalization was a major trigger also in the 
absence of immobilization, although, the VTE risk among hospitalized patients was 
augmented by concurrent immobilization, putting further emphasis on hospitalization as 
a high-risk situation even in the absence of immobilization.  
 
 We found that the rates of adverse events following a first VTE remain high, despite recent 
advances in the diagnosis and management of VTE patients. VTE recurs at particularly high 
rates in the first year following diagnosis. However, the rates remain high for at least 10-
years following the index event, supporting the notion that VTE is a chronic disease with a 
high recurrence risk. 
 
 The risk of recurrence after a first hospital-related VTE appeared to be dependent on the 
reason for hospital-admission in conventional Cox modelling. However, competing risk 
analysis revealed a considerable overestimation due to the competing risk of death, 
especially in patients with cancer-related VTE. Our findings suggest, that patients with 
incident VTEs related to hospitalization for medical illness other than cancer or surgery, 
are at particularly high recurrence risk, even in the presence of competing risk of death. 
These findings could imply that prolonged treatment regimens similar to those 
recommended for unprovoked VTE might be warranted among these patients. 
 
 A low d-dimer (≤ 1500 ng/mL) measured at incident VTE diagnosis was associated with a 
low recurrence risk in a quarter of the VTE patients. The association was particularly 
pronounced among patients with incident DVT and in those with an unprovoked first VTE. 
Our findings suggest that d-dimer, measured at first VTE diagnosis, may be used to identify 
VTE patients at low risk of recurrence and guide decisions on short-term treatment in 




7. Final remarks and future perspectives 
Hospitalization is widely acknowledged as a high-risk situation with respect to VTE. However, 
the underlying mechanisms have not been fully elucidated, and hospital-related VTE remains 
a major challenge. Although mandatory risk assessment programs upon hospital-admission 
have reduced the rates of hospital-associated VTE (126, 127), current risk assessment 
strategies do not embrace all patients at risk, as around half of all VTE cases remains 
associated with current or recent hospitalization (28, 104). Current guidelines recommend 
thromboprophylaxis during the period of immobilization or hospitalization in acutely ill 
hospitalized medical patients at increased risk of thrombosis, but recommend against 
extending prophylaxis beyond the initial period of immobilization or hospital stay (285, 286). 
However, the findings in this thesis emphasize a high VTE-risk also in hospitalized patients 
without concurrent immobilization. Furthermore, the VTE-risk extends beyond hospital-
discharge, as a large proportion of hospital-related VTE cases occur after hospitalization (104, 
110, 287, 288). Importantly, all these events might be considered secondary and therefore 
largely preventable. Extended duration thromboprophylaxis (EDT) beyond hospital-discharge 
mitigate the VTE-risk in hospitalized medical patients, although at the expense of increased 
rate of major bleeding to such a degree that EDT is not universally warranted in unselected 
medical patients (289-298). Consequently, there is a large potential to reduce the burden of 
VTE by means of improved prevention strategies among hospitalized patients, as well as in the 
initial period following hospital-discharge. However, there is urgent need for accurate risk 
stratification tools to identify subgroups of hospitalized patients with a positive risk-benefit 
ratio for EDT without the excess risk of bleeding.  
 Recent advances in the diagnosis and treatment of VTE may have improved the short-
term outcomes after VTE. However, our findings, in accordance with those of others (35, 145, 
147, 149, 151, 152, 299), show that the rates of recurrence and death remain particularly high 
in the following year after a first VTE diagnosis. Importantly, the rates also remain high in the 
long-term, as more than two-thirds of all recurrent VTE cases accumulate in the subsequent 
decade. Although there are prospects of novel anticoagulant agents which do not promote 
any bleeding risk (300, 301), currently, the ultimate challenge in the treatment and prevention 
of VTE is to identify the optimal equipoise of anticoagulant therapy. Current guidelines 
recommend short-term (3 months) over indefinite anticoagulant treatment in patients with a 




diversity of recurrence risk also within subgroups of provoked and unprovoked VTE (178, 198, 
199), meaning that this dichotomy might not be clinically useful and more refined risk 
stratification is necessary (302). Considering our findings, that VTE related to medical 
conditions might invoke a more persistent recurrence risk, prolonged treatment similar to that 
recommended for unprovoked VTE might be justified. Furthermore, the introduction of 
DOACs has improved the safety and convenience of anticoagulation, which could entail an 
improved benefit-to-harm ratio in favor of prolonged anticoagulation. 
Identification of VTE patients at high risk of recurrence is extremely challenging, 
particularly among those with unprovoked VTE. Existing risk assessment models (RAMs) to 
distinguish patients with unprovoked VTE at high and low risk of recurrence have low 
predictive capability and ease of use, and are therefore of limited clinical utility. Genetic risk 
scores for recurrence prediction show promise (204, 206, 208), as do some biomarkers, 
although none have yet prevailed. Combining a GRS with biomarkers and clinical 
characteristics in future RAMs could improve recurrence prediction, and would ideally, also 
offer integrated bleeding risk assessment. Our findings of a low recurrence risk in patients 
with a low d-dimer at the time of first VTE diagnosis could potentially be useful in such RAMs, 
as it is widely available already at the time of VTE diagnosis, and would provide the 
opportunity to make definite decisions on treatment duration upon hospital-discharge. 
However, these are novel findings that has to be confirmed in future studies. We are currently 
working on externally validating these findings in collaboration with a research team within 
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A B S T R A C T
Background: Previous studies have reported that around 50% of patients with venous thromboembolism (VTE)
has undergone recent hospitalization. However, studies on the impact of hospitalization as a trigger factor for
VTE are limited.
Objectives: To investigate the impact of hospitalization with and without concurrent immobilization as a trigger
factor for VTE.
Methods: We conducted a case-crossover study of 530 cancer-free VTE patients. Hospitalizations were registered
during the 90-day period preceding the VTE diagnosis (hazard period), and in four preceding 90-day control
periods. A 90-day washout period between the control- and hazard periods was implemented to avoid potential
carry-over effects. Conditional logistic regression was used to calculate odds ratios (OR) of VTE according to
hospitalization.
Results: In total, 159 (30%) of the VTE-patients had been hospitalized in the hazard period, and the OR of
hospitalization was 9.4 (95% CI: 6.8–12.8). The risk increased slightly with the total number of days spent in
hospital (OR per day: 1.11, 95% CI: 1.04–1.18), and with the number of hospitalizations (OR 8.9, 95% CI:
6.4–12.4 for 1 hospitalization and OR 12.3, 95% CI 6.4–23.6 for ≥2 hospitalizations). Hospitalization without
immobilization was 6-times (OR: 6.3, 95% CI: 4.4–9.2) more common, whereas hospitalization with im-
mobilization was near 20-times (OR: 19.8, 95% CI: 11.5–34.0) more common in the 90-days prior to a VTE
compared to the control periods.
Conclusions: Hospitalization is a major trigger factor for VTE also in the absence of immobilization. However,
immobilization contributes substantially to the risk of VTE among hospitalized patients.
1. Introduction
Venous thromboembolism (VTE), a conceptual term for deep vein
thrombosis (DVT) and pulmonary embolism (PE), is a common disease
with severe complications [1–5]. Population based studies have in-
dicated that around 40–60% of the VTE cases can be attributed to
current or recent hospitalization or nursing home residency [5,6]. Case-
control studies have reported a 7 to 21-fold increased risk of VTE fol-
lowing recent hospitalization [7,8]. Moreover, a longitudinal study
from Olmsted County (US), reported that the risk of experiencing a first
or recurrent VTE was 35-fold increased during the 92 days following a
hospitalization [9]. Although hospitalization is acknowledged as a risk
factor for VTE, the role of hospitalization as a trigger factor for VTE has
not been extensively studied.
Hospitalization is often accompanied by immobilization.
Immobilization is associated with a 2 to 11-fold increased risk of VTE
among hospitalized patients [10,11], and up to 25% of medical patients
developing a hospital-related VTE has been shown to be immobilized
preceding the event [12,13]. Thus, the increased risk of VTE observed
in hospitalized patients may be partly explained by immobilization.
Most previous studies have not been able to disentangle this relation-
ship due to lack of information on immobilization, and some studies
have even used hospitalization as a proxy for immobilization [14]. The
influence of immobilization on the risk of hospital-related VTE, and to
what extent hospitalization without concurrent immobilization serves
as a trigger of VTE, have not been well addressed.
In the present study, we set out to investigate the impact of hospi-
talization as a trigger of VTE, and to explore the influence of
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immobilization on this relationship in a population-based case-cross-
over study of VTE patients. We also investigated the influence of hos-
pital-related factors, such as length of hospital-stay and frequency of
hospital admissions, on the risk of VTE. Our hypothesis was that hos-
pitalization is a major trigger for VTE also in the absence of im-
mobilization, and that the triggering effect is influenced by the length
of hospital-stay and the frequency of hospital-admissions.
2. Methods
2.1. Study population and outcome assessment
The source population comprised of subjects participating in the
fourth survey of the Tromsø study, a single-center, population based,
prospective cohort study, with repeated health surveys of the in-
habitants in the municipality of Tromsø, Norway. The fourth survey
was conducted in 1994/95, and included 27,158 inhabitants above
24 years. Further details about the Tromsø study can be found else-
where [15]. All participants gave an informed written consent, and the
study was approved by The Regional Committee of Medical and Health
Research Ethics. Participants were followed from the inclusion date
(1994/95) through December 31, 2012, and all first-lifetime sympto-
matic, objectively confirmed VTE events (n=707) during the course of
follow-up were recorded by thorough identification and validation as
previously described [16]. These 707 patients formed the basis of our
case-crossover study.
2.2. Study design
In the case-crossover design, each case serves as his or her own
control (self-matching), thereby controlling for risk factors that are
constant within an individual (e.g. inherited thrombophilia), but vary
between study objects. We defined the 90-day period prior to the VTE
as the hazard period, and 4 consecutive 90-day periods preceding the
hazard period as control periods (C1–C4). A 90-day wash-out period
was implemented between the risk and control periods, to avoid po-
tential carry-over effects (Fig. 1). This allows for comparison of ex-
posure-frequency in the hazard period to control periods, and makes
the design especially suited to study the effect of transient exposures
(e.g. hospitalization) on acute events (e.g. VTE). Patients with cancer in
the hazard period were excluded (n= 177), as cancer progression may
change an individual's VTE risk even over a short time-period, and
thereby potentially introduce confounding. Consequently, 530 cancer-
free VTE patients were included in our case-crossover study.
2.3. Measurements
Trained personnel reviewed the medical records for each VTE case,
and systematically collected information on potential trigger factors for
each of the 90-day periods using standardized forms. Moreover, diag-
nostic procedures, surgical and medical treatment, laboratory tests and
diagnosis during hospital admissions, day-case and outpatient clinic
visits in any of the control or hazard periods were recorded. Exposures
extending over several days, were registered and considered to have
occurred if any of the days of exposure fell within the specified 90-day
period.
Hospitalization was defined as being admitted to the hospital
for> 48 h in the control or hazard periods. Hospital admissions> 80
days were not registered as hospitalizations, as these were likely to be
admitted to rehabilitation wards. The date of hospital admission and
hospital discharge was used to estimate the length of hospital stay for
each hospital contact. Re-admissions during each 90-day period were
registered individually, and the total number of hospitalizations and
total number of days spent in hospital was calculated for each 90-day
period. Hospitalizations were categorized according to the main diag-
nosis assigned by the treating physician(s) using the 9th and 10th re-
visions of the International Classification of Diseases and Related Health
Problems (ICD-9 and ICD-10). Each hospital admission was assessed
individually, and patients could therefore contribute with multiple
hospitalizations within each case or control period. Patients were
classified in 7 broad categories, i.e. infection, chronic obstructive pul-
monary disease (COPD), heart failure, acute coronary syndrome (ACS),
neurologic disease, surgery (i.e. both major or minor, or admission to
any surgical ward) or trauma, and others.
Immobilization was defined as the presence of one or more of the
following; confinement to bed ≥3 days, ECOG score of four, or other
immobilizing factors specified in the patient's medical record (e.g.
transient or persistent use of wheelchair, cast immobilization, etc.).
CRP was analyzed in serum with a particle-enhanced immunoturbidi-
metric assay at the Department of Clinical Chemistry.
2.4. Statistical analysis
All statistical analysis were performed using STATA version 14.0
(Stata Corporation LP, College Station, Texas, USA). Baseline char-
acteristics are given as means ± 1SD or percentages. Conditional lo-
gistic regression was used to calculate odds ratios (ORs) with 95%
confidence intervals (CI) for hospitalization in the hazard and control
periods, as well as for the influence of duration of hospital stay and
number of hospital admissions on the risk of VTE. Duration of hospital
stay was analyzed as a continuous variable, and the OR was expressed
per 1-day increase in hospital stay. To separate the effect of total days in
hospital from frequency of admissions on the VTE risk, we performed a
separate analysis adjusting the number of hospital admissions for the
length of hospital stay. In order to address the impact of hospitalization
as a trigger in the absence of immobilization, we performed an analysis
Fig. 1. The case-crossover study design.
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with exposure categorized as not hospitalized, hospitalized without
immobilization and hospitalized with immobilization. Since surgery is
recognized as a strong trigger for VTE, we performed a separate analysis
restricted to patients who did not have surgery.
Hospitalization with immobilization could possibly reflect a more
severe underlying condition and a worse health condition in general. To
test this hypothesis, we estimated the mean maximum CRP-level (mg/
L) during hospitalization in patients with and without immobilization,
as a proxy for the inflammatory state. Furthermore, to examine the
potential role of confounding by occult cancer, we performed sensitivity
analysis excluding patients who developed cancer in the following year
after VTE.
3. Results
Characteristics of the 530 VTE patients are given in Table 1. The
mean age was 68 years, 54.2% were women and 17.7% were obese.
There were 296 (55.8%) DVTs and 228 (43.0%) PEs with or without
concurrent DVT. Among the VTE's, 84.0% (445) were community ac-
quired, 10.6% (56) acquired their VTE in-hospital, and 5.4% (29) were
nursing home residents. An overview of the categorization of hospital
admissions according to the main diagnosis assigned by the treating
physician in the hazard and control periods is provided in Table 2.
There were no substantial differences in the reason for hospitalization
in the hazard compared to the control periods, except that hospitali-
zation with heart failure was more common in the hazard period than in
control periods (4.0% vs. 0.6%).
The OR according to hospitalization, length of hospital stay and
number of hospitalizations, in hazard and control periods are shown in
Table 3. Overall, 30.0% (n=159) of the patients had been hospitalized
at least once in the hazard period (n= 530), compared to 6.2%
(n=132) in the control periods (n= 2120). The hospital admissions
were evenly distributed among the four control periods, with 5.9%
(n=31) occurring in C1, 5.5% (n= 29) in C2, 6.4% (n= 34) in C3 and
7.2% (n= 38) in C4, respectively. Multiple hospitalizations were more
common in the hazard period than in the control periods (5.5% vs.
1.6%), and patients were generally hospitalized for a longer time in the
hazard period than in the control periods (median of 11 days, IQR: 6–18
vs. median of 6 days, IQR: 3–12). The OR for hospitalization as a trigger
of VTE was 9.4 (95% CI: 6.8–12.8) (Table 3). The OR increased ac-
cording to the number of hospitalizations within each period from 8.9
(95% CI: 6.4–12.4) in those with one hospitalization to 12.3 (95% CI
6.4–23.6) in those with≥2 hospitalizations. After adjusting the number
of hospitalization for the total number of days spent in hospital, there
was no significant difference in the VTE risk between those with one
compared to patients with two or more hospitalizations (OR: 1.8, 95%
CI: 0.6–5.2). Overall, there was an 11% increased odds per one day
increase in the total number of days spent in hospital (OR: 1.11, 95% CI:
1.04–1.18), and the OR for hospitalization ≥5 days was 5.2 (95% CI:
1.8–15.1), compared to patients hospitalized for 1–4 days (Table 3).
These results remained unchanged after adjustment for the frequency of
hospital admissions (data not shown).
The ORs according to hospitalization with and without im-
mobilization are shown in Table 4. Overall, 74 (46.5%) of the 159
patients hospitalized in the hazard period were considered to be im-
mobilized, compared to 34 (25.8%) of the 132 patients hospitalized in
the control periods. Hospitalization without immobilization was 6-
times (OR: 6.3, 95% CI: 4.4–9.2) more common, whereas hospitaliza-
tion with immobilization was near 20-times (OR: 19.8, 95% CI:
11.5–34.0) more common in the 90-days prior to a VTE compared to
the control periods. The results were essentially similar when the
analyses were restricted to those who did not have surgery in the ha-
zard period, with an OR of 5.0 (95% CI: 3.2–7.9) and 14.4 (95% CI:
7.4–27.9) for hospitalization without and with immobilization, re-
spectively (Table 4).
Immobilization during the hospital stay could reflect a more severe
underlying condition, and therefore we recorded the maximum CRP
levels measured during the hospital stay for each patient. The mean
maximum CRP-level was 109 ± 96mg/L in hospitalized patients who
were immobilized and 82 ± 89mg/L in hospitalized patients who
were not immobilized. Sensitivity analysis excluding patients who de-
veloped cancer in the following year (n=18) after VTE produced es-
sentially similar results (data not shown).
4. Discussion
In the present case-crossover study, we found that hospitalization
was a major trigger associated with a 9-fold higher risk of VTE. The
triggering effect of hospitalization was mainly dependent on the length
of hospital stay, but not the frequency of hospital admissions. The risk
of VTE increased with 11% per one day increase in total days spent in
hospital during the 90-day hazard period, and the risk was 5-fold in
those with hospital admissions for ≥5 days compared to those with
shorter hospital stays (i.e. 1–4 days). Furthermore, we found that hos-
pitalization without immobilization was over 6-times more common,
and that hospitalization with immobilization was near 20-times more
common, in the 90-day period preceding a VTE compared to the control
periods. The results were comparable when the analyses were restricted
to patients who did not undergo surgery. Our results indicate that
hospitalization is a major trigger factor for incident VTE also in the
absence of immobilization. Moreover, our findings confirm that con-
comitant immobility increases the risk of VTE among hospitalized pa-
tients.
Several studies have investigated hospitalization as a risk factor for
VTE. In a nested case-control study of 625 patients with a first lifetime
VTE and 625 patients without VTE, hospital or nursing home confine-
ment (institutionalization) was an independent risk factor for VTE, with
an OR of 8.0 [7]. When the analysis was stratified according to in-
stitutionalization with or without recent surgery, the odds of VTE was
almost 22-fold and 8-fold increased, respectively, compared to patients
with neither institutionalization nor recent surgery. In the AT-AGE
study, a case-control study of elderly individuals, hospitalization was
associated with an almost 15-fold increased risk of VTE within the first
2 weeks after hospital-discharge [8]. The risk was similar in surgery-
Table 1
Characteristics of venous thromboembolism (VTE) patients
(n= 530).
Age (years) 68.4 ± 14.0
Sex (% women) 54.2 (287)
Obesity (% obese) 17.7 (94)
Deep vein thrombosis (%) 55.8 (296)
Pulmonary embolism (%) 43.0 (228)
Location at VTE onset
Community 84.0 (445)
Hospital 10.6 (56)
Nursing home 5.4 (29)
Values are means ± 1 SD or percentages with numbers in
brackets.
Table 2
Characteristics of hospitalizations in case and control periods.
Control period (n= 158) Hazard period (n= 201)
Infection 15.8% (25) 13.4% (27)
COPDa 4.4% (7) 2.5% (5)
Heart failure 0.6% (1) 4.0% (8)
Acute coronary syndrome 9.5% (15) 6.0% (12)
Neurologic disease 9.5% (15) 8.5% (17)
Surgery or trauma 32.9% (52) 34.3% (69)
Others 27.2% (43) 31.3% (63)
Values are percentages with numbers in brackets.
a COPD: chronic obstructive pulmonary disease.
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and non-surgery-related hospitalizations (OR: 6.6 and 5.5, respec-
tively), when compared to individuals without hospitalization. Fur-
thermore, in a recent cohort study with hospitalization as a time-
varying covariate, the risk of VTE was 35-fold increased in the period
up to 92 days following a hospitalization [9].
Case-crossover studies are suitable to study triggers of acute dis-
eases, since they are designed to answer the question “why did this
disease occur right now?”. This is in contrast to case-control and cohort
studies which compare the risk between individuals, and thereby are
designed to answer the question “why me?”. Although previous studies
have addressed hospitalization as a risk factor for VTE, few studies have
investigated the role of hospitalization as a trigger of VTE using a case-
crossover design. In one previous case-crossover study, any non-surgical
hospitalization or skilled nursing home facility stay was found to be a
significant trigger associated with a 4.2-fold higher risk of VTE [14].
Interestingly, adjustment for other hospital-related factors like major
surgery, infection, blood transfusion, use of central venous catheters,
injuries and medication, did not markedly influence the risk estimates,
even though many of these factors most likely are in the causal
pathway.
Few observational studies have evaluated the influence of length of
hospitalization and frequency of hospital admissions on the risk of VTE.
In a case-control study of older adults (≥60 years) [17], Yousuf et al.
found that hospitalization for 4–6 days and for ≥7 days was associated
with a 2.4- and 3.4-fold increased risk of VTE compared to patients who
were hospitalized for 0–3 days. In a matched case-control study of
outpatients with a VTE diagnosis during the 90-days following hospital
discharge [18], increasing number of hospitalizations and increasing
length of hospital stay was both associated with post-discharge VTE
diagnosis. The VTE risk doubled for each additional hospital-admission
and increased by 17% for each additional day spent in the hospital. In
the present study, we found that the risk of VTE increased with 11% per
one day increase in total days spent in hospital during the 90-day ha-
zard period, and the risk was 5-times higher in those with hospital
admissions ≥5 days compared to 1–4 days. Conversely, we did not find
any substantial differences in the VTE-risk in those with multiple hos-
pitalizations compared to those with a single hospitalization prior to
their VTE. Furthermore, after conditioning on the length of hospital
stay there was no differences in the risk of VTE in those with one
compared to ≥2 hospitalizations, placing further emphasis on
hospitalization as a high risk situation that is mainly dependent on the
length of hospital stay rather than the frequency of admissions.
Immobilization is a strong trigger of VTE which often concurs with
hospitalization. Few studies have been able to disentangle the effect of
immobilization from that of hospitalization, and hospitalization has
frequently been used as a proxy for immobilization when studying the
risk of VTE, as high-quality data on immobilization is often lacking. A
previous meta-analysis on immobilization and VTE-risk among hospi-
talized inpatients reported a relative risk of 1.5 across 7 cohort studies
and an OR of 2.5 across 3 case-control studies [10]. In our study,
hospitalization with immobilization was 3-times more common prior to
a VTE than hospitalization without immobilization, supporting that
immobilization contributes substantially to the risk of VTE among
hospitalized patients. In agreement with our findings, two previous
case-control studies on elderly patients, reported that immobility
mediated the risk of VTE in a dose-response related manner, depending
on both the type and duration of immobility [19], and that the risk was
highest among patients who were bedridden in hospital [8,19]. Our
study showed that hospitalization without immobilization was 6-times
more common prior to a VTE compared to equivalent control periods.
This highlights that hospitalization is a high-risk situation even in the
absence of immobilization, and that thromboprophylaxis should be
considered also among non-immobilized patients. The VTE risk asso-
ciated with hospitalization is dependent on the reason for hospitaliza-
tion (e.g. surgery, cancer, infections or acute medical conditions)
[6,20–23], as well as patient-related risk factors (e.g. age, obesity, co-
morbidities and genetic risk profile) [20–23]. Moreover, the risk can be
directly related to the number of risk factors present [20,22,24], as
thrombosis develops once the accumulation of risk factors in an in-
dividual is sufficient to exceed the thrombosis threshold [25]. Appro-
priate risk stratification among hospitalized patients is therefore chal-
lenging, and further research is needed to develop risk stratification
models that can accurately identify subjects at high risk of hospital-
related VTE.
In addition to being a risk factor in itself, immobilization may reflect
a more severe underlying disease and a generally worse health condi-
tion. Accordingly, we found a higher mean CRP-level in hospitalized
patients who were immobilized compared to hospitalized patients who
were not immobilized, indicating that there could be a difference in
disease severity among these patients. Consequently, there could also
Table 3
Odds ratios (ORs) of exposure in hazard period as compared to control periods.
Control periods (n= 2120) Hazard period (n= 530) OR (95% CI) ORc (95% CI)
Hospitalized (n) 132 159 9.4 (6.8–12.8)
Length of hospital stay (IQR)a 6 (3−12) 11 (6–18) 1.11 (1.04–1.18)
Hospital stay ≥5 daysb 75 134 5.2 (1.8–15.1)
Number of hospitalizations
0 1988 371 Ref.
1 109 130 8.9 (6.4–12.4) Ref.
≥2 23 29 12.3 (6.4–23.6) 1.8 (0.6–5.2)
a Median (interquartile range, IQR).
b Compared to patients hospitalized for 1–4 days.
c Adjusted for the length of hospital stay.
Table 4
Odds ratios (ORs) of VTE according to hospitalization with and without immobilization.
Control periods Hazard period All Restricted to non-surgicala
(n= 2120) (n=530) OR (95% CI) OR (95% CI)
Not hospitalized 1988 374 Ref. Ref.
Hospitalized without immobilization 98 85 6.3 (4.4–9.2) 5.0 (3.2–7.9)
Hospitalized with immobilization 34 74 19.8 (11.5–34.0) 14.4 (7.4–27.9)
a Analysis restricted to patients hospitalized for reasons other than surgery.
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be differences in the use of thromboprohylaxis in patients with and
without restricted mobility, as immobilized patients with severe con-
ditions are more likely to receive anticoagulant treatment. In the pre-
sent study, 36.1% of the patients who were hospitalized without being
immobilized, and 50.9% of those who were hospitalized with im-
mobilization prior to their VTE received thromboprophylaxis, sug-
gesting that our risk estimates may have been underestimated. Our data
strongly indicates confounding by indication for thromboprophylaxis.
Consequently, we could not adjust our analysis for thromboprophylaxis
as this would introduce bias.
There are several strengths of the present study. The case-crossover
design is especially suited to study triggers of disease, as information on
different exposures are collected for several pre-defined time periods,
allowing for comparison of exposure and exposure frequencies across
different time periods in relation to the disease. Furthermore, since
each subject serves as its own control, potential confounders such as
chronic diseases and conditions are controlled for by the design. The
present study included a large sample size of VTE patients recruited
from a general population, which strengthens the external validity of
our results. Moreover, the case-crossover design may partly adjust for
the heterogeneity of the hospitalized population, as each subject serves
as his/her own control [26]. In contrast to many other studies, we had
information on immobilization during the hospital stay. A limitation of
the case-crossover design is that it is susceptible to confounding by
factors that change over time within individuals. However, this can be
minimized by fitting the control periods as close to the hazard periods
as possible. Moreover, all information in this study was collected ret-
rospectively using hospital records, and the data therefore relies on
thorough registration by the treating physicians and other health care
professionals. Consequently, any other factors not accounted for in the
medical records could potentially have influenced our results. Occult
cancer could be a potential confounder in this study. However, sensi-
tivity analysis excluding patients who developed cancer in the fol-
lowing year after VTE produced essentially similar results, indicating a
low probability of confounding by occult cancer.
In conclusion, hospitalization is a major trigger factor for VTE also
in the absence of immobilization. However, immobilization contributes
substantially to the risk of VTE among hospitalized patients.
Furthermore, the hospital-associated risk of VTE is mainly dependent
on the length of hospital stay rather than the frequency of admissions.
Our findings highlight that hospitalization is a high-risk situation also
among patients who are not immobilized.
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Essentials
• Reports on recurrence and mortality after a first venous
thromboembolism (VTE) vary considerably.
• We describe rates of recurrence and mortality in
patients with a first VTE from the Tromsø study.
• The overall recurrence rate was 3.9 per 100 person-
years, but this varied widely with time.
• Despite advances in VTE management, the rates of
adverse events are still fairly high.
Summary. Background: Previous reports on recurrence and
mortality rates after a first episode of venous thromboem-
bolism (VTE) vary considerably. Advances in the manage-
ment and treatment of VTE during the last 15 years may
have influenced the rates of clinical outcomes. Aim: To
estimate the rates of recurrence and mortality after a first
VTE in patients recruited from a large population-based
cohort. Method: From the Tromsø study, patients
(n = 710) with a first, symptomatic, objectively confirmed
VTE were included and followed in the period 1994–2012.
Recurrent episodes of VTE were identified from multiple
sources and carefully validated by review of medical
records. Incidence rates and cumulative incidence rates
with 95% confidence intervals (CIs) of VTE recurrence and
mortality were calculated. Results: The mean age of the
patients was 68 years (range 28–102 years), and 166
(23.4%) had cancer at the time of first VTE. There were
114 VTE recurrences and 333 deaths during a median study
period of 7.7 years (range 0.04–18.2 years). The risk of
recurrence was highest during the first year. The overall
1-year recurrence rate was 7.8 (95% CI 5.8–10.6) per 100
person-years (PY), whereas the recurrence rate in the
remaining follow-up period (1–18 years) was 3.0
(95% CI 2.4–3.8) per 100 PY. The overall 1-year all-cause
mortality rate was 29.9 (95% CI 25.7–34.8) per 100 PY,
and in those without cancer the corresponding rate was
23.6 (95% CI 17.8–31.3) per 100 PY. Conclusion: Despite
advances in VTE management, the rates of adverse events
remained fairly high, particularly in the first year following
a first VTE.
Keywords: cancer; epidemiology; mortality; recurrence;
venous thromboembolism.
Introduction
Venous thromboembolism (VTE) is a common term for
deep vein thrombosis (DVT) and pulmonary embolism
(PE). The annual incidence of VTE is approximately 1–3
per 1000 in the adult population of high-income countries
[1–4], and the risk increases exponentially with age [5].
With high rates of recurrence and mortality, as well as
increased long-term morbidity and functional disability,
VTE remains a major public health concern with a sub-
stantial disease burden [6].
Previously reported rates of recurrence and survival
after a first VTE vary widely, ranging from 0.6% to 5%
at 30 days, and from 25% to 40% at 10 years, for VTE
recurrence [3,7–16], and from 77% to 97% at 1 week,
and from 61% to 75% at 8 years, for survival [3,7,16–18].
The differences in the reported rates may, to some extent,
be ascribed to differences in study design (e.g. clinical tri-
als, cohorts or registry databases with limited case valida-
tion), clinical setting (hospital or community setting), and
the time period over in which the study was conducted.
Advances in diagnostics, management and treatment of
VTE in recent years may have influenced the rates of
adverse outcomes after VTE. The introduction of low
molecular weight heparins for the treatment of acute
VTE in the early 1990s [19] has reduced the length of
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hospital stays after VTE, and a larger proportion of the
VTE cases are currently treated as outpatients [20,21].
Furthermore, increased awareness of VTE risk and the
use of thromboprophylaxis in high-risk situations may
have impacted on recurrence and mortality rates. Finally,
the more widespread use of spiral computed tomography
(CT) to diagnose PE, and the concomitant increased
detection of subsegmental PE [22], may have influenced
the overall outcome rates after a first VTE.
VTE is a multifactorial disease that occurs frequently
in association with cancer and other comorbidities. A
high mortality rate resulting from other conditions will
result in an overestimation of the cumulative incidence
of recurrence in patients with a first VTE, as death is a
competing event [23,24]. Few studies have assessed and
compared the cumulative incidence of recurrence in the
presence of competing risk of death in subgroups of
patients with a first VTE [25,26]. Moreover, many of
the previous studies were carried out several decades
ago [7,13,17], were restricted to either the hospital or
community setting [7,15,27], or included their patients
after completion of anticoagulant treatment (i.e.
3–12 months after the first event) [7,27,28]. We therefore
aimed to estimate the cumulative incidence of recurrence
and mortality after a first VTE by using cases derived
from a general population cohort including both the




Patients with a first lifetime VTE were recruited from the
fourth survey of the Tromsø Study, a population-based
cohort study in which 26 855 subjects age 25–97 years
were enrolled in 1994–1995 and followed up to December
2012, as previously described in detail [29]. The study was
approved by the regional committee for research ethics,
and all participants gave their informed, written consent
to participate. In total, 710 incident symptomatic VTE
cases were included in the study. Recurrent VTE events
and all-cause mortality among the incident cases were
recorded until the end of follow-up on 31 December
2012.
Identification and validation of VTE
All first lifetime episodes of VTE were identified by
searching the hospital discharge registry, the autopsy reg-
istry and the radiology procedure registry at the Univer-
sity Hospital of North Norway, from the date of
enrolment in the Tromsø Study (1994–1995) to 31
December 2012. The University Hospital of North Nor-
way is the only hospital in the region, and all hospital
care and relevant diagnostic radiology for VTE in the
Tromsø community is provided exclusively by this hospi-
tal. We used a broad search strategy, and the relevant dis-
charge codes were ICD-9 codes 325, 415.1, 451, 452, 453,
671.3, 671.4 and 671.9 for the period 1994–1998, and
ICD-10 codes I26, I67.6, I80, I81, I82, O22.3, O22.5,
O87.1 and O87.3 for the period 1999–2012. The hospital
discharge registry included both outpatient clinic visits
and hospitalizations. An additional search of the comput-
erized index of autopsy diagnoses was conducted, and
cases diagnosed with VTE, either as a cause of death or
as a significant condition, were identified. We also
searched the radiology database in order to identify
potential cases of symptomatic objectively confirmed VTE
that may have been missed because of coding errors in
the hospital discharge registry. Trained personnel system-
atically reviewed all relevant diagnostic procedures per-
formed at the Department of Radiology to diagnose VTE
during the 18-year period, and cases with objectively con-
firmed VTE were identified.
The medical records for each potential VTE case
derived from the hospital discharge registry, the autopsy
registry and the radiology procedure registry were
reviewed by trained personnel for case validation. For
subjects derived from the hospital discharge registry and
the radiology procedure registry, an episode of VTE was
verified and recorded as a validated outcome when all
four of the following criteria were fulfilled: (i) signs and
symptoms consistent with DVT or PE were present; (ii)
objectively confirmed by diagnostic procedures (compres-
sion ultrasonography, venography, spiral CT, perfusion–
ventilation scan, pulmonary angiography, or autopsy);
(iii) the medical record indicated that a physician had
made a diagnosis of DVT or PE; and (iv) the patient
received treatment with anticoagulants (heparin, warfarin,
or a similar agent), thrombolytics, or vascular surgery,
unless contraindications were specified. For subjects
derived from the autopsy registry, a VTE event was
recorded as an outcome when the autopsy record (death
certificate) indicated VTE as the cause of death or as a
significant condition contributing to death.
A VTE event was classified as cancer-related, provoked,
or unprovoked, based on the presence of cancer or other
provoking factors at the time of VTE diagnosis. The pres-
ence of cancer was defined as overt cancer at the time of
VTE diagnosis (or, in some cases, if cancer was diagnosed
on the same day as the VTE). Non-melanoma skin cancer
(ICD-10 code C44) was not registered as cancer. VTEs
occurring in patients with active cancer were classified as
cancer-related regardless of other risk factors. In patients
without cancer, a VTE occurring in the presence of one
or more provoking factors was defined as provoked. The
following were regarded as provoking factors: recent hos-
pitalization, surgery, or trauma (within 8 weeks before
the event), an acute medical condition (acute myocardial
infarction, acute ischemic stroke, or acute infections),
immobilization (bed rest for > 3 days, wheelchair use, or
© 2016 International Society on Thrombosis and Haemostasis
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long-distance travel for ≥ 4 h within the last 14 days), or
another factor specifically described as provoking by a
physician in the medical record (e.g. intravascular cathe-
ter). VTEs occurring in patients without cancer or any
provoking factor were classified as unprovoked.
Outcomes
We recorded all VTE recurrences and deaths among the
study participants during follow-up. Recurrent VTEs
were identified and validated with the same approaches
and criteria as used for first VTE described above. Infor-
mation on deaths was collected from the Norwegian Pop-
ulation Registry by use of the unique national person
identification number.
Statistical analyses
Statistical analyses were carried out with STATA ver-
sion 14.0 (Stata Corporation, College Station, TX, USA).
Descriptive statistics for baseline data were reported as
percentages or means (with standard deviations), as
appropriate. For analyses of recurrence, the patients
(n = 710) were followed from the date of their first VTE
until the date of VTE recurrence, date of migration, date
of death, or study end (31 December 2012), whichever
came first. Crude recurrence rates were calculated by
dividing the number of recurrent events by the total per-
son-years (PY) at risk, and expressed per 100 PY. More-
over, recurrence rates were calculated for the various
subtypes of VTE (cancer-related, unprovoked, and pro-
voked) in different time intervals (0–6 months, 6 months
to 1 year, 1–5 years, 5–10 years, and > 10 years) after the
first event. 1-Kaplan–Meier estimates with 95% confi-
dence intervals (CIs) were used to report the cumulative
incidence of recurrence over time in men and women, and
according to subtype and location (DVT and PE) of the
index VTE. Cox proportional hazards regression was
used to calculate the hazard ratios (HRs) of recurrence
and mortality in men and women and according to the
classification (cancer-related, provoked, and unprovoked)
and localization (DVT and PE) of the first VTE adjusted
for age and sex.
For analyses of mortality, subjects were followed from
the date of the first VTE until the date of death or study
end (31 December 2012). Subjects who died on the same
day as the VTE (n = 18) were given 1 day of follow-up in
the analyses. Crude mortality rates were calculated as the
number of deaths divided by the total PY at risk, and
expressed per 100 PY. Similarly, we estimated mortality
rates according to type and localization of the first VTE
in different time intervals, and Kaplan–Meier curves were
used to visualize survival over time for men and women
and according to subtypes of VTE.
The cumulative incidence of VTE recurrence is depen-
dent on both the risk of recurrence and the risk of dying,
and, consequently, recurrence risks are overestimated
when the mortality rate is high. We therefore estimated
the cumulative incidence of recurrence in the presence of
competing risk of death by using the stcrreg and stcurve
cif commands in STATA.
Results
Patient characteristics
The clinical characteristics assessed at the time of incident
(n = 710) and recurrent (n = 114) VTE events are summa-
rized in Table 1. The mean age at the time of the first
Table 1 Baseline and clinical characteristics of incident (n = 710)







Age (years), mean  SD 68.7  13.5 70.6  12.0
Gender (male), no. (%) 329 (46.3) 61 (53.5)
PE, no. (%) 295 (41.5) 46 (40.3)
DVT, no. (%) 415 (58.4) 68 (59.6)
Proximal leg DVT, no. (%) 314 (44.2) 58 (50.8)
Calf vein DVT, no. (%) 131 (18.4) 19 (16.6)
VTE at other site, no. (%) 32 (4.5) 4 (3.5)
Unprovoked, no. (%) 295 (41.5) 55 (48.2)
Cancer-related, no. (%) 166 (23.3) 28 (24.5)
Treatment duration with AC (months), no. (%)
0–3 247 (34.7) 29 (25.4)
3–6 229 (32.2) 13 (11.4)
6–12 137 (19.2) 14 (12.2)
> 12 65 (9.1) 53 (46.5)
Provoking factors, no. (%)
Acute medical condition *,† 102 (14.3) 13 (11.4)
Surgery† 107 (15) 12 (10.5)
Trauma† 56 (7.9) 3 (2.6)
Immobilization 135 (18.9) 20 (17.4)
Bed rest for ≥ 3 days 47 (6.6) 8 (7.0)
Long-haul travel‡ 6 (0.8) 3 (2.6)
Other immobilization 82 (11.5) 9 (7.8)
Other provoking factor 36 (5.0) 5 (4.4)
One provoking factor 182 (25.6) 24 (21.1)
More than one provoking factor 99 (13.9) 11 (9.6)
Clinical risk factors, no. (%)
Recent hospitalization† 288 (40.5) 45 (6.3)
Nursing home 39 (5.5) 8 (7)
Estrogen usage § 40 (5.6) 2 (1.7)
Heredity¶ 20 (2.8) 3 (2.6)
Obesity 116 (16.3) 19 (16.6)
Comorbidity** 157 (22.1) 24 (21.0)
Pregnancy/puerperal period 3 (0.4) –
AC, anticoagulant; DVT, deep vein thrombosis; PE, pulmonary
embolism; SD, standard deviation. *Acute myocardial infarction,
ischemic stroke, or major infectious disease. †Within 8 weeks prior
to the VTE event. ‡Travel exceeding 4 h within the last 14 days.
§Hormone replacement therapy/oral contraceptives. ¶Heredity: fam-
ily history of VTE in first-degree relative before the age of 60 years.
**Comorbidity within the previous year (myocardial infarction,
ischemic stroke, heart failure, inflammatory bowel disease, chronic
infections, chronic obstructive pulmonary disease, or myeloprolifera-
tive disorders).
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VTE was 68.7  13.5 years (range 28–102 years), and the
proportion of men was 46.3%. Furthermore, 42% of the
incident VTE events were classified as unprovoked, 23%
as cancer-related, and 35% as being provoked by a factor
other than cancer. The mean age at recurrence was
70.6 years (range 36–97 years), and the proportion of
men was 46.5%. Among the recurrences, 48.2% were
classified as unprovoked, 24.5% as cancer-related, and
27.3% as being provoked by factors other than cancer.
Recurrent VTE
Of the 710 incident VTE cases, 114 patients had a recur-
rent VTE event (PE in 46 and DVT in 68) during a med-
ian of 2.7 years of follow-up (range 1 day to 18.1 years).
The overall recurrence rate was 3.9 (95% CI 3.3–4.7) per
100 PY; 4.5 (95% CI 3.5–5.8) in men, and 3.4
(95% CI 2.6–4.4) in women. The incidence rates of recur-
rence per 100 PY were 8.5 (95% CI 5.5–13.2) for cancer-
related VTE, 3.4 (95% CI 2.5–4.7) for provoked VTE,
and 3.6 (95% CI 2.7–4.6) for unprovoked VTE.
The recurrence rate varied widely during follow-up, as it
was highest in the beginning and declined in later years.
The overall recurrence rates per 100 PY were 9.2
(95% CI 6.2–13.3) in the first 6 months, 6.3 (95% CI 3.8–
10.3) in the period 6 months to 1 year, 3.5 (95% CI 2.6–
4.6) in the period 1–5 years and 2.3 (95% CI 1.5–3.7) in
the 5–10 years after the index event (Table 2).
The cumulative incidence rates of overall VTE recur-
rence were 1.7% (95% CI 1.0–3.1) at 1 month, 4.3%
(95% CI 3.0–6.2) at 6 months, 7.2% (95% CI 5.4–9.7) at
1 year, 18.8% (95% CI 15–22) at 5 years and 28.3%
(95% CI 23–33) at 10 years of follow-up (Table S1). The
10-year cumulative incidence rates of recurrence were
35.4% in men and 22.0% in women (Fig. 1A), which cor-
responded to a 1.3-fold (95% CI 0.96–2.03) higher risk of
recurrence in men than in women.
The cumulative incidence of VTE recurrence according
to classification of the initial event is shown in Fig. 2A.
The 5-year cumulative incidence rates were 17.9% in
unprovoked, 16.7% in provoked and 26.4% in cancer-
related VTE, respectively (Fig. 2A; Table S1). When
competing risk of death was taken into account, the
corresponding figures were 16.1% in unprovoked, 14.4%
in provoked and 11.4% in cancer-related incident VTE
(Fig. 2B).
The recurrence risk was higher in patients with initial
DVT than in patients with PE throughout the 10-year
period (Fig. 1B). The HR of recurrence was 1.4-fold
higher (HR 1.45, 95% CI 0.96–2.18) in those with DVT
than in those with PE. Furthermore, patients with a first
PE were 2.4-fold more likely to develop a second PE
rather than a DVT, and vice versa (Table 3). Among the
34 patients with a first PE, 24 (70.6%) had recurrent PE
and 10 (29.4%) had recurrent DVT. Correspondingly,
among the 80 patients with a first DVT, 22 (27.5%) had
recurrent PE and 58 (72.5%) had recurrent DVT. Like-
wise, patients with a first unprovoked VTE were more
likely to have their second event unprovoked (Table 4).
Among those with a first unprovoked VTE, 66.7% expe-
rienced a second unprovoked event, 20.4% had a pro-
voked VT, and 12.9% had a cancer-related VTE as the
recurrent episode. Those with a first provoked VTE were
just as likely to have a second provoked or unprovoked
VTE (47.5% versus 45%, respectively), and 7.5% had a
cancer-related VTE as the recurrent episode (Table 4).
All-cause mortality
During follow-up, 333 of the 710 VTE patients died. The
overall mortality rate during a median of 3.4 years of fol-
low-up (range 1 day to 18 years) was 9.7 per 100 PY
(95% CI 8.7–10.8). The crude mortality rate was higher
in women (11.0 per 100 PY, 95% CI 9.5–12.7) than in
men (8.3 per 100 PY, 95% CI 7.1–10.0); however, the
CIs overlapped. Correspondingly, the cumulative proba-
bility of survival beyond 10 years was higher in men
(48.4%, 95% CI 41.5–55.0) than in women (41.1%,
95% CI 35.1–47.1) (Fig. 3A). The higher mortality rate
among women was explained by their higher age at the
Table 2 Incidence rates (IRs) with 95% confidence intervals (CIs) of venous thromboembolism (VTE) recurrence (per 100 person-years) in
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index date, as the HR of death for men versus women
changed from 0.78 (95% CI 0.63–0.97) to 0.96
(95% CI 0.77–1.21) after adjustment for age.
The mortality rate was highest in the first 6 months after
the VTE event, and declined rapidly thereafter (Table 5).
The 1-year mortality rate in patients with cancer-related
VTE was 114.4 (95% CI 94.0–139.3) per 100 PY.
The cumulative incidence of all-cause mortality after
VTE is shown in Table S2. The 10-year cumulative inci-
dence of mortality was highest among those with cancer-
related VTE (88.3%), and lowest among those with
unprovoked VTE (41.5%) (Fig. 3B).
Discussion
The present study was conducted to determine recurrence
and mortality rates after a first event of VTE in a cohort
of patients recruited from the general population in the
period 1994–2012, including both the community and
hospital setting. The overall recurrence rate was 3.9 per
100 PY, but varied widely with time, from 9.2 per
100 PY in the first 6 months to 2.3 per 100 PY in the
5–10 years after the first VTE event. The overall 10-year
cumulative incidence rates of recurrence were 35.4% in
men and 22.0% in women. The cumulative incidence of
recurrence was high among cancer patients, particularly
in the first year (16.3%). However, after competing risk
of death was taken into account, the cumulative incidence
rates of recurrence were 4.9% at 1 year and 11.4% at
5 years in cancer patients, whereas the corresponding
rates in non-cancer patients were 6.3% and 14.4%. The
30-day and 1-year cumulative all-cause mortality rates
after VTE were 19.4% and 62.0% in cancer patients, and














































Fig 1. Cumulative incidence of venous thromboembolism (VTE)
recurrence. (A) 1-Kaplan–Meier curves for men and women. (B)
1-Kaplan–Meier curves according to initial deep vein thrombosis
and pulmonary embolism.









Pulmonary embolism 24 (70.6) 10 (29.4) 34
Deep vein thrombosis 22 (27.5) 58 (72.5) 80
Total 46 (40.3) 68 (59.6) 114
Table 4 Classification of recurrences (%) according to the classifica-




Unprovoked 36 (66.7) 11 (20.4) 7 (12.9) 54
Provoked* 18 (45.0) 19 (47.5) 3 (7.5) 40
Cancer-related 1 (5.0) 1 (5.0) 18 (90.0) 20
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Fig 2. Cumulative incidence of venous thromboembolism (VTE)
recurrence according to classification of the index event. (A)
1-Kaplan–Meier curves. (B) Cumulative incidence after taking
competing risk of death into account.
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Advances in diagnostic tools and the management and
treatment of VTE in recent years may have influenced the
outcome rates after a first VTE. Few studies have recently
described this in a setting that covers provoked and
unprovoked first events derived from both the hospital
and community setting with long-term follow-up starting
from the date of first VTE. Our recurrence rates were
only marginally lower than those reported by Heit et al.
[13], who investigated recurrence among 1791 patients
with a first VTE in the period 1960–1999. They reported
overall cumulative incidence rates of recurrence of 12.9%
at 1 year and 30.4% at 10 years, whereas the correspond-
ing numbers in our study were 7.2% and 28.3%. In the
Worcester study [28], conducted in the period 1999–2003,
the 1-year cumulative incidence of recurrence was 10.9%,
but they did not report on long-term follow-up. Improved
treatment strategies may, to some extent, explain the
lower 1-year cumulative recurrence risk observed in our
study than in the previous studies. Nevertheless, in the
long term, our cumulative incidence of recurrence was
similar to that in previous studies, suggesting a catch-up
effect after the initial period [15,30]. Thus, despite
advances in diagnosis and treatment in recent years, the
rates of recurrence after VTE were still high, particularly
in the long term.
The recurrence rate was highest during the initial
6 months after the VTE in all subgroups, despite the fact
that most patients received anticoagulant therapy in this
period. This highlights the importance of including
patients at the time of the event, particularly for descrip-
tive epidemiologic purposes, as studies that start their fol-
low-up after the withdrawal of anticoagulants will lose a
significant amount of cases that occur in the initial phase.
In agreement with previous studies [25,26], the 5-year
cumulative risk of recurrence was highest among cancer
patients. The mortality rate is high among cancer
patients, and, in the presence of competing risk of death,
the cumulative incidence of recurrence is dependent on
both the risk of recurrence and the risk of dying
[23,24,31]. Therefore, when competing risk of death was
taken into account, the estimated 5-year cumulative risk
of recurrence changed from 26.4% to 11.4% in cancer
patients, and the risk of recurrence in cancer patients was
actually lower than in those with unprovoked and pro-
voked VTE (16.1% and 14.4%, respectively).
In our study, patients with a first DVT had a 1.4-fold
higher risk of recurrence than those with a first PE. This
finding is in agreement with a Canadian study of 646
patients with first unprovoked VTE showing that subjects











































Fig 3. Survival probability after venous thromboembolism (VTE).
(A) Kaplan–Meier curves in men and women. and (B) VTE by clas-
sification of the initial event.
Table 5 All-cause mortality rates (MRs) per 100 person-years in different time intervals after venous thromboembolism (VTE) and according






















































CI, confidence interval. *Without cancer.
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those with PE [32]. Likewise, the study by Prandoni et al.
[18] found that DVTs were 1.4-fold more likely to recur
than PEs. Potential explanations for this phenomenon
may be more efficient clot resolution in the lungs, owing
to high fibrinolytic activity [33], in contrast to venous
valve damage and development of the post-thrombotic
syndrome, which frequently occurs among patients with
DVT [7]. Moreover, the introduction of CT to diagnose
PE may have led to increased detection of subsegmental
PEs, which have a better prognosis with regard to recur-
rence [22].
In accordance with previous studies [18,34,35], the type
of the first VTE was a predictor for the type of recur-
rence, as patients with a first PE were 2.4-fold more likely
to have a second PE rather than a DVT. Moreover, we
showed that those with a first unprovoked VTE were
more likely to have a second unprovoked VTE, whereas
those with a first provoked VTE were just as likely to
have a provoked or unprovoked VTE as their second
event. The latter may be explained by an altered baseline
risk following the first provoked VTE, e.g. residual vein
thrombosis [36,37] or other pathophysiologic changes in
the veins caused by the first VTE increasing the chance of
having a recurrent thrombosis, even in the absence of
provoking factors.
Most previous studies have reported a two-fold to
four-fold higher recurrence rate among men than among
women [27,34,38]. In our study, we confirmed this trend,
but the relative risk of recurrence was only 30% higher in
men than in women, and the difference was not statisti-
cally significant. As the source population for our VTE
cases was restricted to subjects aged ≥ 25 years, our study
population did not contain the very young women with a
first VTE often related to oral contraceptives or preg-
nancy. Generally, the young women with hormone-related
VTE have a low recurrence risk [39], and, as a result, the
risk difference between men and women will be higher in
a VTE population that contains these women. The
cumulative incidence curves for recurrence in men and
women started to separate 3 years after the initial event
in our study, which may partly explain why higher
relative risk differences in men versus women are reported
in studies with a later start of follow-up (after withdrawal
of anticoagulants).
The 1-year mortality rates after VTE remained high
(24% in all VTE patients and 62% in cancer-related VTE
patients), and were remarkably similar to those reported in
a previous Norwegian study of 740 VTE patients recruited
in the period 1995–2001 [40]. We observed a higher sur-
vival rate among men in our crude analyses, but this was
explained by age differences among men and women at the
time of the index event. Subjects with provoked VTE had
poorer survival than those with unprovoked VTE, which
can probably be explained by a higher age and more
comorbidities among those with provoked VTE.
The strengths of our study include the unselected VTE
patients recruited from the general population covering
both the community and the hospital setting, thoroughly
identified and individually validated first and recurrent
events, the relatively long follow-up, and data collected
from a recent calendar period. Patients were treated
according to standard practice. As our study center is the
only diagnostic and treatment facility for all patients in
the area, few cases were lost to follow-up, and we there-
fore believe that our observations reflect the true clinical
course of VTE. Moreover, few previous studies have com-
pared the cumulative incidence of recurrence among sub-
groups in the presence of competing risk of death.
Unfortunately, the study population was too small to for
trends in recurrence and mortality over time to be investi-
gated, and we did not have sufficient information on
causes of death. Moreover, the VTE population was only
representative for the population aged ≥ 28 years. How-
ever, as the incidence increased sharply with age, our
VTE population covered the vast majority of the total
VTEs in the general population. Unfortunately, we did
not have detailed information on the duration of antico-
agulant treatment after VTE. However, adjustment for
the planned duration, which, in most cases, is expected to
reflect the actual duration, did not have a major impact
on the difference in recurrence risk between unprovoked
and provoked VTE.
Despite advances in VTE management in recent years,
the rates of adverse events remained high, especially in
the first year following a VTE. VTE recurs frequently,
and this trend continues for at least 10 years and possibly
longer after the incident event. In order to reduce the dis-
ease burden associated with VTE, future studies should
focus on the development of risk prediction models with
high precision, in order to identify high-risk individuals
with a favorable benefit-to-harm ratio for anticoagulant
treatment.
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online version of this article:
Table S1. Cumulative incidence of venous thromboem-
bolism (VTE) recurrence according to classification of the
index VTE. The Tromsø Study 1994–2012.
Table S2. Cumulative incidence of all-cause mortality
according to time since venous thromboembolism and
classification of the index event. The Tromsø Study 1994–
2012.
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Essentials
• Recurrence risk after a hospital-related venous throm-
boembolism (VTE) is underinvestigated.
• We explored this association in a cohort of patients
with a first VTE from the Tromsø study.
• Stratification on hospital-related factors revealed con-
siderable differences in recurrence risk.
• The recurrence risk was high in cases with a VTE
related to hospitalization for medical illness.
Summary. Background: Hospitalization is a well-estab-
lished risk factor for first venous thromboembolism
(VTE), but the risk of recurrence, particularly in patients
hospitalized for conditions other than cancer or surgery,
has scarcely been investigated. The cumulative incidence
of recurrence in hospital-related VTE may be influenced
by the competing risk of death. Objectives: To investigate
the risk of recurrence and mortality among patients with
a first hospital-related VTE in models with and without
death as a competing event. Methods: Information on
hospital-related risk factors was collected in 822 patients
with a first-lifetime VTE derived from the Tromsø study.
Recurrent VTEs and deaths were recorded during follow-
up (1994–2012). Results: During a median of 2.79 years
of follow-up, 132 patients experienced a recurrent VTE.
Stratification on hospital-related factors revealed consid-
erable differences in recurrence risk. The 5-year cumula-
tive incidence of recurrence was 27.4%, 11.0% and
20.1% in patients with incident VTEs related to cancer,
surgery or other medical illness, respectively, and 18.4%
in patients with a non-hospital-related first VTE. The
mortality rates were high for all subgroups of hospital-
related VTE, except for surgery-related events. Conse-
quently, the cumulative incidence of recurrence dropped
in the competing risk analyses, showing a 5-year cumula-
tive incidence of 14.4%, 11.7% and 9.7% in patients with
a first VTE related to hospitalization for other medical ill-
ness, cancer or surgery, respectively. Conclusions: Our
findings suggest that patients with incident VTEs related
to hospitalization for medical illness other than cancer or
surgery have a high recurrence-risk, even in the presence
of competing risk of death.
Keywords: epidemiology; hospitalization; recurrence; risk
factors; venous thromboembolism.
Introduction
Deep vein thrombosis (DVT) and pulmonary embolism
(PE), collectively referred to as venous thromboem-
bolism (VTE), are frequently associated with consider-
able morbidity and mortality [1–3]. VTE is particularly
common among hospitalized patients, with incidence
rates (IRs) exceeding 100 times greater than those in
community residents [4]. Moreover, 40–50% of the VTE
cases can be attributed to hospitalization, with hospital-
ization for surgery and medical illness accounting for
similar proportions [5].
After an incident episode of VTE, 30–40% experience a
recurrent event within 10 years, and the risk is highest
during the first 6–12 months [2,6–9]. The risk of recur-
rence is dependent on the clinical characteristics of the
initial event. Patients with a first VTE provoked by a
transient risk factor (e.g. surgery) are at low risk of recur-
rence [6,8,10–13], whereas VTEs provoked by a persistent
risk factor, such as active cancer, have a high risk of
recurrence [6,8,12,14,15]. When no provoking risk factor
(transient or persistent) can be identified, the event is clas-
sified as unprovoked, and these patients have an interme-
diate to high risk of recurrence [9–13,16,17]. However,
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categorization along this continuum may be difficult, par-
ticularly for patients where considerable uncertainty exists
regarding the prognostic importance of a risk factor.
Hospitalization in itself is an interim exposure and may
therefore be considered as a transient risk factor, assumed
to yield a low risk of recurrence. However, the risk of
recurrence after a first hospital-related VTE, particularly
hospitalization for conditions other than cancer or sur-
gery, has not been extensively studied. Moreover, as the
mortality rate is expected to be higher among patients
with co-morbidity, the cumulative incidence of recurrence
may be influenced by the competing risk of death, partic-
ularly in these patients [18]. In the present study, we
therefore aimed to investigate the risk of recurrence and
mortality among patients with a first hospital-related
VTE, and to compare the impact of transient and persis-
tent hospital-related factors such as surgery, cancer or
other medical conditions on the risk of recurrence in
models with and without death as a competing event.
Methods
Study population
The source population comprised subjects participating in
the first (1974), second (1979/80), third (1986/87), fourth
(1994/95), fifth (2001/02) and sixth (2007/08) surveys of
the Tromsø study. The Tromsø study is a single-center,
population-based, prospective cohort study, with repeated
health surveys of inhabitants in the municipality of
Tromsø in the north of Norway. Further details about
the Tromsø study can be found elsewhere [19]. The
Regional Committee of Medical and Health Research
Ethics approved the study, and written consent was col-
lected from all participants. Overall, 39 825 unique indi-
viduals, aged 25–97 years, participated in at least one of
the surveys, which yielded an average participation rate
of 78.5% for all surveys. Participants that were still alive
and living in the municipality of Tromsø by 1 January
1994 (n = 33 885) were followed through to 31 December
2012, and all potential cases of first lifetime VTE were
identified by searching the hospital discharge diagnosis
registry, the autopsy registry and the radiology procedure
registry at the University Hospital of North of Norway.
This is the only hospital in the region and serves as the
exclusive provider of all diagnostic radiology procedures
and VTE-related healthcare in the area. Trained person-
nel reviewed the medical records for each potential VTE
case and extracted information for case-validation. A
VTE event was considered verified and recorded when
presence of clinical signs and symptoms of DVT or PE
were combined with objective confirmation tests (com-
pression ultrasonography, venography, spiral computed
tomography, perfusion-ventilation scan, pulmonary
angiography and autopsy) and resulted in a VTE diagno-
sis that required treatment, as previously described [20].
Using the criteria described above, 822 subjects with a
validated first lifetime VTE event were identified and
included in our study.
Patient characteristics
Information on clinical and provoking factors at the time of
and 8 weeks preceding the VTE event, were extracted by
review of medical records using standardized forms. We
defined a VTE as being hospital related when patients were
hospitalized within 8 weeks preceding the VTE (including
patients hospitalized at the time of VTE), had undergone
surgery (with or without subsequent hospitalization) within
8 weeks preceding the event or had active cancer. When
none of these factors could be identified, the event was clas-
sified as non-hospital-related. Cancer was registered as the
provoking factor only when patients had active cancer at the
time of the initial event. Bedrest was defined as confinement
to bed in hospital > 3 days, whereas other immobilization
was defined as transient or persistent use of a wheelchair or
long haul travel > 4 h (i.e. by airplane, train, car or boat).
Hospital-related VTE was classified into three main cate-
gories according to the main provoking factor for the first
VTE following the algorithm: cancer > surgery > hospital-
ization for other medical illness.
Clinical factors included were obesity, use of estrogens,
family history of VTE, pregnancy, puerperium or other co-
morbidities. Participants were classified as obese according
to the World Health Organization definition
(BMI > 30 kg m!2) [21]. Co-morbidity was defined as a
myocardial infarction or a stroke within the last 12 months
preceding the VTE, chronic obstructive pulmonary disease
(COPD), myeloproliferative disorders, systemic lupus ery-
thematosus or a chronic infection.
Outcomes
All cases of recurrent VTE were recorded in the period
1994–2012. The diagnosis of recurrent VTE was made
using the same criteria as described for validating first
lifetime VTE events. Information on mortality was col-
lected from the Norwegian Population Registry.
Statistics
Statistical analyses were performed using STATA version
14.0 (Stata Corporation LP, College Station, TX, USA).
The significance level was set to 0.05. For analyses of
recurrence, subjects were followed from the date of their
first VTE to the first occurring event of a recurrent VTE
(n = 132), death (n = 307), loss to follow-up as a result of
migration (n = 19) or end of follow-up (31 December
2012) (n = 364). Crude IRs of recurrent VTE were calcu-
lated and expressed per 100 person-years at risk. Kaplan–
Meier failure estimates were calculated and visualized
according to hospital-related classification of the first
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VTE (no hospitalization, cancer, surgery or hospitaliza-
tion because of other medical conditions). Moreover, Cox
proportional hazards regression models were performed
to estimate hazard ratios (HRs) with 95% confidence
intervals (CIs) of VTE recurrence according to individual
characteristics associated with the incident VTE event.
The HRs were estimated in two models, allowing for
adjustment of the other provoking factors in those with
multiple provoking factors. Model 1 included age and
sex, and Model 2 was a multivariable model that included
age, sex and all the characteristics of interest (i.e. surgery,
acute medical condition, cancer and bedrest > 3 days).
Furthermore, crude mortality rates per 100 person-years
and HRs of death were calculated using the same models
as described above. The proportional hazards assumption
was tested for all variables using Schoenfeld residuals.
Generally, hospitalized patients have poorer prognosis
than outpatients and healthy subjects. Because the mor-
tality rates were likely to differ among those with and
without hospital-related factors, the rates of VTE recur-
rence in these patients could potentially be overestimated
as a result of competing risk of death. In order to
account for death as a competing event, cumulative inci-
dence functions were performed and visualized using the
user-contributed stcompet suite and the stcrreg cif curve
in STATA (Stata Corporation LP).
Results
Of the 822 patients with validated first lifetime VTE, 19
died on the same day as the VTE occurred and were
therefore excluded from follow-up. The baseline charac-
teristics and the distribution of risk factors among
patients with and without hospital-related first VTE are
shown in Table 1. The patients with hospital-related VTE
were on average 4 years older (mean age = 68.9 " 13.5
vs. 64.9 " 14.7) and more likely to be female (54.4% vs.
49.5%) than those with a non-hospital-related VTE. Only
1.0% of the hospital-related events occurred in patients
with a reported history of first-degree relatives suffering
from a VTE before age 60, whereas 5.9% of the non-hos-
pital-related events occurred in patients with a known
family history of VTE. Furthermore, co-morbid condi-
tions were more common among the hospital-related
events as opposed to the non-hospital-related events
(24.3% vs. 18.8%). The durations of anticoagulant treat-
ment within subgroups of patients with hospital-related
VTE are shown in Table S1.
Recurrence
During the course of 3423 person-years of follow-up, 132
subjects experienced a recurrent episode of VTE. The mean
observation time was 4.3 years, ranging from 1 day to
18.8 years. The overall crude IR of recurrence was 3.9 per
100 person-years (95% CI, 3.3–4.6). Characteristics of the
VTE recurrences are shown in Table S2. A hospital-related
VTE per se was not associated with increased risk of recur-
rent thrombosis (HR, 0.99; 95% CI, 0.69–1.41) in the age-
and sex-adjusted model (Table 2). However, the recurrence
risk varied greatly according to the classification of the first
hospital-related event (Fig. 1A). After 5 years of follow-
up, the cumulative incidence of recurrence was 27.4%
(95% CI, 17.3–41.6) in patients with a first VTE associated
with cancer. Patients with a surgery-related first VTE had
the lowest risk of recurrence after 5 years (11.0%; 95% CI,
5.5–21.1), whereas patients hospitalized because of other
medical illness and non-hospital-related first events had a
20.1% (95% CI, 12.2–32.0) and 18.4% (95% CI, 14.5–
23.1) cumulative recurrence risk after 5 years, respectively.
The recurrence rate was highest during the first 12 months,
especially for cancer-related events and events associated
with other medical illness. When this relationship was
expressed in a Cox proportional hazard model (Table 2),
cancer patients had a 73% higher risk of recurrence (HR,
1.73; 95% CI, 1.06–2.81) and patients with surgery-asso-
ciated events had 47% lower risk of recurrence (HR, 0.53;
95% CI, 0.28–0.99) than those without hospital-related
events. Patients hospitalized with a medical illness other
than cancer or surgery appeared to have similar risk of
recurrence (HR, 1.02; 95% CI, 0.61–1.72) to those with a
Table 1 Characteristics of subjects with hospital-related and non-
hospital-related first venous thromboembolism
Hospital-related
Yes (n = 412) No (n = 410)
Age (years) 68.9 " 13.5 64.9 " 14.7
Sex (% women) 54.4 49.5
Obesity (% obese) 15.5 18.8
Location at onset
Hospital 38.3 –
Nursing home 2.9 4.4
Community 58.8 95.6
Deep vein thrombosis 59.2 57.6
Pulmonary embolism 40.8 42.4
Treatment duration with AC
0–3 months 36.4 16.8
3–6 months 36.7 48.0
6–12 months 20.6 27.6








Acute medical condition 21.6 5.6
Cancer 46.4 0
Confined to bed > 3 days 11.9 1.5
Other immobilization 15.8 7.6
Other provoking factor 7.0 2.9
Values are means " 1 SD or percentages. AC, anticoagulants;
FHVTE, family history of venous thromboembolism .
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non-hospital-related VTE. Further adjustment for duration
of anticoagulant treatment did not influence the risk esti-
mates (data not shown).
The IRs and HRs of VTE recurrence according to indi-
vidual characteristics associated with the first VTE are
presented in Table 3. In the multivariable model, in which
all characteristics were mutually adjusted for, surgery was
significantly associated with decreased risk of VTE recur-
rence, displaying a 61% (HR, 0.39; 95% CI, 0.21–0.71)
lower risk compared with those without a surgery-asso-
ciated first VTE (Table 3). Cancer, on the other hand,
was significantly associated with an almost 2-fold
increased risk of recurrence in this model (HR, 1.95; 95%
CI, 1.21–3.15).
Mortality
In total, 442 patients died during the course of 3896 per-
son-years of follow-up. Estimated mortality rates and
HRs of death according to classification of the first event
are shown in Table 4. Overall, patients with a hospital-
related VTE had a 2.8-fold higher risk of death (HR,
2.76; 95% CI, 2.26–3.37). Compared with non-hospital-
related events, patients with a first VTE event related to
cancer or other medical illness had a 7.4-fold and 2.2-fold
higher risk of death, respectively (HR, 7.39; 95% CI,
5.84–9.35; and HR, 2.20; 95% CI, 1.68–2.88), whereas
patients with a first VTE event related to surgery had a
13% lower risk of death (HR, 0.87; 95% CI, 0.60–1.26).
In multivariable analyses of the individual components,
cancer (HR, 6.09; 95% CI, 4.95–7.49), bedrest > 3 days
(HR, 2.47; 95% CI, 1.77–3.46) and acute medical condi-
tions (HR, 1.36; 95% CI, 1.05–1.78) were all significantly
associated with increased risk of death (Table 5).
Competing risk of death
Cumulative incidence functions (Fig. 1B) showed that
patients with a non-hospital-related first VTE had the
highest risk of recurrence, with a cumulative incidence of
16.4% (95% CI, 12.8–20.4) after 5 years, when death was
included as a competing event. In comparison, patients
with other medical illness had a cumulative incidence of
14.4% (95% CI, 8.4–21.9) after 5 years, whereas cancer
and surgery-related events had a similar cumulative inci-
dence of 11.7% (95% CI, 7.6–17.0) and 9.7% (95% CI,
4.5–17.4) after 5 years, respectively. Sub-distribution HRs
of VTE recurrence according to characteristics associated
with the first VTE are shown in Table 3.
Discussion
In the present study, subjects with a hospital-related first
VTE had a similar risk of recurrence to those with a non-
hospital-related VTE. However, Kaplan–Meier failure
Table 2 Incidence rates and risk of recurrent venous thromboembolism (VTE) by classification of hospital-related first VTE
n Recurrences IR (95% CI)* HR (95% CI†)
Non-hospital-related 410 81 3.7 (3.0–4.6) Reference
Hospital-related‡ 412 51 4.1 (3.1–5.4) 0.99 (0.69–1.41)
Cancer-related 191 22 8.8 (5.8–13.3) 1.73 (1.06–2.81)
Surgery-related 97 11 1.9 (1.0–3.4) 0.53 (0.28–0.99)
Other medical illness 124 18 4.7 (3.0–7.4) 1.02 (0.61–1.72)
CI, confidence interval; HR, hazard ratio; IR, incidence rates. *Per 100 person-years. †Adjusted for age and sex. ‡Hospital-related includes
patients hospitalized within 8 weeks preceding the VTE, who are further classified into three main categories according to the main provoking
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Fig. 1. Cumulative incidence of venous thromboembolism (VTE)
recurrence according to classification of the first VTE event in crude
analyses (A) and with death as a competing event (B). ––––––,
non- hospital-related; , cancer related; , surgery-related;
, other medical illness.
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estimates revealed considerable heterogeneity among the
hospital-related events with regards to recurrence risk.
Patients with index events related to hospitalization for
medical illness other than surgery or cancer had a similar
risk of recurrence to patients with a non-hospital-related
first VTE after 5 years of follow-up. In accordance with
previous studies [6,8,10–13,15], patients with cancer-
related first events were found to have a high risk of
recurrence, whereas patients with surgery-related first epi-
sodes of VTE had a low risk of recurrence after 5 years
of follow-up. A hospital-related first VTE was associated
with a 3-fold higher risk of death compared with non-
hospital-related VTE, and except for surgery-related
events, all subgroups of hospital-related VTE displayed
an increased mortality-risk. Consequently, the cumulative
recurrence rates decreased when competing risk of death
was taken into account. This was particularly pronounced
for cancer-related VTE, which was lower than the cumu-
lative risk among non-hospital-related cases and events
related to hospitalization for other medical illnesses.
The IR of VTE among hospitalized patients is > 100-
fold higher than among community residents [4] and the
risk of a first VTE is significantly increased during the ini-
tial 3-month period after a hospital stay [8]. For transient
risk factors, the risk of VTE recurrence is generally low
as long as the risk factor is removed and the effect of the
risk factor is reversible [8,11,12]. Thus, the transient nat-
ure of hospitalization could imply a low recurrence risk
among those with a first hospital-related VTE. In our
study, however, hospitalization within 8 weeks preceding
an incident VTE event, including patients admitted at the
time of the event, was not associated with a lower risk of
recurrence. Accordingly, a previous study of 1791 patients
with a first VTE recruited and followed in the period
1966–1990, showed no association between recent hospi-
talization (3 months preceding the first VTE) and risk of
recurrence (HR, 1.01) [8].
Although the recurrence risk did not differ among hos-
pital-related and non-hospital-related first VTEs, the rea-
son for hospitalization preceding the first event appeared
to have a major impact on recurrence risk. As shown in
previous studies [6,8,10–12,14–16], surgery, a transient
and reversible risk factor, was associated with a low risk
of recurrence in both conventional and competing risk
analyses. Cancer, a persistent and mostly irreversible risk
factor, was associated with a high risk of recurrence in
conventional Kaplan–Meier analyses. However, compet-
ing risk analyses revealed that this risk was substantially
Table 4 Mortality rates and risk of death by classification of hospi-
tal-related first venous thromboembolism
n Deaths MR (95% CI)* HR (95% CI)†
Non-hospital-
related
410 148 5.8 (4.9–6.8) Reference
Hospital-related‡ 412 294 21.9 (19.5–24.5) 2.76 (2.26–3.37)
Cancer 191 171 65.5 (56.4–76.1) 7.39 (5.84–9.35)
Surgery 97 34 5.4 (3.8–7.5) 0.87 (0.60–1.26)
Other medical
illness
124 89 19.8 (16.1–24.4) 2.20 (1.68–2.88)
CI, confidence interval; HR, hazard ratio; MR, mortality rates. *Per
100 person-years. †Adjusted for age and sex. ‡Hospital-related
includes patients hospitalized within 8 weeks preceding venous
thromboembolism, who are further classified into three main cate-
gories according to the main provoking factor following the algo-
rithm: cancer > surgery > hospitalization for other medical illness.
Table 3 Incidence rates and risk of venous thromboembolism (VTE) recurrence according to individual characteristics associated with the first
VTE




HR (95% CI) SHR (95% CI)†
Surgery 12 1.8 (1.0–3.2) 0.45 (0.25–0.81) 0.39 (0.21–0.71) 0.52 (0.28–0.93)
Acute medical condition 18 5.7 (3.6–9.0) 1.35 (0.82–2.22) 1.32 (0.78–2.25) 1.10 (0.66–1.84)
Bedrest > 3 days 7 6.6 (3.1–13.7) 1.66 (0.78–3.57) 1.85 (0.81–4.21) 0.83 (0.38–1.83)
Cancer 22 8.8 (5.8–13.3) 1.87 (1.17–2.99) 1.95 (1.21–3.15) 0.66 (0.41–1.06)
CI, confidence interval; HR, hazard ratio; IR, incidence rate; SHR, sub-distribution hazard ratio (competing risk analysis).*Per 100 person-
years. †Model 1: adjusted for age and sex. ‡Model 2: adjusted for surgery, acute medical condition, bedrest > 3 days, cancer, age and sex.
Table 5 Mortality rates and risk of death according to individual characteristics associated with the first venous thromboembolism





Surgery 60 8.5 (6.6–10.9) 0.77 (0.59–1.02) 0.62 (0.47–0.82)
Acute medical condition 84 23.1 (18.7–28.6) 1.72 (1.35–2.18) 1.36 (1.05–1.78)
Bedrest > 3 days 47 40.9 (30.7–54.4) 3.01 (2.21–4.09) 2.47 (1.77–3.46)
Cancer 171 65.5 (56.4–76.1) 6.09 (4.95–7.49) 6.09 (4.94–7.51)
CI, confidence intervals; HR, hazard ratio; MR, mortality rate. *Per 100 person-years. †Model 1: adjusted for both age and sex. ‡Model 2:
adjusted for surgery, acute medical condition, bedrest > 3 days, cancer, age and sex.
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overestimated as a result of the high mortality rate among
cancer patients.
Whether hospitalization for medical illnesses other than
cancer or surgery should be regarded as a temporary risk
condition with a low recurrence risk is not well studied.
Heit and colleagues [22] found a non-significant 15%
increased risk of recurrence among those with a first VTE
related to hospitalization for acute medical illness com-
pared with all other VTEs (i.e. hospitalized for other con-
ditions and non-hospitalized). A study of 1626 VTE
patients followed for a median of 50 months after with-
drawal of anticoagulation, reported that patients who had
been bedridden for > 1 week because of a medical disease
preceding the first VTE were more likely to develop
recurrence than those with recent trauma or surgery [9].
However, this study did not distinguish between hospital-
ized and non-hospitalized patients. In our study, we
showed that patients with a first VTE related to hospital-
ization for medical illness other than cancer or surgery
had similar risk of recurrence to subjects with a non-hos-
pital-related VTE, and that the cumulative incidence of
recurrence remained high even after the competing risk of
death was taken into account.
The relatively high rates of recurrence after a first VTE
related to hospitalization for a medical illness point
towards a persistent nature of the VTE risk in these sub-
jects. Several chronic conditions, such as chronic heart and
lung diseases, as well as inflammatory and autoimmune
disorders, are associated with coagulation and fibrinolytic
abnormalities [23–27], endothelial dysfunction [23–27],
increased platelet activation [24,25,27] and inflammation
[23–25,27], which may induce a prothrombotic state.
Moreover, disease-specific mechanisms, such as hypoxia in
COPD patients [24] and right ventricular failure with sub-
sequent venous stasis in patients with congestive heart fail-
ure, [25,26] may add to the VTE risk, and flare-up periods
[27–29] or exacerbations [30,31] that lead to re-hospitaliza-
tion may induce additional prothrombotic risk factors,
such as immobilization. The latter is supported by Heit
et al. [22], who studied hospitalization as an interim expo-
sure after a first VTE and found that patients hospitalized
for a medical illness had an almost 6-fold increased risk of
VTE recurrence during the hospital stay, and a 2.6-fold
increased risk within 92 days post-dismissal.
Previous studies have shown both in-hospital and post-
hospital discharge [32], as well as cancer and several other
medical co-morbidities, to be associated with high mortal-
ity rates after a first VTE [1,7,33,34], whereas the opposite
findings have been reported for various types of surgery
[33]. Accordingly, in the present study, increased mortality
rates were found for all subgroups of VTE patients, except
for those with surgery-related events. Our estimated 6.1-
fold higher mortality risk among cancer patients vs. can-
cer-free subjects is consistent with previous studies in
which risk estimates ranging from 4.5 to 9.5 were reported
[1,7,33,34]. Moreover, our findings of a 2-fold increased
risk of death among patients with acute medical conditions
is in agreement with previous studies showing that heart
diseases, neurologic diseases and chronic lung , renal and
liver diseases are associated with a 2- to 4-fold increased
risk of death in patients with VTE [33,35,36].
In the presence of competing risk of death, the cumula-
tive incidence of recurrence is dependent on both the haz-
ard of recurrence and the hazard of dying, and
consequently, recurrence risks are overestimated when the
mortality rate is high [37–39]. Accordingly, the cumulative
incidences of recurrence were lower in all subgroups after
competing risk analysis in our study. In patients with a first
VTE related to hospitalization for medical illness, the
5-year cumulative recurrence dropped from 20.1% to
14.4%, suggesting a moderate role of hospital-related mor-
tality in estimating recurrence risk among these patients.
The change was much more pronounced in cancer patients
(dropped from 27.4% to 11.7%), and the 5-year cumula-
tive incidence was comparable to that of surgery-related
first VTE (11.7% vs. 9.7%). This result is in contrast to the
study by Heit et al. [22], which reported a 5-year cumula-
tive incidence of 34% in cancer-related VTE and 17% in
secondary non-cancer VTE (including subjects hospitalized
for surgical or medical conditions) in competing risk analy-
sis. The diverging results may in part be explained by the
vast difference in mortality rates between the studies, par-
ticularly among cancer patients, as well as differences in
the length of follow-up and definition of active cancer.
Current guidelines recommend short-term (3 months)
anticoagulant treatment over longer-term treatment in
patients with a DVT or PE provoked by a non-surgical
transient risk factor [40]. Although hospitalization for a
medical condition other than cancer or surgery is a tran-
sient condition, the high recurrence risk among these
patients suggests a more persistent underlying VTE risk
that may justify similar treatment recommendations to
those for unprovoked VTE, as well as increased aware-
ness of recurrence risk in high-risk situations such as re-
hospitalization.
The strengths of the present study include the recruit-
ment of patients with first VTE from a general popula-
tion, the prospective design and long-term follow-up.
Because a single hospital serves the entire study popula-
tion the chance of missing outcomes is very low. More-
over, the combination of multiple approaches to identify
cases, comprehensive medical records review and firm cri-
teria for VTE assessment yields thorough validation of
first and recurrent VTE events. Advances in prevention,
diagnosis and treatment of VTE may have influenced out-
comes during the last two decades and our data have the
advantage of being collected from a recent time period
compared with previous studies [6,8,22]. The study has
limitations. Information on patient characteristics was
collected from medical records and relied on the reporting
by physicians, nurses and other healthcare professionals.
However, the main exposures in this study are major
© 2016 International Society on Thrombosis and Haemostasis
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clinical events for which one would expect a low degree
of under-reporting and misclassification. Unfortunately,
because of the low number of events we had limited sta-
tistical power in subgroups and our findings should there-
fore be interpreted with caution. Moreover, we did not
have the possibility to further investigate the recurrence
risk among different disease entities in patients with a
first VTE related to hospitalization for medical illness.
In conclusion, the risk of recurrence after a hospital-
associated first VTE appeared to be dependent on the
reason for hospitalization. However, except for surgery-
related VTE, this did not hold true in the competing risk
analysis. Our findings suggest that patients suffering from
incident VTEs associated with hospitalization for medical
illness other than cancer or surgery have a high risk of
recurrence, even after competing risk of death is taken
into account.
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Essentials
• Whether D-dimer at incident venous thromboembolism
(VTE) can predict recurrence-risk is unknown.
• We explored this association in 454 cancer-free patients
with a first lifetime VTE.
• A low D-dimer at first VTE diagnosis was associated
with a low recurrence risk.
• The association was predominant in patients with deep
vein thrombosis and unprovoked VTE.
Click to hear Dr Cannegieter’s presentation on venous
thrombosis: prediction of recurrence
Summary. Background: Venous thromboembolism (VTE)
is a common disease with a high recurrence rate. D-dimer
measured after cessation of anticoagulant therapy predicts
recurrence, and is used to decide on treatment prolonga-
tion. However, whether D-dimer measured at first VTE
diagnosis can be used to assess recurrence-risk is unknow-
n. Aims: To investigate the association between D-dimer,
measured at first VTE diagnosis and risk of recurrent
VTE. Methods: Information on clinical risk factors and
laboratory markers were collected in 454 cancer-free
patients with a first VTE. Recurrent VTEs and deaths dur-
ing follow-up (1994–2012) were recorded. Results: During
a median follow-up of 3.9 years, 84 patients experienced a
recurrent VTE. The crude recurrence rate was 1.7 (95%
confidence interval [CI], 1.0–2.9) per 100 person-years in
the lower quartile of D-dimer (≤ 1500 ng mL1), and 4.9
(95% CI, 3.9–6.1) per 100 person-years in the upper
three quartiles combined, yielding an absolute risk
difference of 3.2 per 100 person-years. Patients with
D-dimer ≤ 1500 ng mL1 had 54% lower recurrence-risk
than patients with D-dimer > 1500 ng mL1 (HR, 0.46;
95% CI, 0.25–0.82). The association was particularly pro-
nounced among patients with unprovoked events and deep
vein thrombosis, showing a 66% (HR, 0.34; 95% CI, 0.15–
0.74) and 68% (HR, 0.32; 95% CI, 0.14–0.71) lower recur-
rence risk among patients with D-dimer ≤ 1500 ng mL1,
respectively. Conclusions: A low D-dimer (≤ 1500 ng
mL1) measured at first VTE diagnosis was associated with
a low recurrence risk, particularly among patients with
DVT and unprovoked events. Our findings suggest that a
clinical decision to avoid prolonged anticoagulant treat-
ment could be considered based on low D-dimer at the time
of VTE diagnosis.
Keywords: epidemiology; D-dimer; prediction; recurrence;
venous thromboembolism.
Introduction
Venous thromboembolism (VTE), a conceptual term for
deep vein thrombosis (DVT) and pulmonary embolism
(PE), is a serious disease that recurs in up to 30–40% of
patients within 10 years following the first event [1–5].
Recurrent events can be effectively prevented through sec-
ondary prophylaxis with anticoagulants [6,7], although at
the cost of an increased risk of bleeding [8]. The challenge
therefore lies in identifying patients who may benefit from
extended thromboprophylaxis, but with minimal risk of
bleeding complications. Likewise, to avoid unnecessary
exposure to bleeding risk, it is desirable to identify sub-
jects with low risk of VTE recurrence in whom short-term
treatment with anticoagulants would be sufficient.
D-dimer, a global biomarker of coagulation activation
and fibrinolysis, is commonly used in clinical algorithms for
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the diagnostic work-up of patients with suspected VTE
[9,10]. Several studies have shown that elevated D-dimer
levels measured during or after cessation of anticoagulant
therapy are associated with increased risk of recurrence in
patients with unprovoked VTE [11–13] and are therefore
regularly applied to assess individual recurrence risk and
guide decisions on treatment prolongation [14–17]. How-
ever, this strategy is resource demanding both for the
patient and the healthcare system because of additional
blood sampling and outpatient clinic visits for evaluation of
recurrence risk. Information on D-dimer is widely available
for most VTE patients at the time of diagnosis. Therefore,
there is a clinical rationale to explore whether D-dimer,
measured at the time of first VTE diagnosis (i.e. before initi-
ation of anticoagulant therapy), can be used to distinguish
between patients at high and low risk of recurrence. Our
hypothesis was that low plasma D-dimer concentration at
VTE diagnosis could identify subjects at low risk of recur-
rence. Therefore, we aimed to investigate the association
between D-dimer, measured at the time of the first VTE
diagnosis, and risk of recurrent VTE.
Methods
Study population
The source population comprised subjects participating in
≥ 1 of the six currently conducted surveys of the Tromsø
study (hereby referred to as Tromsø 1–6), who were still
alive and living in Tromsø by 1 January 1994
(n = 33 885). The Tromsø study is a single-center, popu-
lation-based prospective cohort study, with repeated
health surveys of inhabitants in Tromsø, Norway.
Detailed information about the Tromsø study can be
found elsewhere [18]. The study was approved by the
Regional Committee of Medical and Health Research
Ethics, and all participants gave their informed written
consent. The overall attendance rates were high, ranging
from 85% in Tromsø 2 to 66% in Tromsø 6, with an
average of 78.5% for the six surveys.
Participants were followed from the date of inclusion in
1994 through to the end of the study on 31 December 2012.
All potential cases of first lifetime VTE during follow-up
were identified by searching the hospital discharge diagnosis
registry, the autopsy registry and the radiology procedure
registry at the University Hospital of North of Norway
(UNN), which is the exclusive provider of all in- and outpa-
tient VTE-related diagnostic procedures and VTE-related
healthcare in the Tromsø region. Trained personnel
reviewed the medical records for each potential VTE case
and extracted information for case validation, as well as
information on clinical risk factors and laboratory markers,
using standardized forms. A VTE event was considered ver-
ified and recorded when presence of clinical signs and symp-
toms of DVT or pulmonary embolism were combined with
objective confirmation tests (compression ultrasonography,
venography, spiral computed tomography, perfusion-venti-
lation scan, pulmonary angiography or autopsy) and
resulted in a VTE diagnosis that required treatment, as pre-
viously described [19]. Applying these criteria, we identified
822 subjects with a thoroughly validated first lifetime VTE
diagnosis. D-dimer has low specificity for the diagnosis of
VTE as it is often elevated in conditions such as malig-
nancy, infections or inflammatory states [20–22]. Conse-
quently, we excluded VTE patients with active cancer
(n = 124) and patients already hospitalized for other condi-
tions when the VTE occurred (n = 158). Moreover, patients
with missing D-dimer values (n = 86) were excluded, which
left us with 454 included VTE patients in our study.
Patient characteristics
Information on clinical and provoking factors at the time
of and 8 weeks preceding the VTE event was obtained for
all eligible patients. The VTE event was classified as pro-
voked if preceded by (i) major surgery, trauma or an acute
medical condition (acute myocardial infarction, ischemic
stroke or major infectious disease) within 8 weeks prior to
the event, (ii) marked immobilization (confinement to bed
>3 days, confinement to wheelchair or long-distance travel
exceeding 4 hours within the last 14 days prior to the
event) or (iii) any other factor specifically described in the
medical records to have provoked the VTE (e.g. intravascu-
lar catheter). If no provoking factor could be identified, the
VTE was classified as unprovoked.
Clinical risk factors included were obesity, family history
of VTE, use of estrogens, pregnancy, puerperium or other
co-morbidities. The classification of obesity was made
according to the definition from the World Health Organi-
zation (BMI > 30 kg m2) [23]. Family history of VTE was
defined as having a first-degree relative who suffered from a
VTE before the age of 60 years. Co-morbidity was defined
as having a myocardial infarction or a stroke within the last
12 months preceding the VTE, chronic obstructive pul-
monary disease, myeloproliferative disorders, systemic
lupus erythematosus (SLE) or chronic infection.
D-dimer measurements
D-dimer levels were assessed as part of the diagnostic
work-up of patients with suspected VTE, and a negative
test was defined as a D-dimer value < 500 ng mL1. All
blood samples were analyzed at the Department of Clini-
cal Chemistry at the University Hospital of North Nor-
way. In the period 1994–98 the NycoCard D-Dimer
(Nycomed Pharma, Oslo, Norway) assay, based on the
immunometric flow-through principle, was used to assess
D-dimer. In the remaining period (1998–2012) D-dimer
was assayed with the STA-Liatest D-Di FM from
Stago (Diagnostica Stago, Asnieeres, France). This test
quantitatively measures D-dimer levels by the immuno-
turbidimetric method (liquid reagent).
© 2017 International Society on Thrombosis and Haemostasis
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Outcome registration of recurrent VTE and deaths
All recurrent VTE events during follow-up in the period
1994 through to 2012 were identified and validated using
the same criteria as described for the validation of first
lifetime VTE events. Information on mortality was
obtained from the Norwegian Population Registry.
Statistics
For analyses of recurrence, subjects were followed from
the date of their first VTE to the first occurring event of
either recurrent VTE, death or loss to follow-up as a
result of migration, or end of follow-up (31 December
2012). The study population was divided into quartiles
based on D-dimer levels (quartile 1, ≤ 1500 ng mL1;
quartile 2, 1600–3000 ng mL1; quartile 3, 3100–
7000 ng mL1; quartile 4, ≥ 7100 ng mL1). Crude inci-
dence rates (IRs) of recurrent VTE were calculated across
categories of D-dimer and expressed per 100 person-years
at risk. Cox proportional hazards regression models were
used to estimate hazard ratios (HRs) with 95% confi-
dence intervals (CIs). In the analysis across quartiles of
D-dimer, the highest quartile was set as the reference. To
test our hypothesis that low levels of D-dimer could iden-
tify patients at low risk of recurrence, we dichotomized
the D-dimer variable by merging the upper three quartiles
and used this upper category as the reference group. The
HRs were estimated in two models; the first was adjusted
for age and sex, and the second was additionally adjusted
for duration of anticoagulant treatment. The proportional
hazards assumption was tested for all variables using
Shoenfeld residuals. Cumulative incidences were calcu-
lated and visualized in 1-Kaplan-Meier (1-KM) plots,
both for overall VTE and in subgroups of VTE (i.e.
among provoked and unprovoked first VTE events, and
among first DVTs and PEs). In analyses according to
clinical presentation, patients were classified as having
isolated DVT or PE (with or without concurrent DVT).
In the presence of competing risk by death the cumula-
tive incidence of recurrence is dependent on both the haz-
ard of VTE and the hazard of death, and consequently
the 1-KM is often overestimated in the regular analyses
[24–26]. In order to evaluate the influence of the compet-
ing risk by death, sub-distribution hazard ratios (SHRs)
and cumulative incidence functions (CIFs) were per-
formed and visualized for overall VTE recurrence using
the stcrreg and the stcrreg cif curve commands in Stata.
All statistical analyses were performed using Stata version
14.0 (Stata Corporation LP, College Station, TX, USA).
Previous studies have shown that women with estro-
gen-related VTE and patients with distal DVT have a low
risk of recurrence [16,27–30]. As these conditions may
also be associated with low D-dimer levels, we performed
sensitivity analyses in patients without estrogen-associated
VTE, as well as in patients with proximal DVT, in order
to rule out potential confounding by such low-risk
groups.
Results
Baseline characteristics and distribution of risk factors
according to quartiles of D-dimer are presented in
Table 1. Compared with the upper three quartiles, sub-
jects in the lowest quartile tended to be younger and
more likely female, and a slightly higher proportion were
obese. Additionally, patients in the lowest quartile tended
to be treated with anticoagulants for a shorter duration
of time (< 6 months) than patients in the upper three
quartiles. Co-morbidities and acute medical conditions
were less common among patients with a D-dimer in the
lowest quartile.
Of the 454 eligible patients with a validated first life-
time VTE, 84 patients experienced a recurrent VTE event
during a median of 3.9 years of follow-up. Crude recur-
rence rates and hazard ratios of recurrent VTE according
to quartiles of D-dimer are presented in Table 2. Com-
pared with quartile 4, patients with a D-dimer value in
quartile 2 (HR, 0.88; 95% CI, 0.50–1.58) and quartile 3
(HR, 1.00; 95% CI, 0.56–1.57) had a similar risk of recur-
rence, whereas patients with a D-dimer below
1500 ng mL1 had a 55% lower risk of recurrence (HR,
0.45; 95% CI, 0.23–0.89). The results were essentially sim-
ilar in the competing risk model. The 10-year cumulative
incidence of recurrence was 33.2% (95% CI, 21.2–49.5),
34.2% (95% CI, 23.0–48.7) and 34.8% (95% CI, 21.6–
52.9) among patients with a D-dimer value in quartile 2,
3 and 4, respectively, and 14.4% (95% CI, 8.4–23.8) in
patients with a D-dimer value in quartile 1 (Fig. 1A). The
corresponding 1- and 5-year cumulative incidence esti-
mates were 1.7% (95% CI, 0.4–6.6) and 8.5% (95% CI,
4.5–15.8) in quartile 1, 6.0% (95% CI, 2.8–13.0) and
22.9% (95% CI, 15.1–33.9) in quartile 2, 7.8% (95% CI,
4.0–15.0) and 23.7% (95% CI, 15.6–35.1) in quartile 3,
and 9.0% (95% CI, 4.8–16.6) and 23.0% (95% CI, 15.4–
33.6) in quartile 4. In competing risk analyses (Fig. 1B),
the 10-year cumulative incidence estimate of recurrence
dropped by almost 10% in the upper three quartiles
(quartile 2: 24.2%, quartile 3: 26.2% and quartile 4:
24.8%), whereas it remained essentially unchanged in
patients with a D-dimer in the lowest quartile (14.1%).
Analyses restricted to the time after termination of anti-
coagulant therapy produced similar results (Figure S2).
Risk estimates of recurrent VTE according to a D-dimer
cut-off of ≤ 1500 ng mL1, for overall VTE and in sub-
groups of VTE patients, are shown in Table 3. For overall
VTE, the crude incidence rate was 1.7 (95% CI, 1.0–2.9)
per 100 person-years in the lower quartile
(≤ 1500 ng mL1) and 4.9 (95% CI, 3.9–6.1) per 100 per-
son-years in the upper three quartiles combined, yielding
an absolute risk difference of 3.2 per 100 per year. The
overall recurrence risk was 53% lower in patients with a
© 2017 International Society on Thrombosis and Haemostasis
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D-dimer ≤ 1500 ng mL1 as compared with patients with
a D-dimer > 1500 ng mL1 (HR, 0.47; 95% CI, 0.26–0.84)
in the age- and sex-adjusted model. Stratification by pro-
voked and unprovoked VTE, and by DVT and PE,
revealed that the association was particularly pronounced
among unprovoked events and among patients with inci-
dent DVT, showing a 64% (HR, 0.36; 95% CI, 0.17–0.77)
and 69% (HR, 0.31; 95% CI, 0.14–0.70) reduced risk of
recurrence, respectively. D-dimer ≤ 1500 ng mL1 was
also associated with lower risk estimates in patients with
provoked VTE (HR, 0.69; 95% CI, 0.27–1.72) and patients
with PE (HR, 0.78; 95% CI, 0.33–1.87), but the results
were not statistically significant (Table 3). Additional
adjustment for duration of anticoagulant treatment had
negligible effect on the risk estimates (Table 3, Model 2).
Cumulative incidence of VTE recurrence according to
quartiles of D-dimer in patients with unprovoked VTE and
DVT are shown in Fig. 2. Among patients with unprovoked
VTE, a similar pattern to that for overall VTE was observed
(Fig. 2A), with considerably higher 10-year cumulative inci-
dences among patients with D-dimer levels above than
below 1500 ng mL1 (quartile 2, 39.7%, 95% CI 23.9–60.9;
quartile 3, 39.8%, 95% CI 24.7–59.6; quartile 4, 26.4%,
95% CI 15.3–43.2; vs. quartile 1, 12.8%, 95% CI 6.5–24.4).
In quartile 1, the 1- and 5-year cumulative incidences of
recurrence were 1.4% (95% CI, 0.2–9.3) and 10.5% (95%
CI, 5.1–20.9), respectively. Among patients with DVT, the
10-year cumulative incidence of recurrence ranged from
14.6% (95% CI, 7.1–28.7) among patients with a D-dimer
value below 1500 ng mL1 to 51.3% (95% CI, 31.5–74.6) in
patients with a D-dimer ≥ 7100 ng mL1 (Fig. 2B). In sub-
jects with provoked VTE and PE, the cumulative incidence
of recurrence was essentially similar to that of overall VTE
in those with D-dimer ≤ 1500 ng mL1 (16.7% and 13.6%),
but the effect across quartiles was not as consistent as for
unprovoked VTE and DVT (Figure S1).
Table 1 Baseline characteristics across quartiles (Q) of D-dimer
Q1 (n = 122) Q2 (n = 105) Q3 (n = 116) Q4 (n = 111)
D-dimer range (ng mL1) ≤ 1500 1600–3000 3100–7000 ≥ 7100
Age (years) 62.0  16.23 66.1  13.6 66.4  14.5 69.1  14.3
Sex (% women) 59.8% 46.7% 45.7% 49.6%
Obesity (% obese) 21.3% 18.1% 19.0% 13.5%
Deep vein thrombosis 58.2% 57.1% 60.3% 49.5%
Pulmonary embolism 41.8% 42.9% 39.7% 50.5%
Treatment duration with AC
0–3 months 21.3% 14.3% 20.7% 11.7%
3–6 months 54.1% 52.4% 44.8% 44.1%
6–12 months 21.3% 25.7% 26.7% 35.1%
> 12 months 3.3% 7.6% 7.8% 9.0%
Duration of symptoms
0–2 days 36.9% 34.3% 29.3% 41.4%
3–7 days 27.1% 39.1% 38.8% 31.5%
>7 days 32.9% 22.9% 29.3% 20.7%
Clinical risk factors
Estrogens 9.8% 5.7% 8.6% 6.3%
FHVTE 6.6% 6.7% 4.3% 4.5%
Co-morbidity (%) 14.8% 21.9% 18.1% 20.7%
Pregnancy/postpartum 1.6% 1.0% 0.0% 2.7%
Surgery (%) 13.1% 10.5% 16.4% 12.6%
Trauma (%) 13.1% 6.7% 9.5% 9.9%
Acute medical condition (%) 2.5% 7.6% 9.5% 14.4%
Confined to bed > 3 days preceding 1.6% 1.0% 3.4% 2.7%
Other immobilization 15.6% 6.7% 10.4% 12.6%
Other provoking factor 4.1% 2.9% 3.5% 2.7%
Values are means  1 SD or percentages. AC, anticoagulants; FHVTE, family history of VTE; VTE, venous thromboembolism.
Table 2 Incidence rates and risk of recurrent venous thromboembolism (VTE) by quartiles (Q) of D-dimer
D-dimer (ng mL1) Recurrences IR (95% CI)* HR (95% CI) SHR (95% CI)
Q4 (≥ 7100) 23 5.43 (3.61–8.17) Ref. Ref.
Q3 (3100–7000) 24 4.65 (3.11–6.93) 1.00 (0.56–1.77) 1.07 (0.60–1.90)
Q2 (1600–3000) 23 4.60 (3.06–6.92) 0.88 (0.50–1.58) 0.98 (0.64–1.76)
Q1 (0–1500) 14 1.71 (1.02–2.90) 0.45 (0.23–0.89) 0.53 (0.27–1.06)
HRs are adjusted for age and sex. CI, confidence interval; HR, hazard ratio; IR, incidence rate; SHR, sub-distribution hazard ratio.*Per 100
person-years.
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Analysis restricted to patients without estrogen-related
VTE and analysis of patients with proximal DVT showed
similar results (Table S1).
Discussion
In the present study, we investigated whether D-dimer
measured at the time of VTE diagnosis, before initiation
of anticoagulant therapy, was associated with risk of
recurrence. We found that subjects with a D-dimer value
≤ 1500 ng mL1 had a substantially lower risk of VTE
recurrence compared with patients with a D-dimer
> 1500 ng mL1. The overall incidence rate of recurrence
was 1.7 per 100 person-years in those with D-dimer
≤ 1500 ng mL1, and the 10-year cumulative incidence
was 14%. The association between low D-dimer and
recurrence was particularly pronounced among patients
with incident DVT and in patients with a first unpro-
voked VTE event, who had a 69% and 64% lower risk of
recurrence, respectively. The corresponding absolute risk
differences were 4.1 and 3.5 per 100 persons per year.
Our findings suggest that a low D-dimer measured at the
time of VTE diagnosis may aid decisions on short-term
treatment, particularly in patients with unprovoked VTE.
However, our findings need to be confirmed in additional
observational studies and tested in clinical randomized
studies.
To our knowledge, no previous study has investigated
the association between D-dimer measured at the time of
VTE diagnosis and the risk of recurrent events. In THE-
VTE study [31], patients with an elevated D-dimer level
(> 500 ng mL1), measured 2–3 months after discontinu-
ation of anticoagulation, had a more than 2-fold higher
risk of recurrence than patients with a normal D-dimer
level, and the absolute recurrence rate was 1.8 per 100
person-years in those with normal D-dimer. In a cohort
of 610 VTE patients [32], D-dimer levels measured shortly
after discontinuation of anticoagulant therapy were
related to risk of recurrence, with the risk being 40% and
70% reduced in patients with a D-dimer in the range
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Fig. 1. Cumulative incidence of venous thromboembolism (VTE)
recurrence stratified by quartiles of D-dimer in crude analyses
(Panel A) and with death as a competing event (Panel B).
Table 3 Incidence rates and risk of recurrent venous thromboembolism (VTE) by categories of D-dimer
D-dimer (ng mL1) Recurrences IR (95% CI)* HR (95% CI)† HR (95% CI)‡
Overall
Q2–Q4 (≥ 1600) 70 4.86 (3.85–6.14) Ref. Ref.
Q1 (0–1500) 14 1.71 (1.02–2.90) 0.47 (0.26–0.84) 0.46 (0.25–0.82)
Unprovoked
Q2–Q4 (≥ 1600) 46 5.43 (4.07–7.25) Ref. Ref.
Q1 (0–1500) 8 1.57 (0.79–3.14) 0.36 (0.17–0.77) 0.34 (0.15–0.74)
Provoked
Q2–Q4 (≥ 1600) 24 4.05 (2.71–6.03) Ref. Ref.
Q1 (0–1500) 6 1.95 (0.88–4.35) 0.69 (0.27–1.72) 0.68 (0.27–1.73)
DVT
Q2–Q4 (≥ 1600) 50 5.77 (4.37–7.61) Ref. Ref.
Q1 (0–1500) 7 1.40 (0.67–2.95) 0.31 (0.14–0.70) 0.32 (0.14–0.71)
PE
Q2–Q4 (≥ 1600) 20 3.49 (2.25–5.40) Ref. Ref.
Q1 (0–1500) 7 2.20 (1.05–4.62) 0.78 (0.33–1.87) 0.66 (0.27–1.63)
CI, confidence interval; HR, hazard ratio; IR, incidence rate. *Per 100 person-years. †HRs are adjusted for age and sex. ‡HRs are adjusted for
age, sex and duration of anticoagulant treatment.
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250–750 ng mL1 and < 250 ng mL1, respectively, as
compared with patients with a D-dimer ≥ 750 ng mL1.
Furthermore, a 2.6-fold increased risk of recurrence was
found for patients with elevated compared with normal D-
dimer in a patient level meta-analysis investigating the abil-
ity of D-dimer to assess recurrence risk after unprovoked
VTE [13]. The annualized recurrence rates ranged from 2.0
to 4.2, and from 7.4 to 10.2, per 100 for those with normal
compared with elevated D-dimer, respectively [13]. In the
PROLONG study [33], elevated D-dimer measured
1 month after discontinuation of treatment was associated
with a 2.5-fold increased risk of adverse outcomes (recur-
rent VTE or major bleeding), and the absolute rates were
4.4 and 10.9 per 100 person-years for patients with normal
and elevated D-dimer, respectively.
Current treatment guidelines for VTE recommend at
least 3 months of anticoagulant therapy [34], with subse-
quent evaluation of the risk–benefit ratio for extended
therapy in patients with unprovoked DVT or PE. Whether
D-dimer levels measured 1 month after anticoagulation
withdrawal can be used to select patients with unprovoked
VTE who can stop anticoagulant therapy is debated [27].
In our study, patients with a D-dimer level
≤ 1500 ng mL1 measured in the acute phase of VTE had
a low absolute risk of recurrence. Noticeably, the recur-
rence rates observed in the lowest D-dimer category in our
study were similar to [31] or lower than [13,33] the rates
among patients with normal D-dimer (i.e. < 500 ng mL1)
in studies that measured D-dimer after treatment
withdrawal. The absolute recurrence rates in those with
D-dimer ≤ 1500 ng mL1 were 1.7% at 1 year and 8.5%
at 5 years for overall VTE, and correspondingly 1.4% and
10.5% in those with unprovoked VTE. Of note, these rates
are below the rates considered acceptable to justify stop-
ping anticoagulation (5% at 1 year and 15% at 5 years)
according to the recommendation from the Subcommittee
on Control of Anticoagulation of the International Society
of Thrombosis and Haemostasis [35]. However, because of
limited statistical power in subgroups, some of the confi-
dence intervals exceeded the upper limit of the recom-
mended rates, and our findings should therefore be
interpreted with some caution.
As information on D-dimer is widely available for most
VTE patients at the time of diagnosis, the potential use
of D-dimer to identify patients at low risk of recurrence
may have great clinical utility for the initial decision on
treatment duration and further follow-up of the patients.
Current risk prediction models for VTE recurrence
among patients with a first unprovoked VTE, such as the
Vienna prediction model [16], the DASH prediction rule
[15] and the Men continue and HER DOO2 rule [17], all
make use of D-dimer measurements during or after anti-
coagulation, together with clinical predictors, to distin-
guish patients at high and low risk of recurrence. The
clinical elements included in these rules can usually be
assessed at the initial patient examination. Thus, if
D-dimer assessment before start of anticoagulation can
be utilized in similar upcoming prediction models to iden-
tify patients at low risk of recurrence, it may prove valu-
able for both clinicians and patients. For the clinicians, it
may provide the opportunity to make decisions on treat-
ment duration upon hospital discharge, and reduce the
need for additional outpatient care after discontinued
treatment. For the patients, information on the prognosis
of the disease may provide well-appreciated reassurance
and, as the need for additional blood sampling is reduced,
the patients will be less subjected to additional discomfort.
Women with estrogen-related first VTEs and patients
with distal DVT have previously been shown to have a
low risk of recurrence [16,27–30]. To investigate whether
the observed association could be driven by such low-risk
patient groups, we performed separate analyses excluding
women with estrogen-associated first VTEs, as well as
analysis restricted to patients with proximal DVT. The
results of these sub-studies were essentially similar to
those of the overall analysis and analysis of all DVT
patients, respectively. Furthermore, neither adjustment
for duration of anticoagulant treatment nor analysis of
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Fig. 2. Cumulative incidence of venous thromboembolism (VTE)
recurrence stratified by quartiles of D-dimer in patients with unpro-
voked VTE (Panel A) and in patients with deep vein thrombosis
(DVT) (Panel B).
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the cumulative incidence with and without death as a
competing event after cessation of anticoagulant treat-
ment noticeably altered the results.
Recruitment of VTE patients from a general popula-
tion, high attendance rates, prospective design and long-
term follow-up are among the main strengths of the pre-
sent study. Furthermore, all VTE-related health care in
the municipality of Tromsø is provided by a single hospi-
tal, which together with comprehensive case validation
through a multimodal approach, firm criteria and exten-
sive review of medical records, enhances the probability
of a complete and accurate VTE register. The study also
has some limitations. Around 16% of the eligible patients
were excluded because of missing D-dimer values. How-
ever, patient characteristics and incidence rates of recur-
rence were essentially similar in those with and without
missing values of D-dimer, indicating that the missing
value was presumably at random, and thereby would not
be likely to introduce selection bias. Second, two different
assays were used to assess D-dimer levels during the study
period. Although the Sta-Liatest has consistently reported
excellent analytical properties [36–38], there are conflict-
ing results regarding the NycoCard D-dimer assay. How-
ever, the majority of the D-dimer measurements were
assessed using the Sta-Liatest (Diagnostica Stago) and
when we restricted our analysis to include only measure-
ments from the validated Sta-Liatest (Diagnostica
Stago) the results remained essentially the same (data
not shown). It is therefore unlikely that comprehensive
misclassification has occurred as a result of the poor
analytical properties of the NycoCard D-dimer assay.
Unfortunately, we did not have information on post-
anticoagulation D-dimer values in our study. Thus, we
could not assess whether patients with a low D-dimer at
the time of first VTE diagnosis had a negative D-dimer
(< 500 ng mL1) after anticoagulation.
In conclusion, a low D-dimer (≤ 1500 ng mL1) mea-
sured at the time of first VTE diagnosis identified a quarter
of the patients as having a low risk of recurrence. The asso-
ciation was particularly pronounced among patients with a
first unprovoked event and in patients with DVT. Our find-
ings suggest that D-dimer, measured at VTE diagnosis,
may be used to identify VTE patients at low risk of recur-
rence and guide decisions on short-term anticoagulation in
these patients. Further studies are needed to confirm our
findings and to investigate whether D-dimer, measured at
the time of first VTE diagnosis, could replace or improve
the contemporary use of post-anticoagulation D-dimer
measurements in existing prediction models.
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